

May 2026

CURRICULUM VITAE

Name: Steven A. Rosenberg, M.D., Ph.D.

Date & Place of Birth: August 2, 1940; New York City, New York

Citizenship: United States

Marital Status: Married, three children

Education:

1957-1961 - B.A. (with general honors) The Johns Hopkins University,
Baltimore, Maryland

1961-1964 - M.D. The Johns Hopkins University, Baltimore, MD

1964-1968 - Ph.D. in Biophysics, Harvard University,
Cambridge, Massachusetts
(Thesis: The Proteins of Erythrocyte Membranes)

Military Service:

1970-1972 - United States Public Health Service
National Cancer Institute, National Institutes of Health
Bethesda, Maryland

Board Certification:

1975 - Surgery, American College of Surgeons

Chronology of Positions Held:

1963-1964 - Internship, in Surgery, Peter Bent Brigham Hospital,
Boston, Massachusetts

1964-1968 - Graduate Student, Department of Biophysics,
Harvard University, Cambridge, Massachusetts

1968-1969 - Resident, in Surgery, Peter Bent Brigham Hospital,
Boston, Massachusetts

Chronology of Positions Held: (cont.)

- 1969-1970 - Research Fellow in Immunology (with Dr. John David),
Harvard Medical School, Boston, Massachusetts
- 1970-1972 - Clinical Associate, Immunology Branch,
National Cancer Institute, Bethesda, Maryland
- 1972-1974 - Resident, in Surgery, Peter Bent Brigham Hospital,
Boston, Massachusetts
- 1974-Present Chief Surgery Branch National Cancer Institute,
Bethesda, Maryland
- 1979-Present Professor of Surgery, Uniformed Services University
of the Health Sciences, Bethesda, Maryland
- 1988-Present Professor of Surgery - George Washington University
School of Medicine and Health Sciences,
Washington, District of Columbia
- 2015-Present Foreign Adjunct Professor in Cell Therapy
Karolinska Institutet, Department of Laboratory Medicine
Stockholm, Sweden

Membership:

- National Academy of Medicine, National Academy of Sciences
- National Academy of Sciences
- National Academy of Inventors

Honors:

- 1961 Phi Beta Kappa
- 1963 Alpha Omega Alpha Honorary Medical Society
- 1981 Meritorious Service Medal, U.S. Public Health Service,
"For pioneering work in the treatment of soft tissue
sarcomas and osteogenic sarcoma"
- 1985 Armand Hammer Cancer Prize, "For pioneering work in
cancer research"

1986 Meritorious Service Medal, U.S. Public Health Service,
"For unsurpassed excellence and leadership in basic
research, and clinical investigation relating to the cellular
biology and immunology of cancer and its treatment"

1986 Honorary Doctorate Degree, Ben Gurion University, Beer Sheba, Israel
Honors: (cont.)

1986 Dr. Friedrich Sasse Prize, Berlin, Germany

1987 Distinguished Alumnus Award, Johns Hopkins University

1987 Nils Alwell Prize, Stockholm, Sweden

1987 Institute of Medicine, National Academy of Sciences

1988 Simon M. Shubitz Prize, University of Chicago Cancer
Research Center "For excellence in cancer research"

1988 Griffuel Prize for Research, French Association for
Research on Cancer (ARC)

1988 Milken Family Foundation Cancer Award, "For
outstanding work in the field of cancer research"

1988 Armand Hammer Cancer Prize, "For pioneering research in cancer
immunotherapy"

1989 Hadassah Women's Zionist Organization of America Myrtle Wreath Award,
"In recognition of his outstanding contributions to the preservation of life and
alleviation of suffering through superior medical research"

1990 Scientist of the Year, Research and Development
Magazine

1991 Lifetime Science Award, Institute for Advanced Studies in
Immunology and Aging

1991 Karnofsky Prize, American Society of Clinical Oncology

1991 Jeffrey A. Gottlieb Award, The University of Texas MD
Anderson Cancer Center, "For outstanding achievement in
cancer therapeutic research"

- 1991 Sheen Award, American College of Surgeons, National Westminster Bank NJ
- 1992 G. Burroughs Mider Lectureship Award, National Institutes of Health, "For recognition and appreciation of outstanding contributions to biomedical research"

Honors: (cont.)

- 1992 Meritorious Scientific Achievement Award, Cilag, "Outstanding research in the field of biologic therapies of cancer"
- 1992 Golden Plate Award, American Academy of Achievement
- 1992 Distinguished Service Medal, U.S. Public Health Service, "For uniquely insightful application of basic immunology to the development of new and effective cancer treatment, gene therapy and vaccine research"
- 1992 The Surgeon General's Exemplary Service Medal, U.S. Public Health Service
- 1992 International Chiron Award for Biomedical Research and Training, Genoa, Italy
- 1992 Arizona Cancer Center's Donald Ware Waddell Award for major contributions in cancer research.
- 1993 Claude Jacquillat Award for "Outstanding accomplishments in cancer research"
- 1993 The Medical Resource Foundation's David C. Fainer Award for "Work with cellular biology and immunology in cancer"
- 1996 The John Wayne Award for Clinical Research, Society of Surgical Oncology
- 1998 Institute for Scientific Information, Most cited author in Oncology from 1981-1998.
- 2002 The Heath Memorial Award for "Outstanding contributions to the care of patients with cancer", The University of Texas MD Anderson Cancer Center
- 2002 American Surgical Association Foundation
Flance-Karl Award "For innumerable contributions"

to the science of clinical surgery”

- 2002 Outstanding Mentor Award “For demonstrating excellence in mentoring and guiding the careers of trainees in biomedical research”, National Cancer Institute

Honors: (cont.)

- 2003 American-Italian Cancer Foundation Scientific Excellence in Medicine Award
- 2005 Lila Gruber Memorial Cancer Research Award, American Academy of Dermatology
- 2005 Richard V. Smalley, MD, Memorial Award, International Society for Biological Therapy of Cancer
- 2006 Alan S. Rabson Award for Excellence in NCI Intramural Research
- 2006 American Surgical Association Medallion for Scientific Achievement
- 2006 Astute Clinician Lecture award, U.S. Department of Health and Human Services, NIH Director’s Afternoon Lecture Series.
- 2007 Herbert and Maxine Block Memorial Award for Distinguished Achievement in Cancer, Comprehensive Cancer Center at the Ohio State University.
- 2007 Sergio Lombroso Award in Cancer Research, Weizmann Institute of Science.
- 2007 Statesman Award, American Society of Clinical Oncology.
- 2008 Abbott Laboratories Award in Clinical and Diagnostic Immunology
- 2008, 2009,
2010, 2011,
2012, 2014,

2017	Federal Technology Transfer Award, CCR, National Cancer Institute
2009	Johns Hopkins School of Medicine Distinguished Medical Alumnus Award
2010	AABB Karl Landsteiner Memorial Award and Lectureship
<u>Honors: (cont.)</u>	
2011	John K. Lattimer Lecturer, American Urological Association.
2011	William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, Cancer Research Institute, NYC
2012	Keio Medical Science Prize, Keio University, Tokyo, Japan
2013	Giants of Cancer Care, OncologyLive
2014	Massry Prize, Meira, and Shaul G. Massry Foundation, UCLA/USC
2015	Fellow of the AACR Academy, American Association for Cancer Research
2015	American Cancer Society Medal of Honor
2015	Betty Ford Lifetime Achievement Award of Distinction, Susan G. Komen Foundation
2015	Samuel J. Heyman Service to America Medals – Federal Employee of the Year, Partnership for Public Service
2016	Novartis Prize for Clinical Immunology
2016	James Ewing Award, Society of Surgical Oncology
2018	Excellence in Technology Transfer Award, Federal Laboratory Consortium for Technology Transfer
2018	Jacobson Innovation Award, American College of Surgeons
2018	Albany Medical Center Prize in Medicine and Biomedical Research, Albany Medical Center

- 2018 NCI Director's Award for Administrative Performance, National Cancer Institute
- 2018 NCI Director's Award for Translational Science, National Cancer Institute

Honors: (cont.)

- 2019 Nathan Davis Award for Outstanding Government Service, Executive Branch, American Medical Association.
- 2019 Diana Helis Henry Medical Research Foundation and Adrienne Helis Malvin Research Foundation Prize in Cancer Research, Baylor College of Medicine/Helis Research Foundation.
- 2019 AAI-Steinman Award for Human Immunology Research, American Association of Immunologists.
- 2019 Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research
- 2019 Edogawa NICHE Prize, Edogawa Hospital and Nichi-in Centre for Regenerative Medicine
- 2019 Anthony Cerami Award in Translational Medicine, Feinstein Institute for Medical Research
- 2020 Excellence in Technology Transfer Award for "New, First-in-class Immunotherapy, for Treatment of Recurrent, Metastatic Cervical Cancer," Federal Laboratory Consortium
- 2020 AACR-CRI Lloyd J. Old Award in Cancer Immunology, American Association for Cancer Research
- 2020 Samuel D. Gross Prize, Philadelphia Academy of Surgery
- 2020 NIH Director's Award, Congressional Visits Team
- 2020 Establishment of the annual Steven A. Rosenberg Scholars Prize in Cancer Immunotherapy, Society for Immunotherapy of Cancer (SITC)

- 2020 Hubert H. Humphrey Award for Distinguished Service, HHS Award
- 2021 Dan David Prize in Molecular Medicine, Tel Aviv University, Israel

Honors: (cont.)

- 2021 Secretary's Award for Distinguished Service (NIH) HHS Department Awards
- 2021 Fellow of the Academy of Immuno-Oncology Society for Immunotherapy of Cancer (SITC)
- 2022 Pezcoller Foundation – AACR International Award for Extraordinary Achievement in Cancer Research (AACR)
- 2022 ICON in Surgery Award, American College of Surgeons
- 2023 President Biden awarded Dr. Rosenberg the National Medal of Technology and Innovation, the nation's highest honor for technological achievement, He was cited for "his pioneering work in the development of the first effective immunotherapies for patients with advanced cancer, now used globally".
- 2023 European Society for Medical Oncology, Immuno-Oncology Award
- 2024 American Association for Cancer Research, Lifetime Achievement Award
- 2025 Edward Netter Leadership Award–Alliance for Cancer Gene Therapy (ACGT)
- 2025 Ted Couch Lectureship in Cancer Research–The H. Lee Moffitt Cancer Center and Research Institute

Activities:

- 1974-1979 Member, U.S. - U.S.S.R. Cooperative Cancer Immunotherapy Program
- July 1, 1977 – present Lecturer in Surgery, part time, Johns Hopkins University
- June 1978 – 1986 Member, Editorial Board,

American Journal of Clinical Oncology

1983 – 1986	Member, Board of Directors, American Society of Clinical Oncology
1990 - 1995, 2000 - present	Editor-in-Chief, <u>Journal of Immunotherapy</u>
1991 – 2000	Board of Governors, Weizmann Institute of Science
1995 – present	Editor, <u>The Cancer Journal</u>
1997 – 2010	Member Medical Board, Medical Executive Committee, Clinical Center, National Institutes of Health

Societies:

Society of University Surgeons

Society of Surgical Oncology Surgical Biology Club II

Halsted Society

Transplantation Society

American Association of Immunologists

American Association for Cancer Research

American College of Surgeons

American Society of Clinical Oncology

Society for Immunotherapy of Cancer (SITC)

BIBLIOGRAPHY- BOOKS

Steven A. Rosenberg, M.D., Ph.D.

1. Rosenberg, S.A. (ed.): Serologic Analysis of Human Cancer Antigens, New York: Academic Press, 1980.
2. Terry, W.D. and Rosenberg, S.A. (eds.): Immunotherapy of Human Cancer, New York: Elsevier North-Holland, 1982.
3. DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.): Cancer: Principles and Practice of Oncology, First Edition through 11th Edition, Philadelphia: J.B. Lippincott, 1982, 1985, 1989, 1993, 1997, 2001, 2005, 2008, 2011, 2015, 2019.
4. DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.): Important Advances in Oncology, Philadelphia: J.B. Lippincott, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994.
5. DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.): AIDS - Etiology, Diagnosis, Treatment and Prevention, Philadelphia: J.B. Lippincott, 1985, 1988.
6. Rosenberg, S.A. (ed.): Surgical Treatment of Metastatic Cancer, Philadelphia: J.B. Lippincott, 1987.
7. DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.): Biologic Therapy of Cancer, First and Second Edition, Philadelphia: J.B. Lippincott, 1991, 1995.
8. Rosenberg, S.A. and Barry, J.: The Transformed Cell. New York, NY: G.B. Putnam, 1992.
9. Rosenberg, S.A.(eds.):Principles and Practices of The Biologic Therapy of Cancer, 3rd edition. Philadelphia, J.B. Lippincott, 2000.
10. DeVita, V.T., Hellman, S., and Rosenberg, S.A.: Progress in Oncology, Jones and Bartlett: Massachusetts, 2002, 2003, 2004.

BIBLIOGRAPHY (h-index 222)

Steven A. Rosenberg, M.D., Ph.D.

1. Rosenberg, J.C., Assimacopoulos, C., Lober, P., Rosenberg, S.A., and Zimmermann, B.: The malignant melanoma of hamsters. I. Pathologic characteristics of a transplanted melanotic and amelanotic tumor. Cancer Res. 21:627, 1961.
2. Rosenberg, S.A., Kodani, M., and Rosenberg, J.C.: The malignant melanoma of hamsters. II. Growth and morphology of a transplanted melanotic and amelanotic tumor in tissue culture. Cancer Res. 21:632-635, 1961.
3. Rosenberg, S.A.: In vivo and in vitro demonstration of tumor immunity to the transplanted melanoma of hamsters. Bull. Hopkins Hosp. 108:386-387, 1961.
4. Rosenberg, J.C., Assimacopoulos, C., and Rosenberg, S.A.: The malignant melanoma of hamsters: III. Effects of sex and castration on the growth of the transplanted tumor. NY Acad. Sci., USA 100:297-304, 1963.
5. Rosenberg, S.A.: A study of the etiological basis of primary pulmonary hypertension. Am. Heart J. 68:484-489, 1964.
6. Rosenberg, S.A., Brief, D.K., Kinney, J.M., Herrera, M.G., Wilson, R.E., and Moore, F.D.: The syndrome of dehydration, coma and severe hyperglycemia without ketosis in patients convalescing from burns. N. Engl. J. Med. 272:931-938, 1965.
7. Rosenberg, S.A. and Guidotti, G.: The protein of human erythrocyte membranes. I. Preparation, solubilization and partial characterization. J. Biol. Chem. 243:1985-1992, 1968.
8. Rosenberg, S.A. and McIntosh, J.R.: Erythrocyte membranes: Effects of sonication. Biochem. Biophys. Acta 163:285-289, 1968.
9. Rosenberg, S.A.: A computer evaluation of equations for predicting the potential across biological membranes. Biophys. J. 9:500-509, 1969.
10. Rosenberg, S.A., Ledeen, K.S., and Kline, T.: Automatic identification and measurement of cells by computer. Science. 163:1065-1067, 1969.
11. Rosenberg, S.A. and Guidotti, G.: The fractionation of the protein components of human erythrocyte membranes. J. Biol. Chem. 244:5118- 5124, 1969.
12. Rosenberg, S.A. and Guidotti, G.: The proteins of erythrocyte membrane: Structure and arrangement in the membrane. In Jamieson, G.A. and Greenwalt, T.J. (Eds.): Red Cell Membrane, Philadelphia: J.B. Lippincott, 1969.

13. Ledeen, K.S. and Rosenberg, S.A.: A computer display system for the identification of malignant cells in cytology smears. Biomed. Sci. Instrum. 6:208-212, 1969.
14. Nathan, C.F., Rosenberg, S.A., Karnovsky, M.L. and David, J.R.: Effects of MIF-rich supernatants on macrophages. Fifth Leukocyte Culture Conf. 5:629-638, 1970.
15. Rosenberg, S.A. and David, J.R.: Inhibition of leukocyte migration: An evaluation of this in vitro assay of delayed hypersensitivity in man to a soluble antigen. J. Immunol. 105:1447-1452, 1970.
16. Markowitz, J., Rosenberg, S.A. and Wolf, M.: Automation of the medical history. Proc. Ann. Conf. Engin. Med. Biol. 23:3, 1970.
17. Rogentine, G.N., Jr., Rosenberg, S.A., Merritt, C.B., Yankee, R.A., Leventhal, B.G., Graw, R.G., Greipp, P., Whang, Peng J. and Fahey, J.L.: Successful allogeneic bone marrow transplantation in aplastic anemia. Blood 36:829, 1970.
18. Rosenberg, S.A. and David, J.R.: In vitro assay for inhibition of migration of human blood leukocytes. In Bloom, B. and Glade, P. (Eds.): In Vitro Methods in Cell Mediated Immunity, New York: Academic Press, 1971, pp. 297-300.
19. Rosenberg, S.A., Ledeen, K.S., Kline, T. and Markowitz, J.: Distinguishing normal from malignant cells on Papanicolaou smears using computer measurements of standard morphologic criteria. Acta Cytol. 15:246-250, 1971.
20. Jackson, G.G. and Rosenberg, S.A.: Self-administered histories let doctor concentrate on patient. Mod. Hosp. 116:122-123, 1971.
21. Rosenberg, S.A. and Ledeen, K.S.: Computers with eyes. The use of visual input computer systems for microscopic diagnosis in medicine. J Assoc. Adv. Med. Instrum. 5:173-177, 1971.
22. Rosenberg, S.A., Fox, E. and Churchill, W.H.: Spontaneous regression of hepatic metastases from gastric carcinoma. Cancer 29:472-474, 1972.
23. Rosenberg, S.A. and Levy, R.: Synthesis of nuclear associated proteins by lymphocytes within minutes after contact with phytohemagglutinin. J. Immunol. 108:1105-1109, 1972.
24. Levy, R. and Rosenberg, S.A.: The early stimulation of protein synthesis in sensitized guinea pig lymph node cells by antigen. J. Immunol. 108:1073-1079, 1972.
25. Rosenberg, S.A. and Levy, R.: A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis. J. Immunol. 108:1080-1087, 1972.

26. Rosenberg, S.A., Levy, R., Schechter, B., Ficker, S. and Terry, W.D.: A rapid microassay of cellular immunity in the guinea pig and mouse. Transplantation 13:541-545, 1972.
27. Rosenberg, S.A. and Einstein, A.B., Jr.: Sialic acids on the plasma membrane of cultured human lymphoid cells: Chemical aspects and biosynthesis. J. Cell. Biol. 53:466-473, 1972.
28. Rosenberg, S.A., Plocinik, B.A. and Rogentine, G.N., Jr.: "Unmasking" of human lymphoid cell heteroantigens by neuraminidase treatment. J. Natl. Cancer Inst. 48:1271-1276, 1972.
29. Rosenberg, S.A. and Rogentine, G.N., Jr.: Natural antibodies in human immune surveillance. Surg. Forum 23:96-98, 1972.
30. Rosenberg, S.A. and Rogentine, G.N., Jr.: Natural human antibodies to hidden membrane components. Nature: New Biol. 239:203-204, 1972.
31. Levy, R., Levy, S., Rosenberg, S.A. and Simpson, R.T.: Selective stimulation of nonhistone chromatin protein synthesis in lymphoid cells by phytohemagglutinin. Biochem. 12:224-228, 1973.
32. Rosenberg, S.A.: Problems with leukocyte migration inhibition technique in the study of human tumor immunity. Natl. Cancer Inst. Monogr. 37:139-140, 1973.
33. Levy, R. and Rosenberg, S.A.: Proteins synthesized in lymphoid cells early after activation by phytohemagglutinin. Cell. Immunol. 7:92-107, 1973.
34. Schechter, B., Rosenberg, S.A., Levy, R., Ficker, S. and Terry, W.D.: Early evaluation of mixed leukocyte interactions in mice and guinea pigs using measurements of protein synthesis. Cell. Immunol. 6:261-272, 1973.
35. Lavrin, D.H., Rosenberg, S.A., O'Connor, R. and Terry, W.D.: Immunoprophylaxis of methylcholanthrene-induced tumors in mice using Bacillus Calmette-Guerin (BCG) and Methanol Extracted Residue (MER). Cancer Res. 33:472-477, 1973.
36. Rosenberg, S.A., Henrichon, M., Coyne, J.A. and David, J.R.: Guinea pigs lymphotoxin (LT): I. In vitro studies of LT produced in response to antigen stimulation of lymphocytes. J. Immunol. 110:1623-1629, 1973.
37. Rogentine, G.N., Rosenberg, E.B., Merritt, C.B., Rosenberg, S.A., Yankee, R.A., Graw, R.G., Jr., Greipp, P., Whang-Peng, J. and Fahey, J.L.: Antilymphocyte globulin as the sole immunosuppressant for bone marrow transplantation in aplastic anemia. A case report. Transplantation 15:514-517, 1973.

38. Coyne, J.A., Remold, H.G., Rosenberg, S.A. and David, J.R.: Guinea pig lymphotoxin (LT): II. Physicochemical properties of LT produced by lymphocytes stimulated with antigen or concanavalin A: Its differentiation from migration inhibitory factor (MIF). J. Immunol. 110:1630-1637, 1973.
39. Adkinson, N.F., Rosenberg, S.A. and Terry, W.D.: Early detection of lymphocyte stimulation and mixed lymphocyte interaction in man with a semi-micro protein synthesis assay. J. Immunol. 112:1426-1434, 1974.
40. Rosenberg, S.A. and Schwarz, S.: Murine antibodies to a cryptic membrane antigen. Possible explanation for neuraminidase induced increase in cell immunogenicity. J. Natl. Cancer Inst. 52:1151-1155, 1974.
41. Rosenberg, S.A.: Natural antibodies to unmasked tumor antigens: Their potential value for immune therapy. Horizons in tumor immunology. Arch. Surg. 109:17-29, 1974.
42. Rosenberg, S.A., Schwarz, S. and Baker, A.R.: Natural antibodies to "cryptic" membrane antigens exposed by treatment with neuraminidase. Behring Inst. Mitteilungen 55:204-208, 1974.
43. Wilson, R.E., Alexander, P., Rosenberg, S.A. and Simmons, R.L.: Horizons in tumor immunology. A seminar. Arch. Surg. 109:17-19, 1974.
44. Rosenberg, S.A.: Future prospects for immunotherapy. Cancer 36:821-824, 1975.
45. Cohen, M.H., Schour, L., Felix, E.L., Bernstein, A.D., Chretien, P.B., Rosenberg, S.A. and Ketcham, A.S.: Staging laparotomy in the treatment of metastatic melanoma of the lower extremities. Ann. Surg. 182:710-714, 1975.
46. Rosenberg, S.A. and Harken, A.H.: A simple test to determine the site of bleeding in the upper gastrointestinal tract. Surg. Gynecol. Obstet. 142:241-242, 1976.
47. Rosenberg, S.A.: Surgical treatment of malignant melanoma. Cancer Treat. Rep. 60:159-163, 1976.
48. Rosenberg, S.A. and Rapp, H.J.: Intralesional immunotherapy of melanoma with BCG. Med. Clin. North Am. 60:419-430, 1976.
49. Rosenberg, S.A.: Cancer Immunology. In: Munster, A.M. (ed.). Surgical Immunology, New York: Grune & Stratton, Inc., 1976, pp. 231-281.
50. Rosenberg, J.C., Colburn, W.A., Brennan, P., Lysz, K., Paultke, M., Stubbs, S.S. and Rosenberg, S.A.: In vitro effect of methylpred- nisolone on protein synthesis of activated canine thymus-derived lymphocytes. Transplant. Proc. 7:547-556, 1975.

51. Sears, H.F. and Rosenberg, S.A.: Increased reliability of cellular immune assays with cryopreserved lymphocytes: Studies in humans. Surg. Forum 17:160-162, 1976.
52. Cohen, M.H., Felix, E., Jessup, J. and Rosenberg, S.A.: Treatment of metastatic melanoma by intralesional injection of BCG, organic chemical and C. Parvum. In: Crispen, R.G. (ed.), Neoplasm Immunity; Mechanisms. Proc. of Chicago Symposium, 1976, pp. 121-134.
53. Sachs, D.H., Leight, G., Cone, J., Schwarz, S., Stuart, L. and Rosenberg, S.A.: Transplantation in miniature swine. I: Fixation of the major histocompatibility complex. Transplantation 22:559-567, 1976.
54. Rosenberg, J.C., Lysz, K., Strefling, A. and Rosenberg, S.A.: Steroid suppression of protein synthesis of activated human lymphocytes. J. Surg. Res. 20:255-260, 1976.
55. Sears, H.F. and Rosenberg, S.A.: Advantages of using cryopreserved lymphocytes for the sequential evaluation of human immune competence. I. Mitogen stimulation. J. Natl. Cancer Inst. 58:183-187, 1977.
56. Parker, G.A. and Rosenberg, S.A.: Serologic identification of multiple tumor-associated antigens on murine sarcomas. J. Natl. Cancer Inst. 58:1303-1309, 1977.
57. Rosenberg, S.A.: Lysis of human normal and sarcoma cells in tissue culture by normal human serum: Implications for experiments in human tumor immunology. J. Natl. Cancer Inst. 58:1233-1238, 1977.
58. Rosenberg, S.A. and Terry, W.: Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:323-388, 1977.
59. Leight, G.S., Sachs, D.H., Williams, G.M. and Rosenberg, S.A.: Transplantation in miniature swine. Transplant. Proc. 9:575-577, 1977.
60. Leight, G.S., Sachs, D.H. and Rosenberg, S.A.: Transplantation in miniature swine. II. In vitro parameters of histocompatibility in MSLA homozygous minipigs. Transplantation 23:271-276, 1977.
61. Parker, G.A., Hyatt, C. and Rosenberg, S.A.: Normal adult murine cells in tissue culture express fetal antigens. Transplantation 23:161-163, 1977.
62. Parker, G.A. and Rosenberg, S.A.: Cross reacting antigens in chemically induced sarcomas are fetal determinants. J. Immunol. 118:1590-1594, 1977.

63. Rosenberg, S., Schwarz, S., Anding, H., Hyatt, C. and Williams, G.M.: Comparison of multiple assays for detecting human antibodies directed against surface antigens on normal and malignant human tissue culture cells. J. Immunol. Methods 17:225-239, 1977.
64. Thorpe, W.P., Parker, G.A. and Rosenberg, S.A.: Expression of fetal antigens by normal human skin cells grown in tissue culture. J. Immunol. 119:818-823, 1977.
65. Romolo, J.L., Goldberg, N.H., Hande, K.R. and Rosenberg, S.A.: The effect of hydration on plasma methotrexate levels. Cancer Treat. Rep. 61:1393-1396, 1977.
66. Reilly, J.J., Neifeld, J.P. and Rosenberg, S.A.: Clinical course and management of accidental adriamycin extravasation. Cancer 40:2053-2056, 1977.
67. Cohen, M.H., Ketcham, A.S., Felix, E.L., Li, S.H., Tomaszewski, M.M., Costa, J., Rabson, A.S., Simon, R.M. and Rosenberg, S.A.: Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann. Surg. 186:635-642, 1977.
68. Stoller, R.G., Hande, K.R., Jacobs, S., Rosenberg, S.A. and Chabner, B. A.: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N. Engl. J. Med. 297:630-634, 1977.
69. Goldberg, N.H., Romolo, J.L., Austin, E.H., Drake, J. and Rosenberg, S.A.: Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate. Cancer 41:52-55, 1977.
70. Hande, K.R., Balow, J.E., Drake, J.C., Rosenberg, S.A. and Chabner, B.A.: Methotrexate and hemodialysis. Ann. Intern. Med. 87:495, 1977.
71. Rosenberg, S.A., Parker, G. and Thorpe, W.P.: Serologic studies of murine and human sarcomas. In Sela, M. (ed.). Pontificiae Academiae Scientiarum Scripta Varia, Rome, Ex Aedibus Academicis in Civitate Vaticana, 1977, pp. 93-119.
72. Rosenberg, S.A., Parker, G.A. and Thorpe, W.P.: Expression of oncofetal antigens by murine and human normal cells in tissue culture. Isr. J. Med. Sci. 14:98-104, 1978.
73. Pinedo, H.M., Chabner, B.A., Nieuwenhuis, M.G. and Rosenberg, S.A.: Soft tissue sarcoma in adults. In Maurice J. Staquet., (ed.). Randomized Trials in Cancer: A Critical Review by Sites, New York: Raven Press, 1978, pp. 359-375.
74. Norton, J.A., Shulman, N.R., Corash, L., Smith, R.L., Au, F. and Rosenberg, S.A.: Severe thrombocytopenia following intralesional BCG therapy. Cancer 41:820-826, 1978.

75. Rosenberg, S.A., Seipp, C. and Sears, H.F.: Clinical and immunologic studies of disseminated BCG infection. Cancer 41:1771-1780, 1978.
76. Rosenberg, S.A., Kent, H., Costa, J., Webber, B.L., Young, R., et al.: Prospective randomized evaluation of the role of limb sparing surgery, radiation therapy and adjuvant chemo-immunotherapy in the treatment of adult soft-tissue sarcomas. Surgery 84:62-69, 1978.
77. Schaner, E.G., Chang, A.E., Doppman, J.L., Conkle, D.M., Flye, M.W., and Rosenberg, S.A.: Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: A prospective radiologic pathologic study. Am. J. Roent. 131:51-54, 1978.
78. Weingrad, D.N. and Rosenberg, S.A.: Early lymphatic spread of osteogenic and soft tissue sarcomas. Surgery 84:231-240, 1978.
79. Au, F.C., Webber, B. and Rosenberg, S.A.: Pulmonary granulomas induced by BCG. Cancer 41:2209-2214, 1978.
80. Breiter, D.N., Diasio, R.B., Neifeld, J.P., Roush, M.L. and Rosenberg, S.A.: Serum copper and zinc measurements in patients with osteogenic sarcoma. Cancer 42:598-602, 1978.
81. Sears, H.F., Tondreau, S.C. and Rosenberg, S.A.: Advantages of cryopreserved lymphocytes for sequential evaluation of human immune competence. II. Mixed lymphocyte cultures and mononuclear cell subpopulations. J. Natl. Cancer. Inst. 61:1011-1016, 1978.
82. Leight, G.S., Kirkman, R., Rasmussen, B.A., Rosenberg, S.A., Sachs, D.H., Terrill, R. and Williams, G.M.: Transplantation in miniature swine. III. Effects of MSLA and A-O blood group matching on skin allograft survival. Tissue Antigens 12:65-74, 1978.
83. Strausser, J.L. and Rosenberg, S.A.: In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J. Immunol. 121:1491-1495, 1978.
84. Rosenberg, S.A., Spiess, P.J. and Schwarz, S.: In vitro growth of murine T-cells. I. Production of factors necessary for T-cell growth. J. Immunol. 121:1946-1950, 1978.
85. Rosenberg, S.A., Schwarz, S. and Spiess, P.J.: In vitro growth of murine T-cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. J. Immunol. 121:1951-1955, 1978.
86. Rosenberg, S.A.: Soft tissue sarcomas: New approaches to therapy. In: Rosenberg, S.A. (ed.). Topics in Cancer, Physician Programs, Inc., 1978.

87. Rosenberg, S.A.: Soft tissue sarcomas: Natural history. In Rosenberg, S.A. (ed.). Topics in Cancer, Physician Programs, Inc., 1978.
88. Thorpe, W.P. and Rosenberg, S.A.: Serologic analysis of human tumor antigens. I. Anti-sarcoma antibodies in the serum of patients with osteogenic sarcoma. J. Natl. Cancer Inst. 62:1143-1150, 1979.
89. Thorpe, W., Loeb, W., Hyatt, C. and Rosenberg, S.A.: Alkaline phosphatase measurements of paired normal and osteosarcoma tissue culture lines obtained from the same patient. Cancer Res. 39:277-279, 1979.
90. Chang, A.E., Schaner, E.G., Conkle, D.M., Flye, M.W., Doppman, J.L., and Rosenberg, S.A.: Evaluation of computed tomography in the detection of pulmonary metastases: A prospective study. Cancer 43:913-916, 1979.
91. Rosenberg, S.A., Chabner, B., Young, R., Seipp, C., Levine, A.S., Costa, J., Hanson, T.A., Head, G. and Simon, R.: Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat. Rep. 63:739-751, 1979.
92. Thorpe, W.P., Reilly, J.J. and Rosenberg, S.A.: Prognostic significance of alkaline phosphatase measurement in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43:2178-2181, 1979.
93. Rosenberg, S.A., Flye, M.W., Conkle, D., Seipp, C., Levine, A.S. and Simon, R.: Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. Cancer Treat. Rep. 63:753-756, 1979.
94. Woltering, E.A., Thorpe, W.P., Reed, J.K., Jr., and Rosenberg, S.A.: Split-thickness skin grafting of the plantar surface of the foot after wide excision of cutaneous neoplasms. Surg. Gynecol. Obstet. 149:229-232, 1979.
95. Bramwell, V.H., Voute, P.A., Rosenberg, S.A. and Pinedo, H.M.: Adjuvant treatment of soft-tissue sarcoma in children and adults. Recent Results Cancer Res. 68:60-74, 1979.
96. Wexler, H. and Rosenberg, S.A.: Pulmonary metastases from autochthonous methylcholanthrene-induced murine tumors: A suggested model for evaluating cancer therapy. Brief Communication - J. Natl. Cancer Inst. 63:1393-1395, 1979.
97. Kirkman, R.L., Colvin, R.B., Flye, M.W., Leight, G.S., Rosenberg, S.A., Williams, G.M. and Sachs, D.H.: Transplantation in miniature swine. VI. Factors influencing survival of renal allografts. Transplantation 28:18-23, 1979.
98. Brown, J.M., Thorpe, W.P. and Rosenberg, S.A.: A sensitive assay for the detection of cytotoxic antibodies to mammalian cell surface antigens. J. Immunol. Methods 30:23-35, 1979.

99. Rosenberg, S.A., Tondreau, S.C., Shoffner, P.C., Hyatt, C., Brown, J.M., Thorpe, W. and Sindelar, W.: Serologic analysis of human tumor antigens. II. Reactivity of sera from eleven osteogenic sarcoma patients against autologous and allogeneic tumor cells. Surgery, 86:258-265, 1979.
100. Chang, A.E., Shiling, D.J., Stillman, R.C., Goldberg, N.H., Seipp, C.A., Barofsky, I., Simon, R.M. and Rosenberg, S.A.: Delta-9-Tetrahydrocannabinol as an anti-emetic in cancer patients receiving high dose methotrexate. A prospective, randomized evaluation. Ann. Intern. Med. 91:819-824, 1979.
101. Levine, A.M. and Rosenberg, S.A.: Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer 44:2291-2293, 1979.
102. Strausser, J.L. and Rosenberg, S.A.: Growth of human T-cells following in vitro allograft sensitization. In: Escobar, M.R. and Friedman, H. (eds.). Macrophages and Lymphocytes, New York: Plenum Press, 1980, pp. 269-273.
103. Stern, R., Wilczek, J., Thorpe, W., Rosenberg, S.A., and Cannon, G.: Procollagens as markers for the cell of origin of human bone tumors. Cancer Res. 40:325-328, 1980.
104. Sears, H.F., Simon, R. and Rosenberg, S.A.: Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. Cancer Treat. Rep. 64:589-597, 1980.
105. Lotze, M.T., Strausser, J.L., Line, B.R. and Rosenberg, S.A.: Tumor lysis by human T lymphocytes in long term culture and their distribution in vivo: Implications for immunotherapy. Surg. Forum 30:404-406, 1980.
106. Levine, A.M., Triche, T. and Rosenberg, S.A.: Osteosarcoma cells in tissue culture: II. Characterization and localization of alkaline phosphatase activity. Clin. Orthop. 146:259-268, 1980.
107. Brown, J.M. and Rosenberg, S.A.: Serologic analysis of human solid tumor antigens. In: Rosenberg, S.A. (ed.). Serologic Analysis of Human Cancer Antigens, New York: Academic Press, 1980.
108. Brown, J.M., Catapano, M.S. and Rosenberg, S.A.: Natural antibodies in human sera which react with tissue cultured cells. In: Rosenberg, S.A. (ed.). Serologic Analysis of Human Cancer Antigens, New York: Academic Press, 1980.
109. Yron, I., Wood, T.A., Spiess, P.J. and Rosenberg, S.A.: In vitro growth of murine T cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J. Immunol. 125:238-245, 1980.

110. Rosenberg, S.A., Brown, J.M., Thorpe, W.P., Hyatt, C., Shoffner, P. and Tondreau, S.: Serologic studies of the antigens on human osteogenic sarcoma. In: Rosenberg, S.A. (ed.). Serologic Analysis of Human Cancer Antigens, New York: Academic Press, 1980, pp. 93-116.
111. Rosenberg, S.A., Schwarz, S., Spiess, P.J. and Brown, J.M.: In vitro growth of murine T cells. III. Method for separation of T cell growth factor (TCGF) from concanavalin A and biological activity of the resulting TCGF. J. Immunol. Methods 33:337-350, 1980.
112. Rosenberg, S.A., Spiess, P.J. and Schwarz, S.: In vitro growth of murine T cells. IV. Use of T cell growth factor (TCGF) to clone lymphoid cells. Cell. Immunol. 54:293-306, 1980.
113. Mathisen, D.J. and Rosenberg, S.A.: Comparison of in vivo cell distribution following either intraperitoneal or intravenous injection of lymphoid cells. Transplantation 29:347-349, 1980.
114. Lotze, M.T., Strausser, J.L. and Rosenberg, S.A.: In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells. J. Immunol. 124:2972-2978, 1980.
115. Mathisen, D.J. and Rosenberg, S.A.: The in vivo distribution of transferred syngeneic, allogeneic, and xenogeneic lymphoid cells: Implication for the adoptive immunotherapy of tumors. J. Immunol. 124:2295-2300, 1980.
116. Rosenberg, S.A. and Sindelar, W.F.: Surgery and adjuvant radiationchemo-immunotherapy in soft tissue sarcomas: Result of treatment at the National Cancer Institute. In: van Oosterom, A.T., et al. (eds.). Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas, The Hague/Boston/London, Martinus Nijhoff Publ., 1980, pp. 397-412.
117. Rosenberg, S.A. and Sindelar, W.F.: Surgery and adjuvant chemo-immunotherapy in osteosarcoma: Review of treatment at the National Cancer Institute. In: van Oosterom, A.T., et al. (eds.). Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas, The Hague/Boston/London, Martinus Nijhoff Publ., 1980, pp. 301-316.
118. Seipp, C.A., Chang, A.E., Shilling, D.J. and Rosenberg, S.A.: In search of an effective antiemetic - A nursing staff participates in marijuana research. Cancer Nurs. 3:271-276, 1980.
119. Austin, E., Brennan, M.F. and Rosenberg, S.A.: The effects of protein calorie restriction on the immune response to skin allografts in the rat. Transplantation 30:219-225, 1980.

120. Catapano, M.S., Brown, J.M. and Rosenberg, S.A.: Levels of cytotoxic reactivity to cultured normal skin fibroblasts in sera from normal and sarcoma-bearing patients. Cancer Res. 40:979-983, 1980.
121. Lotze, M.T., Line, B.R., Mathisen, D.J. and Rosenberg, S.A.: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J. Immunol. 125:1487-1493, 1980.
122. Rosenberg, S.A.: Treatment of soft tissue and bony sarcomas: Review of studies at the National Cancer Institute. Natl. Cancer Inst. Monogr. 56:24-244, 1981.
123. Shamberger, R.C., Sherins, R.J. and Rosenberg, S.A.: The effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma. Cancer 47:2368-2374, 1981.
124. Reichert, C.M., Rosenberg, S.A., Webber, B.L. and Costa, J.: Malignant melanoma: Search for occult lymph node metastases. Hum. Pathol. 12:449-451, 1981.
125. Sener, S.F., Brown, J.M., Hyatt, C.L., Terry, W.D. and Rosenberg, S.A.: Serologic analysis of human tumor antigens. III. Reactivity of patients with melanoma and osteogenic sarcoma to cultured tumor cells and fibroblasts in the immune adherence assay. Cancer Immunol. Immunother. 11:243-250, 1981.
126. Shamberger, R.C., Sherins, R.J., Ziegler, J.L., Glatstein, E. and Rosenberg, S.A.: Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. J. Natl. Cancer Inst. 67:1213-1218, 1981.
127. Rosenberg, S.A. and Glatstein, E.: Perspectives on the role of surgery and radiation therapy in the treatment of soft tissue sarcomas of the extremities. Semin. Oncol. 8:190-200, 1981.
128. Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser J.L., and Rosenberg, S.A.: Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T cell growth factor (TCGF). Cancer Res. 41:4420-4425, 1981.
129. Lotze, M.T. and Rosenberg, S.A.: In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin free T cell growth factor (TCGF) and an analysis of its activity. J. Immunol. 126:2215-2220, 1981.
130. Strausser, J.L., Mazumder, A., Grimm, E.A., Lotze, M.T. and Rosenberg, S.A.: Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J. Immunol. 127:266-271, 1981.

131. Shamberger, R.C., Rosenberg, S.A., Seipp, C.A. and Sherins, R.J.: The effects of high dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment for osteosarcoma. Cancer Treat. Rep. 65:739-746, 1981.
132. Gottdiener, J.S., Mathisen, D.J., Borer, J.S., Bonow, R.O., Myers, C.E., Barr, L.H., Schwartz, D.E., Bacharach, S.L., Green, M.V. and Rosenberg, S.A.: Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann. Intern. Med. 94:430-435, 1981.
133. Lotze, M.T., Duncan, M.A., Gerber, L.H., Woltering, E.A. and Rosenberg, S.A.: Early versus delayed shoulder motion following axillary dissection: A randomized prospective study. Ann. Surg. 193:288-295, 1981.
134. Spiess, P.J. and Rosenberg, S.A.: A simplified method for the production of murine T cell growth factor free of lectin. J. Immunol. Methods 42: 213-222, 1981.
135. Rosenstein, M., Eberlein, T., Kemeny, M.M., Sugarbaker, P.H. and Rosenberg, S.A.: In vitro growth of murine T cells: VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. J. Immunol. 127:566-571, 1981.
136. Fisher, R.I., Terry, W.D., Hodes, R.J., Rosenberg, S.A., Makuch, R., Gordon, H.G. and Fisher, S.G.: Adjuvant immunotherapy or chemotherapy for malignant melanoma: Preliminary report of the National Cancer Institute randomized clinical trial. Surg. Clin. North Am. 61:1267-1277, 1981.
137. Eberlein, T.J., Rosenstein, M.M. and Rosenberg, S.A.: Successful adoptive immunotherapy of a disseminated murine cancer using immunized cells expanded in T-cell growth factor. Surg. Forum 32:452-454, 1981.
138. Rosenberg, S.A., Tepper, J., Glatstein, E., Costa, J., Young, R., Seipp, C. and Wesley, R.: Adjuvant chemotherapy for patients with soft tissue sarcomas. Surg. Clin. North Am. 61:1415-1423, 1981.
139. Chang, A.E., Shiling, D.J., Stillman, R.C., Goldberg, N.H., Seipp, C.A., Barofsky, I. and Rosenberg, S.A.: A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47:1746-1751, 1981.
140. Rosenberg, S.A. and Glatstein, E.: The management of local and regional soft tissue sarcomas. In: Carter, S.K., Glatstein, E. and Livingston, R.B. (eds.). Principles of Cancer Treatment, New York: McGraw-Hill, 1982, pp. 697-706.

141. Terry, W.D., Hodes, R.J., Rosenberg, S.A., Fisher, R.I., Makuch, R., Gordon, H.G. and Fisher, S.G.: Treatment of Stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: Preliminary analysis of a prospective randomized trial. In: Terry, W.D. and Rosenberg, S.A. (eds.). Immunotherapy of Cancer in Man, New York: Elsevier North-Holland, 1982, pp. 251-257.
142. Rosenberg, S.A., Rapp, H., Terry, W., Zbar, B., Costa, J., Seipp, C. and Simon, R.: Intralesional BCG therapy of patients with primary stage I melanoma. In: Terry, W.D. and Rosenberg, S.A. (ed.). Immunotherapy of Cancer in Man, New York: Elsevier North-Holland, 1982, pp. 239-244.
143. Sugarbaker, P.H., Barofsky, I., Rosenberg, S.A. and Gianola, F.J.: Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery 91:17-23, 1982.
144. Rosenberg, S.A.: Principles of surgical oncology. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.). Cancer: Principles and Practice of Oncology, Philadelphia: J.B. Lippincott, 1982, pp. 93-102.
145. Rosenberg, S.A.: Soft tissue sarcomas: recent advances in treatment. Surg. Rounds 5:36-58, 1982.
146. Eberlein, T.J., Rosenstein, M., Spiess, P.J. and Rosenberg, S.A.: Generation of long term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma. J. Natl. Cancer Inst. 69:109-116, 1982.
147. Rosenberg, S.A., Eberlein, T., Grimm, E., Mazumder, A. and Rosenstein, M.: Adoptive transfer of lymphoid cells expanded in T-cell growth factor: Murine and human studies. In: Fefer, A., Goldstein, A.L. (eds.). The Potential Role of T-Cell Subpopulations in Cancer Therapy, New York: Raven Press, 1982, pp. 161-171.
148. Eberlein, T.J., Rosenstein, M., Spiess, P., Wesley, R. and Rosenberg, S.A.: Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor. Cancer Immunol. Immunother. 13:5-13, 1982.
149. Grimm, E.A., Mazumder, A. and Rosenberg, S.A.: In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor. Cell. Immunol. 70:248-259, 1982.
150. Grimm, E.A. and Rosenberg, S.A.: Production and properties of human IL-2. In: Fathman, G. and Fitch, F.W. (eds.). Isolation, Characterization and Utilization of T Lymphocyte Clones, New York: Academic Press, 1982, pp. 57-82.

151. Mazumder, A.M., Grimm, E.A., Zhang, H.Z. and Rosenberg, S.A.: Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res. 42:913-918, 1982.
152. Rosenberg, S.A., Grimm, E.A., Lotze, M.T. and Mazumder, A.: The growth of human lymphocytes in T-cell growth factor: Potential applications to tumor immunotherapy. In: Mizel, S.B. (ed.). Lymphokines, New York: Academic Press, 1982, 7:213-247.
153. Grimm, E.A., Mazumder, A., Zhang, H.Z. and Rosenberg, S.A.: The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823-1841, 1982.
154. Rosenberg, S.A., Eberlein, T.J., Grimm, E.A., Lotze, M.T., Mazumder, A. and Rosenstein, M.: The development of long-term cell lines and lymphoid clones reactive against murine and human tumors: A new approach to the adoptive immunotherapy of cancer. Surgery 92:328-336, 1982.
155. Rosenberg, S.A.: Potential use of expanded T-lymphoid cells and T-cell clones for the immunotherapy of cancer. In: Fathman, G. and Fitch, F.W. (eds.). Isolation, Characterization and Utilization of T Lymphocyte Clones, New York: Academic Press, 1982, pp. 451-466.
156. Eberlein, T.J., Rosenstein, M. and Rosenberg, S.A.: Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J. Exp. Med. 156:385-397, 1982.
157. Rosenberg, S.A., Tepper, J., Glatstein, E., Costa, J., Baker, A., Brennan, M., deMoss, E., Seipp, C., Sindelar, W.F., Sugarbaker, P. and Wesley, R.: The treatment of soft tissue sarcomas of the extremities: Prospective randomized evaluations of 1) limb-sparing surgery plus radiation therapy compared to amputation and 2) the role of adjuvant chemotherapy. Ann. Surg. 196:305-315, 1982.
158. Rosenberg, S.A., Suit, H.D., Baker, L.H. and Rosen, G.: Sarcomas of the soft tissue and bone. In: DeVita V.T., Hellman, S., and Rosenberg, S.A. (eds.). Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1982, pp. 1037-1093.
159. Mastrangelo, M.J., Rosenberg, S.A., Baker, A.R. and Katz, H.R.: Cutaneous melanoma. In: DeVita, V.T., Hellman, S., and Rosenberg, S.A. (eds.). Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1982, pp. 1124-1170.
160. Rosenberg, S.A.: Soft tissue sarcomas: Natural history. In: Silver, R.T. (ed.). Clinical Topics in Cancer - Diagnosis and Treatment I, New York: Le Jacq Publ. Co., 1982, pp. 433-438.

161. Rosenberg, S.A.: New approaches to therapy of soft tissue sarcomas. In: Silver, R.T. (ed.). Clinical Topics in Cancer - Diagnosis and Treatment, II, New York: Le Jacq Publ. Co., 1982, pp. 439-443.
162. Dresdale, A.R., Barr, L.H., Bonow, R.O., Mathisen, D.J., Myers, C.E., Schwartz, D.E., d'Angelo, T. and Rosenberg, S.A.: Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin induced cardiomyopathy. Am. J. Clin. Oncol. 5:657-663, 1982.
163. Brown, J.B., Shoffner, P.C., Tondreau, S.P., Matthews, E.J., Terry, W.D. and Rosenberg, S.A.: Cytotoxic antibody reactivity in sera of melanoma patients against allogeneic and autologous cultured tumor cells and fibroblasts. Cancer Res. 42:2216-2222, 1982.
164. Tepper, J., Rosenberg, S.A. and Glatstein, E.: Radiation therapy technique in soft tissue sarcomas of the extremity - policies of treatment at the National Cancer Institute. Intl. J. Radiat. Oncol. Biol. Phys. 8:263-273, 1982.
165. Dresdale, A., Bonow, R.O., Wesley, R., Palmeri, S.T., Barr, L., Mathieson, D., D'Angelo, T. and Rosenberg, S.A.: Prospective evaluation of doxorubicin induced cardiomyopathy resulting from post-surgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52:51-60, 1983.
166. Almaraz, R., Ballinger, W., Sachs, D.H. and Rosenberg, S.A.: The effect of peripheral lymphoid cells on the incidence of lethal graft versus host disease following allogeneic mouse bone marrow trans- plantation. J. Surg. Res. 34:133-144, 1983.
167. Sharp, T.G., Sachs, D.H., Fauci, A.S., Messerschmidt, G.L. and Rosenberg, S.A.: T-cell depletion of human bone marrow using monoclonal antibody and complement mediated lysis. Transplantation 35:112-120, 1983.
168. deMoss, E.V., Lichter, A.S., Lippman, M., Gerber, N.L., Reichert, C.M., Edwards, B.K., Schain, W.S., Gorrell, C.R., D'Angelo, T. and Rosenberg, S.A.: In: Harris, J.R., Hellman, S. and Silen, W. (eds.). Complete axillary lymph node dissection prior to radiotherapy for primary breast cancer. Conservative Management of Breast Cancer - New Surgical and Radiotherapeutic Techniques, Philadelphia: J.B. Lippincott, 1983, pp. 163-182.
169. Rosenberg, S.A.: What's new in surgery? Oncology. Bull. Am. Coll. Surgeons 68:26-29, 1983.
170. Rosenberg, S.A., Tepper, J., Glatstein, E., Costa, J., Young, R., Baker, A., Brennan, M.F., deMoss, E.V., Seipp, C., Sindelar, W.F., Sugarbaker, P.H. and Wesley, R.: Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 52:424-434, 1983.

171. Donohue, J.H. and Rosenberg, S.A.: The fate of interleukin-2 following in vivo administration. J. Immunol. 130:2203-2208, 1983.
172. Mazumder, A., Grimm, E.A. and Rosenberg, S.A.: The lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol. Immunother. 15:1-10, 1983.
173. Rosenstein, M., Eberlein, T., Schwarz, S. and Rosenberg, S.A.: Simplified techniques for the isolation of alloreactive cell lines and clones with specific cytotoxic or proliferative activity. J. Immunol. Methods 61:183-193, 1983.
174. Sindelar, W.F., Kinsella, T., Tepper, J., Travis, E.L., Rosenberg, S.A. and Glatstein, E.: Experimental and clinical studies with intraoperative radiotherapy. Surg. Gynecol. Obstet. 157:205-219, 1983.
175. Rosenberg, S.A., Spiess, P.J. and Schwarz, S.: In vivo administration of interleukin-2 enhances specific alloimmune responses. Transplantation 35:631-634, 1983.
176. Duncan, M.A., Lotze, M.T., Gerber, L.H. and Rosenberg, S.A.: Incidence recovery, and management of serratus anterior muscle palsy after axillary node dissection. Phys. Ther. 63:1243-1247, 1983.
177. Mazumder, A. and Rosenberg, S.A.: Lysis of fresh human solid tumors by activated autologous lymphocytes: Potential applications to tumor immunotherapy. In: Chabner, B.A. (ed.). Rational Basis for Chemotherapy, UCLA, Symposia on Molecular and Cellular Biology, New York: Alan R. Liss, Inc., 1983, Vol. 1, pp. 359-377.
178. Mazumder, A., Grimm, E.A. and Rosenberg, S.A.: Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. J. Immunol. 130:958-964, 1983.
179. Grimm, E.A., Gorelik, E., Rosenstein, M.M. and Rosenberg, S.A.: The lymphokine-activated killer cell phenomenon: In vitro and in vivo studies. In: Cohen, S. and Oppenheim, J. (eds.). Proceedings of the Third International Lymphokine Congress. New York: Academic Press, 1983, pp. 739-748.
180. Kim, B., Rosenstein, M., Weiland, D., Eberlein, T.J. and Rosenberg, S.A.: Clonal analysis of the lymphoid cells mediating skin allograft rejection in vivo by cloned Ly 1⁺2⁻ proliferative, noncytotoxic long term cell lines. Transplantation 36:525-532, 1983.
181. Grimm, E.A., Ramsey, K.M., Mazumder, A., Wilson, D.J., Djeu, J.Y. and Rosenberg, S.A.: Lymphokine-activated killer cell phenomenon: II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory CTL, and NK cells. J. Exp. Med. 157:884-897, 1983.

182. Putnam, J.B., Roth, J.A., Wesley, M.N., Johnston, M.R. and Rosenberg, S.A.: Survival following aggressive resection of pulmonary metastases from osteogenic sarcoma: Analysis of prognostic factors. Ann. Thorac. Surg. 36:516-523, 1983.
183. Grimm, E.A., Robb, R.J., Roth, J.A., Neckers, L.M., Lachman, L.B., Wilson, D.J. and Rosenberg, S.A.: Lymphokine-activated killer cell (LAK) phenomenon: III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK. J. Exp. Med. 158:1356-1361, 1983.
184. Mazumder, A., Rosenstein, M. and Rosenberg, S.A.: Lysis of fresh NK-resistant tumor cells by lectin activated syngeneic and allogeneic murine splenocytes. Cancer Res. 43:5729-5734, 1983.
185. Rosenberg, S.A.: Adjuvant chemotherapy of adult soft tissue sarcomas. In: Baker, L.H. (ed.). Soft Tissue Sarcomas. Boston: Martinus Nijhoff, 1983, pp. 85-99.
186. Weiland, D.J., Kim, B., Rosenstein, M. and Rosenberg, S.A.: Adoptive transfer of T-lymphocyte clones can mediate skin graft rejection. Surg. Forum 34:410-412, 1983.
187. Eberlein, T.J., Rosenstein, M. and Rosenberg, S.A.: Successful systemic adoptive immunotherapy of a disseminated solid syngeneic murine tumor with long-term cultured T cells. Transplant. Proc. 15:396-398, 1983.
188. Grimm, E.A. and Rosenberg, S.A. The human lymphokine-activated killer cell phenomenon. In: E. Pick, M. Candy, (ed.). Lymphokines, New York: Academic Press, 1983, pp. 279-311.
189. Putnam, J.B., Roth, J.A., Wesley, M.N., Johnston, M.R. and Rosenberg, S.A.: Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas. J. Thorac. Cardiovasc. Surg. 87:260-268, 1984.
190. Rosenstein, M., Eberlein, T.J. and Rosenberg, Steven A.: Adoptive immunotherapy of established syngeneic solid tumors: Role of T lymphoid subpopulations. J. Immunol. 132:2117-2122, 1984.
191. Donohue, J.H. and Rosenberg, S.A.: In vivo administration of lymphokines: A new approach to immune regulation. Surg. Forum 34:408-410, 1984.
192. Mazumder, A., Eberlein, T.J., Grimm, E.A., Wilson, D.J., Keenan, A.M., Aamodt, R. and Rosenberg, S.A.: Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53:896-905, 1984.
193. Lampert, M.H., Gerber, L.H., Glatstein, E., Rosenberg, S.A. and Danoff, J.V.: Soft tissue sarcoma: functional outcome after wide local excision and radiation therapy. Arch. Phys. Med. Rehabil. 65:477-480, 1984.

194. Keller, S.M., Rosenbaum, R.C. and Rosenberg, S.A.: The significance of bone scan abnormalities in patients with osteogenic sarcoma. J. Surg. Oncol. 26:122-129, 1984.
195. Flye, M.W., Woltering, G. and Rosenberg, S.A.: Aggressive pulmonary re-section for metastatic osteogenic and soft tissue sarcomas. Ann. Thorac. Surg. 37:123-127, 1984.
196. Rosenstein, M., Yron, I., Kaufmann, Y. and Rosenberg, S.A.: Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res. 44:1946-1953, 1984.
197. Rosenberg, S.A., Rosenstein, M., Grimm, E., Lotze, M. and Mazumder, A.: The use of lymphoid cells expanded in IL-2 for the adoptive immunotherapy of murine and human tumors. In: Allan L. Goldstein (ed.). Thymic Hormone and Lymphokines, New York: Plenum Publishing Corp, 1984, pp. 191-207.
198. Rosenstein, M. and Rosenberg, S.A.: The generation of lytic and proliferative clones to syngeneic tumor: In vitro and in vivo studies. J. Natl. Cancer Inst. 72:1161-1165, 1984.
199. Rosenberg, S.A.: Extremity soft tissue sarcomas. In: J.L. Cameron (ed.). Current Surgical Therapy, St. Louis: C.V. Mosby, 1984, pp. 544-547.
200. Mazumder, A. and Rosenberg, S.A.: Successful immunotherapy of NK-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J. Exp. Med. 159:495-507, 1984.
201. Donohue, J.H., Lotze, M.T., Robb, R.J., Rosenstein, M., Brazier, R.M., Jaffe, E.S. and Rosenberg, S.A.: In vivo administration of purified Jurkat-derived interleukin-2 in mice. Cancer Res. 44:1380-1386, 1984.
202. Donohue, J.H., Rosenstein, M., Chang, A.E., Lotze, M.T., Robb, R.J. and Rosenberg, S.A.: The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocyte to cure a disseminated syngeneic lymphoma. J. Immunol. 132:2123-2128, 1984.
203. Kaufmann, Y., Chang, A.E., Robb, R.J. and Rosenberg, S.A.: Mechanism of action of cyclosporin A: Inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas. J. Immunol. 133:3107-3111, 1984.
204. Rosenberg, S.A.: The adoptive immunotherapy of cancer: Accomplishments and prospects. Cancer Treat. Rep. 68:233-255, 1984.
205. Rosenberg, S.A.: The organization of surgical oncology in university departments of surgery. Surgery 95:632-634, 1984.

206. Rosenberg, S.A.: Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. J. Biol. Response Mod. 3:501-511, 1984.
207. Grimm, E.A., Vose, B.M., Chu, E.W., Wilson, D.J., Lotze, M.T., Rayner, A.A. and Rosenberg, S.A.: The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells from normal tissue. Cancer Immunol. Immunother. 17:83-89, 1984.
208. Rosenberg, S.A., Grimm, E.A., McGrogan, M., Doyle, M., Kawasaki, E., Kohts, K. and Mark, D.F.: Biological activity of recombinant human interleukin-2 produced in E. coli. Science 223:1412-1414, 1984.
209. Costa, J., Wesley, R.A., Glatstein, E. and Rosenberg, S.A.: The grading of soft tissue sarcomas: Results of a clinico-histo-pathological correlation in a series of 163 cases. Cancer 53:530-541, 1984.
210. Kaufmann, Y. and Rosenberg, S.A.: Blocking by cyclosporin A antigen-induced maturation and lymphokine secretion by cytotoxic T lymphocyte hybridomas. Transplantation 38:148-151, 1984.
211. Sharp, T.G., Sachs, D.H., Matthews, J.G., Maples, J., Woody, J.N. and Rosenberg, S.A.: Harvest of human bone marrow directly from bone. J. Immunol. Methods 69:187-195, 1984.
212. Lotze, M.T., Robb, R.J., Frana, L.W., Seipp, C.A., Sharrow, S.S., Longo, D.L., Gelmann, E.P. and Rosenberg, S.A.: Clinical studies with purified human IL-2 in patients with the acquired immuno- deficiency syndrome and cancer. UCLA Symposium on Acquired Immune Deficiency Syndrome, New York: Alan R. Liss, 198 1984, pp. 409-423.
213. Mulé, J.J., Shu, S., Schwarz, S.L. and Rosenberg, S.A.: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487-1489, 1984.
214. Rosenberg, S.A.: Prospective randomized trials demonstrating the efficacy of adjuvant chemotherapy in adult patients with soft tissue sarcomas. Cancer Treat. Rep. 68:1067-1078, 1984.
215. Rosenberg, S.A., Shu, S. and Mule, J.J.: Approaches to the adoptive immunotherapy of cancer. In: Tadao, A., Tsubura, E., and Urushizaki, I., (eds.). "Manipulation of Host Defense Mechanisms", Amsterdam: Excerpta Medica, 1984, pp. 70-81.
216. Chang, A.E. and Rosenberg, S.A.: Systemic administration of recombinant interleukin-2 in mice. Surg. Forum 35:137-139, 1984.

217. Rayner, A.A., Grimm, E.A., Lotze, M.T. and Rosenberg, S.A.: Demonstration of shared recognition and lysis of autologous and allogeneic fresh human tumors by cloned lymphokine activated killer (LAK) cells. Surg. Forum 35:415-417, 1984.
218. Lotze, M.T., Robb, R.J., Sharrow, S.O., Frana, L.W. and Rosenberg, S.A.: Systemic administration of interleukin-2 in humans. J. Biol. Response Mod. 3:475-482, 1984.
219. Lotze, M.T. and Rosenberg, S.A.: In vivo use of cytokines. Clin. Immunol. Newsletter 5:116-120, 1984.
220. Rosenberg, S.A.: The impact of emerging biotechnologies on cancer care. Am. Coll. Surg. Bull. 69:2-4, 1984.
221. Chang, A.E., Hyatt, C.L. and Rosenberg S.A.: Systemic administration of recombinant human interleukin-2 in mice. J. Biol. Response Mod. 3:561-572, 1984.
222. Ettinghausen, S.E., Mule, J.J. and Rosenberg, S.A.: Immunotherapy of lung micrometastases from a murine sarcoma with recombinant interleukin-2: Mechanism of action. Surg. Forum 36:394-396, 1985.
223. Matory, Y., Chang, A.E., Spiess, P. and Rosenberg, S.A.: Acute toxicity of recombinant interleukin-2 in rodents. Surg. Forum 36:411-412, 1985.
224. Lafreniere, R. and Rosenberg, S.A.: Successful therapy of hepatic metastases from several murine tumors using lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2). Surg. Forum 36:392-394, 1985.
225. Steller, E.P., Ottow, R.T., Sugarbaker, P.H., Matthews, W. and Rosenberg, S.A.: Recombinant IL-2 and adoptively transferred LAK cells in the treatment of experimental peritoneal carcinomatosis. Surg. Forum 36:390-392, 1985.
226. Rosenberg, S.A.: Combined-modality therapy of cancer. What is it and when does it work? N. Engl. J. Med. 312:1512-1514, 1985.
227. Mulé, J.J. and Rosenberg, S.A.: Successful adoptive immunotherapy of established metastases with lymphokine activated killer cells and recombinant interleukin-2. In: Herberman, R., Wiltout, Gorelik, E. (eds.). Immune Responses to Metastases, Volume 2, Boca Raton: CRC Press, 1985, pp. 69-94.
228. Glenn, J., Sindelar, W.F., Kinsella, T., Glatstein, E., Tepper, J., Costa, J., Baker, A., Sugarbaker, P., Brennan, M.F., Seipp, C., Wesley, R., Young, R.C. and Rosenberg, S.A.: Results of multi-modality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery 97:316-325, 1985.

229. Patow, C.A., Pruet, C.W., Fetter, T.W. and Rosenberg, S.A.: Nasogastric tube perforation of the nasopharynx. South. Med. J. 78:1362-1365, 1985.
230. Glenn, J., Kinsella, T., Glatstein, E., Tepper, J., Baker, A., Sugarbaker, P., Sindelar, W., Roth, J., Brennan, M., Costa, J., Seipp, C., Wesley, R., Young, R.C. and Rosenberg, S.A.: A randomized prospective trial of adjuvant chemotherapy in adults with soft-tissue sarcomas of the head and neck, breast and trunk. Cancer 55:1206-1214, 1985.
231. Rosenberg, S.A.: Adjuvant chemotherapy of adult patients with soft tissue sarcomas. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.). Important Advances in Oncology, Philadelphia: J.B. Lippincott, 1985, pp. 273-294.
232. Roth, J.A., Putnam, J.B., Wesley, M.N. and Rosenberg, S.A.: Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients. Cancer 55:1361-1366, 1985.
233. Mulé, J. J., Rosenstein, M., Shu, S. and Rosenberg, S.A.: Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes is dependent upon a host component(s). Cancer Res. 45:526-531, 1985.
234. Rayner, A.A., Grimm, E.A., Lotze, M.T., Wilson, D.J. and Rosenberg, S.A.: Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumors. J. Natl. Cancer Inst. 75:67-75, 1985.
235. Chang, A.E., Lotze, M.T., Ames, R.S., Roth, J.A. and Rosenberg, S.A.: A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma. J. Immunopharm. 7:17-31, 1985.
236. Reichert, C.M., Rosenstein, M., Von Glatz, J., Hsu, S.M. and Rosenberg, S.A.: Curative intravenous adoptive immunotherapy of Meth A murine sarcoma: A histologic and immunohistochemical assessment. Lab. Invest. 52:304-313, 1985.
237. Kaufmann, Y., Moscovitch, M., Robb, R.J., Rosenberg, S.A. and Berke, G.: Antigen/mitogen induced cytolytic activity and IL-2 secretion in memory-like CTL-hybridomas. In: Henkart, P. and Martz, H. (eds.). Mechanism of Cellular Mediated Cytotoxicity II, New York: Plenum Press, 1985, pp. 535-550.
238. Rosenberg, S.A., Seipp, C.A., White, D.E. and Wesley, R.: Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high grade soft tissue sarcomas of the extremities. J. Clin. Oncol. 3:698-709, 1985.
239. Shu, S. and Rosenberg, S.A.: Adoptive immunotherapy of newly-induced murine sarcomas. Cancer Res. 45:1657-1662, 1985.

240. Shapiro, E., Kinsella, T.J., Makuch, R.W., Fraass, B.A., Glatstein, E., Rosenberg, S.A. and Sherins, R.J.: Effects of fractionated irradiation of endocrine aspects of testicular function. J. Clin. Oncol. 3:1232-1239, 1985.
241. Longo, D.L., Steis, R.G., Lane, H.C., Lotze, M.T., Rosenberg, S.A., Preble, O., Masur, H., Rook, A.H., Fauci, A.S., Jacob, J. and Gelmann, E.P.: Malignancies in the AIDS patient: Natural history, treatment strategies, and preliminary results. Annu. NY Acad. Sci. Acquired Immune Deficiency Syndrome 437:421-430, 1985.
242. Mulé, J.J., Shu, S. and Rosenberg, S.A.: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J. Immunol. 135:646-652, 1985.
243. Potter, D.A., Glenn, J., Kinsella, T., Glatstein, E., Lack, E.E., Restrepo, C., White, D.E., Seipp, C.A., Wesley, R. and Rosenberg, S.A.: Patterns of recurrence in patients with high-grade soft tissue sarcomas. J. Clin. Oncol. 3:353-366, 1985.
244. Rosenberg, S.A., Mule, J.J., Spiess, P.J., Reichert, C.M. and Schwarz, S.: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant IL-2. J. Exp. Med. 161:1169-1188, 1985.
245. Lotze, M.T., Frana, L.W., Sharrow, S.O., Robb, R.J. and Rosenberg, S.A.: In vivo administration of purified human interleukin-2. I. Half life and immunologic effects of the Jurkat cell line derived IL-2. J. Immunol. 134:157-166, 1985.
246. Lotze, M.T., Matory, Y.L., Ettinghausen, S.E., Rayner, A.A., Sharrow, S.O., Seipp, C.A., Custer, M.C. and Rosenberg, S.A.: In vivo administration of purified human interleukin-2. II. Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol. 135:2865-2875, 1985.
247. Ettinghausen, S.E., Lipford, E.H., Mule, J.J. and Rosenberg, S.A.: Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues. J. Immunol. 135:1488-1497, 1985.
248. Lynch, D.H., Gress, R.E., Needleman, B.W., Rosenberg, S.A. and Hodes, R.J.: T cell responses to Mls determinants are restricted by cross-reactive MHC determinants. J. Immunol. 134:2071-2078, 1985.
249. Ettinghausen S.E., Lipford, E.H., Mule, J.J., and Rosenberg, S.A.: Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer (LAK) cells. J. Immunol. 135:3623-3635, 1985.
250. Matory, Y., Chang, A.E., Lipford, N., Brazier, R., Hyatt, C.L., McDonald, H.D. and Rosenberg S.A.: The toxicity of recombinant human interleukin-2 in rats following intravenous infusion. J. Biol. Response Mod. 4:377-390, 1985.

251. Sharp, T.A., Gress, R.E., Sachs, D.H. and Rosenberg, S.A.: Assessment of mixed lymphocyte reactivity in human bone marrow cell cultures. Transplantation 40:551-556, 1985.
252. Lotze, M.T. and Rosenberg, S.A.: Treatment of tumor patients with purified human interleukin-2. In: Cellular and Molecular Biology of Lymphokines, New York: Academic Press, 1985, pp. 711-721.
253. Lotze, M.T., Frana, L.W., Seipp, C.A., Sharrow, S.O., Rosenberg, S.A.: Immunologic changes in patients with cancer given interleukin-2 (IL-2) in a phase I trial. Surg. Forum 35:407-408, 1985.
254. Rosenberg, S.A. and Mule, J.J.: Immunotherapy of cancer with lymphokine activated killer cells and recombinant interleukin-2. Surgery 98:437-444, 1985.
255. Lafreniere, R. and Rosenberg, S.A.: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res. 45:3735-3741, 1985.
256. Kawamura, H., Rosenberg, S.A. and Berzofsky, J.A.: Immunization with antigen and interleukin-2 in vivo overcomes Ir genetic low responsiveness. J. Exp. Med. 162:381-385, 1985.
257. Rosenberg, S.A.: Lymphokine activated killer cells: A new approach to the immunotherapy of cancer. Guest editorial, J. Natl. Cancer Inst. 75:595-603, 1985.
258. Rayner, A.A., Grimm, E.A., Lotze, M.T., Chu, E.W. and Rosenberg, S.A.: Lymphokine-activated killer (LAK) cell phenomenon. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55:1327-1333, 1985.
259. Rosenberg, S.A.: The changing approach to cancer surgery. Hosp. Pract. 20:105-107, 1985.
260. Lafreniere, R. and Rosenberg, S.A.: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J. Immunol. 135:4273-4280, 1985.
261. Andriole, G., Mule, J.J., Hansen, C.T., Linehan, W.M. and Rosenberg, S.A.: Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J. Immunol. 135:2911-2913, 1985.
262. Shu, S. and Rosenberg, S.A.: Adoptive immunotherapy of a newly induced sarcoma: Immunologic characteristics of effector cells. J. Immunol. 135:2895-2903, 1985.

263. Kinsella, T.J., Sindelar, W.F., DeLuca, A.M., Pezeshkpour, G., Smith, R., Maher, M., Terrill, R., Miller, R., Mixon, A., Harwell, J.F., Rosenberg, S.A. and Glatstein, E.: Tolerance of peripheral nerve to intraoperative radiotherapy (IORT): Clinical and experimental studies. Intl. J. Radiat. Oncol. 11:1579-1585, 1985.
264. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J., Seipp, C.A., Simpson, C. and Reichert, C.M.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313:1485-1492, 1985.
265. Lafreniere, R., Mule, J.J. and Rosenberg, S.A.: Lymphokine activated killer cells and recombinant Interleukin-2: A new approach to the immunotherapy of cancer. In: Joji Ishigeui (ed.). Recent Advances in Chemotherapy, Kyoto: Tokyo Press, 1985, pp. 75-82.
266. Yang, J.C., Mule, J.J. and Rosenberg, S.A.: Characterization of the murine lymphokine-activated killer precursor and effector cell. Surg. Forum 36:408-410, 1985.
267. Lafreniere, R. and Rosenberg, S.A.: A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J. Natl. Cancer Inst. 76:309-322, 1986.
268. Mulé, J.J., Ettinghausen, S.E., Spiess, P.J., Shu, S. and Rosenberg, S.A.: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: An analysis of survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res. 46:676-683, 1986.
269. Rosenberg, S.A., Glatstein, E. and Chang, A.E.: The role of adjuvant chemotherapy in the treatment of soft tissue sarcomas: Review of NCI studies. In: A.T. van Oosterom, J.A.M. van Unnik (eds.). Management of Soft Tissue and Bone Sarcomas New York: Raven Press, 1986, pp. 201-214.
270. Chang, A.E., Sugarbaker, P.H. and Rosenberg, S.A.: Quality of life after different treatment modalities for soft tissue sarcoma: Review of NCI studies. In: A.T. van Oosterom, J.A.M. van Unnik (eds.). Management of Soft Tissue and Bone Sarcomas, New York: Raven Press, 1986, pp. 225-232.
271. Shu, S., Chou, T. and Rosenberg, S.A.: In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J. Immunol. 136:3891-3898, 1986.
272. Danforth, D.N., Jr., Findlay, P.A., McDonald, H.D., Lippman, M.E., Reichert, C.M., d'Angelo, T., Gorrell, C.R., Gerber, N.L., Rosenberg, S.A. and deMoss, E.V.: Complete axillary lymph node dissection for Stage I, II carcinoma of the breast. J. Clin. Oncol. 4:655-662, 1986.

273. Mulé, J.J., Yang, J., Shu, S. and Rosenberg, S.A.: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J. Immunol. 136:3899-3909, 1986.
274. Rosenberg, S.A. and Lotze, M.T.: Cancer immunotherapy using interleukin-2 and interleukin-2 activated lymphocytes. Annu. Rev. Immunol. 4:681-709, 1986.
275. Rosenberg, S.A.: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.). Important Advances in Oncology, Philadelphia: J.B. Lippincott, 1986, pp. 55-91.
276. Palmeri, S.T., Bonow, R.O., Myers, C.E., Seipp, C., Jenkins, J., Green, M.V., Bacharach, S.L. and Rosenberg, S.A.: Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am. J. Cardiol. 58:607-613, 1986.
277. Yang, J.C. and Rosenberg, S.A.: Immunotherapy of cancer with lymphokine-activated killer cells and interleukin 2. In: North, R.J. and Steiman, R.M. (eds.). Mechanisms of Host Resistance to Infectious Agents, Tumors and Allografts, New York: Rockefeller University Press, 1986, pp. 424-440.
278. Muul, L.M., Director, E.P., Hyatt, C.L. and Rosenberg, S.A.: Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J. Immunol. Methods 88:265-275, 1986.
279. Rosenberg, S.A.: The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin. Oncol. 13:200-206, 1986.
280. DeVita, V.T., Lippman, M., Hubbard, S.M., Ihde, D.C. and Rosenberg, S.A.: The effect of combined modality therapy on local control and survival. Int. J. Radiat. Oncol. Biol. Phys. 12:487-501, 1986.
281. Yang, J., Mule, J. and Rosenberg, S.A.: Murine lymphokine activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells. J. Immunol. 137:715-722, 1986.
282. Ettinghausen, S.E. and Rosenberg, S.A.: Immunotherapy of murine sarcomas using lymphokine activated killer (LAK) cells: Optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 46:2784-2792, 1986.
283. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Vetto, J.T., Seipp, C.A. and Simpson, C.: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2. Surgery 100:262-272, 1986.

284. Papa, M.Z., Mule, J.J. and Rosenberg, S.A.: The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and non-immunogenic murine tumors of three distinct histologic types. Cancer Res. 46:4973-4978, 1986.
285. Matis, L.A., Shu, S., Groves, E.S., Zinn, S., Chou, T., Kruisbeek, A.M., Rosenstein, M. and Rosenberg, S.A.: Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin-2: Correlation with clonal IL-2 receptor expression. J. Immunol. 136:3496-3501, 1986.
286. Lotze, M.T., Chang, A.E., Seipp, C.A., Simpson, C., Vetto, J.T. and Rosenberg, S.A.: High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity and histologic findings. J. Am. Med. Assoc. 256:3117-3124, 1986.
287. Rosenstein, M., Ettinghausen, S.E. and Rosenberg, S.A.: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J. Immunol. 137:1735-1742, 1986.
288. Rosenberg, S.A. and Mule, J.J.: New approaches to the adoptive immunotherapy of established metastatic cancer using lymphokine-activated killer cells and recombinant interleukin-2. In: Lapis, K, Liotta, LA, Rabson, AS (ed.). The Biochemistry and Molecular Genetics of Cancer Metastases, Boston: Martinus Nijhoff Publ., 1986, pp. 307-319.
289. Ettinghausen, S.E., Bonow, R.O., Palmeri, S.T., Seipp, C.A., Steinberg, S.M., White, D.E., and Rosenberg, S.A.: Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft tissue sarcomas. Arch. Surg. 121:1445-1451, 1986.
290. Potter, D.A., Kinsella, T., Glatstein, E., Wesley, R., White, D.E., Seipp, C.A., Chang, A.E., Lack, E.E., Costa, J. and Rosenberg, S.A.: High-grade soft tissue sarcomas of the extremities. Cancer 58:190-205, 1986.
291. Henkart, P.A., Yue, C.C., Yang, J. and Rosenberg, S.A.: Cytolytic and biochemical properties of cytoplasmic granules of lymphokine activated killer cells. J. Immunol. 137:2611-2617, 1986.
292. Chang, A.E., Shu, S., Chou, T., Lafreniere, R. and Rosenberg, S.A.: Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res. 46:3426-3430, 1986.
293. Seipp, C.A., Simpson, C. and Rosenberg, S.A.: Clinical trials with IL-2. Oncol. Nurs. Forum 13:25-29, 1986.

294. Ettinghausen, S.E. and Rosenberg, S.A.: The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. New Approaches to Immunotherapy - Springer Seminars to Immunopathology, Springer Seminars in Immunopathology, 9:51-71, 1986.
295. Rosenberg, S.A., Spiess, P. and Lafreniere, R.: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986.
296. Lotze, M.T. and Rosenberg, S.A.: Protocol design for lymphokine testing in clinical studies of human cancer. Lymphokine Res. 5:S177-S181, 1986.
297. Papa, M.Z., Vetto, J.T., Ettinghausen, S.E., Mule, J.J. and Rosenberg, S.A.: Effects of corticosteroid on the anti-tumor activity of lymphokine activated killer cells and interleukin-2 in mice. Cancer Res. 46:5618-5623, 1986.
298. Lotze, M.T. and Rosenberg, S.A.: Results of clinical trials with the administration of interleukin-2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology 172:420-437, 1986.
299. Lotze, M.T., Custer, M.C. and Rosenberg, S.A.: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch. Surg. 121:1373-1379, 1986.
300. Lotze, M.T., Matory, Y.L., Rayner, A.A., Ettinghausen, S.E., Vetto, J.T. Seipp, C.A. and Rosenberg, S.A.: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764-2772, 1986.
301. Shiloni, E., Lafreniere, R., Mule, J.J., Schwarz, S.L. and Rosenberg, S.A.: Effect of immunotherapy with allogeneic lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) on established pulmonary and hepatic metastases in mice. Cancer Res. 46:5633-5640, 1986.
302. Muul, L.M. and Rosenberg, S.A.: New approaches to the immunotherapy of cancer based on the systemic administration of lymphokine activated killer cells and recombinant interleukin-2. Immunol. 714-722, 1986.
303. Asher, A.L., Mule, J.J., Shiloni, E. and Rosenberg, S.A.: Anti-tumor activity of human recombinant tumor necrosis factor (hRTNF) against newly-induced murine tumors. Surg. Forum 37:427-430 1986.
304. Topalian, S.L., Muul, L.M. and Rosenberg, S.A.: Growth and immunologic characteristics of lymphocytes infiltrating human tumor. Surg. Forum 37:390-391, 1986.

305. Magrath, I., Sandlund, J., Rayner, A., Rosenberg, S.A., Arasi, V. and Miser, J.: A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother. Pharmacol. 25-28, 1986.
306. Rizzoni, W.E., Pass, H.I., Wesley, M.N., Rosenberg, S.A. and Roth, J.A.: Resection of recurrent pulmonary metastases in patients with soft-tissue sarcomas. Arch. Surg. 121:1248-1251, 1986.
307. Ward, B.A., Chou, T., Chang, A.E., Shu, S. and Rosenberg, S.A.: Specific adoptive immunotherapy: Characterization of lymphoid subpopulations involved in tumor rejection. Surg. Forum 37:416-418, 1986.
308. Lafreniere, R., Rosenstein, M. and Rosenberg, S.A.: In vitro expansion of lymphokine-activated killer cells leads to increased numbers of cells which can mediate the reduction of murine hepatic and pulmonary metastases when adoptively transferred with recombinant interleukin-2. Surg. Forum 37:394-396, 1986.
309. Belldgrun, A., Linehan, M., Robertson, C.N. and Rosenberg, S.A.: Isolation and characterization of lymphocytes infiltrating human renal cell cancer: Possible application for therapeutic adoptive immunotherapy. Surg. Forum 37:671-673, 1986.
310. Lefreniere, R., Rosenstein, M.S. and Rosenberg, S.A.: Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. J. Immunol. Methods 94:37-49, 1986.
311. Ettinghausen, S.E. and Rosenberg, S.A.: Vascular leak syndrome (VLS) associated with the administration of lymphokine-activated killer cells (LAK) and interleukin-2 (IL-2) to mice. Surg. Forum 37:388-389, 1986.
312. Vetto, J.T., Papa, M.Z., Lotze, M.T., Chang, A.E. and Rosenberg, S.A.: Reduction of toxicity of interleukin-2 and lymphokine activated killer cells in humans by the administration of corticosteroids. J. Clin. Oncol. 5:496-503, 1987.
313. Shiloni, E., Eisenthal, A., Sachs, D. and Rosenberg, S.A.: Antibody dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J. Immunol. 138:1992-1998, 1987.
314. Asher, A., Mule, J.J., Reichert, C.M., Shiloni, E. and Rosenberg, S.A.: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol. 138:963-974, 1987.
315. Ottow, R.T., Steller, E.P., Sugarbaker, P.H., Wesley, R.A. and Rosenberg, S.A.: Immunotherapy of intraperitoneal cancer with interleukin-2 and lymphokine activated killer cells reduces tumor load and prolongs survival in murine models. Cell. Immunol. 104:366-376, 1987.

316. Muul, L.M., Spiess, P.J., Director, E.P. and Rosenberg, S.A.: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138:989-995, 1987.
317. Chang, A.E., Matory, Y.L., Dwyer, A.J., Hill, S.C., Girton, M.E., Girton, R.T., Steinberg, S.M., Knop, R.H., Frank, J.A., Hyams, D., Doppman, J.L. and Rosenberg, S.A.: Magnetic resonance imaging versus computed tomography in the evaluation of soft tissue tumors of the extremities. Ann. Surg. 205:340-348, 1987.
318. Fauci, A.S., Rosenberg, S.A., Sherwin, S.A., Dinarello, C.A., Longo, D.L., and Lane, H.C.: NIH Conference. Immunomodulators in clinical medicine. Ann. Intern. Med. 106:421-433, 1987.
319. Lotze, M.T., Roberts, K., Custer, M.C., Segal, D.A. and Rosenberg, S.A.: Specific binding and lysis of human melanoma by IL-2 activated cells coated with anti-T3 or anti-Fc receptor cross-linked to anti-melanoma antibody: A possible approach to the immunotherapy of human tumors. J. Surg. Res. 42:580-589, 1987.
320. Ettinghausen, S.E., Moore, J.G., White, D.E., Platanius, L., Young, N.S. and Rosenberg, S.A.: Hematologic effects of immunotherapy with lymphokine activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69:1654-1660, 1987.
321. Edge, S.B., Funkhouser, W.K., Berman, A., Seipp, C., Tanner, A., Wesley, R., Rosenberg, S.A. and Chang, A.E.: High dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide induced emesis: A randomized double blind study. Am. J. Clin. Oncol. 10:257-263, 1987.
322. Lotze, M.T., Custer, M.C., Sharrow, S.O., Rubin, L.A., Nelson, D.L., and Rosenberg, S.A.: In vivo administration of purified human interleukin-2 to patients with cancer. Development of interleukin-2 receptor positive cells and circulating soluble IL-2 receptors following IL-2 administration. Cancer Res. 47:2188-2195, 1987.
323. Shu, S., Chou, T. and Rosenberg, S.A.: Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139:295-304, 1987.
324. Eisenthal, A., Lafreniere, R., Lefor, A.T. and Rosenberg, S.A.: Effect of anti B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res. 47:2771-2776, 1987.
325. Lynch, D.H., Weiland, D.J., Rosenberg, S.A. and Hodes, R.J.: Different specificities of cloned T cells assessed by in vitro proliferation assays and by the ability to mediate skin graft rejection in vivo. Transplantation 43:408-411, 1987.

326. Mulé, J.J. and Rosenberg, S.A.: Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. Prog. Clin. Biol. Response 244:79-91, 1987.
327. Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, J.T., Seipp, C.A., Simpson, C.G. and White, D.E.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med. 316:889-897, 1987.
328. Belldegrun, A., Webb, D.E., Austin, H.A., Steinberg, S.M., White, D.E., Linehan, W.M. and Rosenberg, S.A.: Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann. Int. Med. 106:817-822, 1987.
329. Mulé, J.J., Yang, J.C., Lafreniere, R., Shu, S. and Rosenberg, S.A.: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285-294, 1987.
330. Lotze, M.T. and Rosenberg, S.A.: Letter to the Editor. J. Am. Med. Assoc. 257:1730-1731, 1987.
331. Topalian, S.L., Muul, L.M., Solomon, D. and Rosenberg, S.A.: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127-141, 1987.
332. Skibber, J.M., Lotze, M.T., Uppenkamp, I., Ross, W. and Rosenberg, S.A.: Identification and expansion of human lymphokine activated killer cells: Implications for the immunotherapy of cancer. J. Surg. Res. 42:613-621, 1987.
333. Mulé, J.J., Smith, C.A. and Rosenberg, S.A.: Interleukin-4 (B-cell stimulatory factor-1) can mediate the induction of LAK activity directed against fresh tumor cells. J. Exp. Med. 166:792-797, 1987.
334. Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D. and Rosenberg, S.A.: The neuropsychiatric effects of the treatment with interleukin-2 and lymphokine activated killer cells. Ann. Intern. Med. 107:293-300, 1987.
335. Rosenberg, S.A.: Combined treatment approaches to soft tissue sarcomas. Hosp. Pract. 22:151-166, 1987.

336. Muul, L.M., Nason-Burchenal, K., Carter, C.S., Cullis, H., Slavin, D., Hyatt, C., Director, E.P., Leitman, S.F., Klein, H.G. and Rosenberg, S.A.: Development of an automated closed system for generation of human lymphokine activated killer (LAK) cells for use in adoptive immunotherapy. J. Immunol. Methods 101:171-181, 1987.
337. Roberts, K., Lotze, M.T. and Rosenberg, S.A.: Separation and functional studies of the human lymphokine activated killer cell. Cancer Res. 47:4366-4371, 1987.
338. Topalian, S.L. and Rosenberg, S.A.: Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Acta Haematologica. 78:75-76, 1987.
339. McKenna, W.G., Barnes, M.M., Kinsella, T.J., Rosenberg, S.A., Lack, E.E., and Glatstein, E.: Combined modality treatment of adult soft tissue sarcomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 13:1127-1133, 1987.
340. Rosenberg, S.A.: Letter to the Editor. N. Engl. J. Med. 317:962-963, 1987.
341. Carter, C.S., Leitman, S.F., Cullis, H., Muul, L.M., Nason-Burchenal, K., Rosenberg, S.A. and Klein, H.G.: Use of a continuous-flow cell separator in density gradient isolation of lymphocytes. Transfusion 27:362-365, 1987.
342. Skibber, J.M., Lotze, M.T., Seipp, C.A., Salicido, R. and Rosenberg, S.A.: Limb-sparing surgery for soft tissue sarcomas: Wound related morbidity in patients undergoing wide local excision. Surgery 102:447-452, 1987.
343. Muul, L.M., Burchenal, K., Hyatt, C., Schwarz, S., Slavin, D., Director, E.P. and Rosenberg, S.A.: Studies of serum free culture medium in the generation of lymphokine activated killer cells. J. Immunol. Methods 105:183-192, 1987.
344. Topalian, S.L. and Rosenberg, S.A.: Tumor-specific lysis by long-term cultured tumor infiltrating lymphocytes. Surg. Forum 38:434-435, 1987.
345. Cohen, P.J., Lotze, M.T., Roberts, J.R., Rosenberg, S.A. and Jaffe, E.S.: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am. J. Pathol. 129:208-216, 1987.
346. Weber, J.S., Jay, G., Tanaka, K. and Rosenberg, S.A.: Immunotherapy of a murine tumor with interleukin-2; increased sensitivity after MHC Class I gene transfection. J. Exp. Med. 166:1716-1733, 1987.
347. Wiebke, E.A., Lotze, M.T. and Rosenberg, S.A.: Tumor cell susceptibility to lysis: Marked increase in lysis by tumor infiltrating lymphocytes following target stimulation with interferon- α and tumor necrosis factor- α . Implications for immunotherapy. Surg. Forum 38:436-438, 1987.

348. Spiess, P.J., Yang, J.C. and Rosenberg, S.A.: In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 79:1067-1075, 1987.
349. Chang, A.E. and Rosenberg, S.A.: Immunotherapy of cancer utilizing interleukin-2 and lymphokine activated killer cells. In: Kimura K., et al. (eds.). Cancer Chemotherapy: Challenges for the Future, Volume 2, Amsterdam: Excerpta Medica, 1987, pp. 38-45.
350. Belldgrun, A., Topalian, S.L., Linehan, M., Robertson, C. and Rosenberg, S.A.: Growth and antitumor activity of tumor-involved draining lymph node cells versus tumor-infiltrating lymphocytes from patients with renal cell cancer. Surg. Forum 38:688-690, 1987.
351. Gaspari, A.A., Lotze, M.T., Rosenberg, S.A., Stern, J.B. and Katz, S.I.: Dermatologic changes associated with interleukin-2 administration. J. Am. Med. Assoc. 258:1624-1629, 1987.
352. Skibber, J.M., Lotze, M.T., Muul, L.M., Uppenkamp, I.K., Ross, W. and Rosenberg, S.A.: Human lymphokine-activated killer cells: Further isolation and characterization of the precursor and effector cell. Nat. Immun. Cell. Growth Regul. 6:291-305, 1987.
353. Matis, L.A., Bookman, M. and Rosenberg, S.A.: Cloning with antigens and interleukin-2 of murine T lymphocytes having distinct function. Methods Enzymol. 150:342-351, 1987.
354. Rosenberg, S.A. and Chang, A.E.: Adjuvant chemotherapy for the treatment of extremity soft-tissue sarcomas: National Cancer Institute Experience. In: W.F. Enneking (ed.). Limb Salvage in Musculoskeletal Oncology, New York: Churchill Livingstone Inc., 1987, pp. 327-332.
355. Cotran, R.S., Pober, J.S., Gimbrone, Jr., M.A., Springer, T.A., Wiebke, E.A., Gaspari, A.A., Rosenberg, S.A. and Lotze, M.T.: Endothelial activation during interleukin-2 (IL-2) immunotherapy: A possible mechanism for the vascular leak syndrome. J. Immunol. 140:1883-1888, 1988.
356. Belldgrun, A., Muul, L.M. and Rosenberg, S.A.: Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: Isolation, characterization and antitumor activity. Cancer Res. 48:206-214, 1988.
357. Rosenberg, S.A.: Development of new immunologic approaches to cancer therapy. Blood Purif. 6:69-76, 1988.
358. Belldgrun, A., Uppenkamp, I. and Rosenberg, S.A.: Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer. J. Urol. 139:150-155, 1988.

359. Papa, M.Z., Yang, J.C., Vetto, J.T., Shiloni, E., Eisenthal, A. and Rosenberg, S.A.: Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 48:122-129, 1988.
360. Rosenberg, S.A.: Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: DeVita, V., Hellman, S. and Rosenberg, S.A. (eds.). Important Advances in Oncology, Philadelphia: J.B. Lippincott, 1988, pp. 217-257.
361. Rosenberg, S.A.: The immunotherapy of cancer using interleukin-2: current status and future prospects. Immunol. Today 9:58-62, 1988.
362. Kern, K.A., Brunetti, A., Norton, J.A., Chang, A.E., Malawer, M., Lack, E., Finn, R.D., Rosenberg, S.A. and Larson, S.M.: Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med. 29:181-186, 1988.
363. Simpson, C., Seipp, C.A. and Rosenberg, S.A.: The current status and future applications of interleukin-2 and adoptive immunotherapy in cancer treatment. Semin. Oncol. Nurs. 4:132-141, 1988.
364. Topalian, S., Solomon, D., Avis, F.P., Chang, A.E., Freerksen, D.L., Linehan, W.M., Lotze, M.T., Robertson, C.N., Seipp, C.A., Simon, P., Simpson, C.G. and Rosenberg, S.A.: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J. Clin. Oncol. 6:839-853, 1988.
365. Mulé, J.J., Schwarz, S.L., Roberts, A.B., Sporn, M.B. and Rosenberg, S.A.: Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol. Immunother. 26:95-100, 1988.
366. Lefor, A.T., Eisenthal, A. and Rosenberg, S.A.: Heterogeneity of lymphokine activated killer cells induced by interleukin-2: Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts. J. Immunol. 140:4062-4069, 1988.
367. Carter, C.S., Leitman, S.F., Cullis, H., Muul, L.M., Nason-Burchenal, K., Rosenberg, S.A. and Klein, H.G.: Technical aspects of lymphokine-activated killer cell production. J. Clin. Apheresis 4:113-117, 1988.
368. Rosenberg, S.A., Lotze, M.T. and Mulé, J.J.: NIH Conference: New approaches to the immunotherapy of cancer using interleukin-2. Ann. Intern. Med. 108:853-864, 1988.
369. Eisenthal, A., Shiloni, E. and Rosenberg, S.A.: Characterization of IL-2 induced murine cells which exhibit ADCC activity. Cell. Immunol. 115:257-272, 1988.

370. Ettinghausen, S.E., Puri, R.K. and Rosenberg, S.A.: Increased vascular permeability in organs mediated by the systemic administration of lymphokine activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst. 80:177-188, 1988.
371. Kinsella, T.J., Sindelar, W.F., Lack, E., Glatstein, E. and Rosenberg, S.A.: Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas. J. Clin. Oncol. 6:18-25, 1988.
372. Saris, S.C., Rosenberg, S.A., Friedman, R.B., Rubin, J.T., Barba, D. and Oldfield, E.H.: Penetration of recombinant interleukin-2 across the blood cerebrospinal fluid barrier. J. Neurosurg. 69:29-34, 1988.
373. Eisenthal, A. and Rosenberg, S.A.: Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma. Clin. Expl. Metastasis 6:387-400, 1988.
374. Mulé, J.J., Asher, A., McIntosh, J., Lafreniere, R., Shiloni, E., Lefor, A., Reichert, C.M. and Rosenberg, S.A.: Anti-tumor effects of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: Tumor size influences the response to therapy. Cancer Immunol. Immunother. 26:202-208, 1988.
375. Chang, A.E., Kinsella, T., Glatstein, E., Baker, A.R., Sindelar, W.F., Lotze, M.T., Danforth, D.N., Sugarbaker, P.H., Lack, E.E., Steinberg, S.M., White, D.E. and Rosenberg, S.A.: Adjuvant chemotherapy for patients with high grade soft tissue sarcomas of the extremity. J. Clin. Oncol. 6:1491-1500, 1988.
376. Rosenberg, S.A.: The development of new immunotherapies for the treatment of cancer using interleukin-2: A review. Ann. Surg. 208:121-135, 1988.
377. McIntosh, J.K., Mulé, J.J., Merino, M.J. and Rosenberg, S.A.: Synergistic anti-tumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-a. Cancer Res. 48:4011-4017, 1988.
378. Wiebke, E.A., Rosenberg, S.A. and Lotze, M.T.: Acute immunologic effects of interleukin-2 therapy in cancer patients: Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J. Clin. Oncol. 6:1440-1449, 1988.
379. Ognibene, F.P., Rosenberg, S.A., Lotze, M., Skibber, J., Parker, M.M., Shelhamer, J.H. and Parrillo, J.E.: Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750-754, 1988.

380. Webb, D.E., Austin, H.A., Belldgrun, A., Vaughan, E., Linehan, W.M. and Rosenberg, S.A.: Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin. Nephrol. 30:141-145, 1988.
381. Aebersold, P., Carter, C.S., Hyatt, C., Johnson, S., Ottaway, K., Leitman, S.F. and Rosenberg, S.A.: A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials. J. Immunol. Methods 112:1-7, 1988.
382. Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J.P. and White, D.E.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319:1676-1680, 1988.
383. Yang, J.C. and Rosenberg, S.A.: Current approaches to the adoptive immunotherapy of cancer. Adv. Exp. Med. Biol. 233:459-467, 1988.
384. Schwartzentruber, D., Lotze, M.T. and Rosenberg, S.A.: Colonic perforation: An unusual complication of therapy with high-dose interleukin-2. Cancer 62:2350-2353, 1988.
385. Cameron, R.B., McIntosh, J.K. and Rosenberg, S.A.: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid interferon-alpha in the treatment of established murine hepatic metastases. Cancer Res. 48:5810-5817, 1988.
386. Weber, J.S. and Rosenberg, S.A.: Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 48:5818-5824, 1988.
387. Rosenberg, S.A.: Cancer therapy with interleukin-2: Immunologic manipulations can mediate the regression of cancer in humans. J. Clin. Oncol. 6:403-406, 1988.
388. Kawakami, Y., Rosenberg, S.A. and Lotze, M.T.: Interleukin-4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168:2183-2191, 1988.
389. Rosenberg, S.A., Schwarz, S. and Spiess, P.: Combination immunotherapy for cancer: Synergistic anti-tumor interactions of interleukin-2, alpha-interferon and tumor infiltrating lymphocytes. J. Natl. Cancer Inst. 80:1393-1397, 1988.
390. Chang, A.E. and Rosenberg, S.A.: Clinical evaluation and treatment of soft tissue tumors. In: Enzinger, F.M. and Weiss, S.W. (eds.). Soft Tissue Tumors, St. Louis: C.V. Mosby, 1988, pp. 19-42.

391. Lotze, M.T. and Rosenberg, S.A.: Interleukin-2 as a pharmacologic reagent. In: K. Smith (ed.). Lymphokines, Orlando: Academic Press, 1988.
392. Eisenthal, A., Cameron, R.B. Uppenkamp, I. and Rosenberg, S.A.: Effect of combined therapy with lymphokine activated killer (LAK) cells, interleukin-2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res. 48:7140-7145, 1988.
393. Belldegrün, A., Kasid, A., Uppenkamp, M. and Rosenberg, S.A.: Cellular and molecular characterization of a helper/inducer T cell clone with lytic specificity isolated from renal cell carcinoma ascitic fluid. Surg. Forum 39:698-700, 1988.
394. Lee, R.E., Gaspari, A.A., Lotze, M.T., Chang, A.E. and Rosenberg, S.A.: Interleukin-2 and psoriasis. Arch. Dermatol. 124:1811-1815, 1988.
395. McIntosh, J.K., Mulé, J.J., Krosnick, J. and Rosenberg, S.A.: Combination lymphokine therapy: Synergistic antitumor effects of tumor necrosis factor, interleukin-2, and interferon-alpha against established murine subdermal and hepatic tumors. Surg. Forum 39:452-454, 1988.
396. Lotze, M.T. and Rosenberg, S.A.: The immunologic treatment of cancer. CA - Cancer J. Clinicians 38:68-94, 1988.
397. Mulé, J.J., Krosnick, J.A. and Rosenberg, S.A.: Interleukin-4 regulation of murine lymphokine-activated killer (LAK) activity in vitro: Effects on the interleukin-2 induced expansion, cytotoxicity and phenotype of LAK effectors. J. Immunol. 142:726-733. 1989.
398. Fisher, B., Packard, B.S., Read, E.J., Carrasquillo, J.A., Carter, C.S., Topalian, S.L., Yang, J.C., Yolles, P., Larson, S.M. and Rosenberg, S.A.: Tumor localization of adoptively transferred Indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7:250-261, 1989.
399. Lefor, A.T., Mulé, J.J. and Rosenberg, S.A.: Lymphokine activated killer cells: Biology and therapeutic efficacy. In: Reynolds, C.W. and Wiltout, R.H. (eds.). Functions of the Natural Immune System, New York: Plenum Publ. Co., 1989, pp. 39-56.
400. Lee, R.E., Lotze, M.T., Skibber, J.M., Tucker, E., Bonow, R.O., Ognibene, F.P., Carrasquillo, J.A., Shelhamer, J.H., Parillo, J.E. and Rosenberg, S.A.: Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 7:7-20, 1989.
401. McIntosh, J.K., Mulé, J.J., Krosnick, J.A. and Rosenberg, S.A.: Combination cytokine immunotherapy with tumor necrosis factor-alpha, interleukin-2 and interferon-alpha and its synergistic antitumor effects in mice. Cancer Res. 49:1408-1414, 1989.

402. Belldegrun, A., Webb, D.E., Austin, H.A., Steinberg, S.M., Linehan, W.M. and Rosenberg, S.A.: Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancers: Effect of pretherapy nephrectomy. J. Urol. 141:499-503, 1989.
403. Mulé, J.J. and Rosenberg, S.A.: Immunotherapy with lymphokine combinations. In: DeVita, H., Hellman, S. and Rosenberg, S.A. Important Advances in Oncology, Philadelphia: J.B. Lippincott, 1989, pp. 99-126.
404. Stotter, H., Wiebke, E.A., Tomita, S., Belldegrun, A., Topalian, S., Rosenberg, S.A. and Lotze, M.T.: Cytokines alter target cell susceptibility to lysis: II. Evaluation of tumor infiltrating lymphocytes. J. Immunol. 142:1769-1777, 1989.
405. Jablons, D.M., Mulé, J.J., McIntosh, J.K., Sehgal, P.B., May, L.T., Huang, C.M., Rosenberg, S.A. and Lotze, M.T.: Interleukin-6/interferon B-2 as a circulating hormone: Induction by cytokine administration in humans. J. Immunol. 142:1542-1547, 1989.
406. Eisenthal, A. and Rosenberg, S.A.: The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2 induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha. J. Immunol. 142:2307-2313, 1989.
407. McIntosh, J.K., Jablons, D.M., Mulé, J.J., Nordan, R.P., Rudikoff, S., Lotze, M.T. and Rosenberg, S.A.: In vivo induction of interleukin-6 by administration of exogenous cytokines and detection of de novo serum levels of interleukin-6 in tumor bearing mice. J. Immunol. 143:162-167, 1989.
408. Puri, R.K., Travis, W.D. and Rosenberg, S.A.: Decrease in interleukin-2 induced vascular leakage in the lungs of mice by administration of recombinant interleukin-1 alpha in vivo. Cancer Res. 49:969-976, 1989.
409. Barba, D., Saris, S.C., Holder, C., Rosenberg, S.A. and Oldfield, E.H.: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70:175-182, 1989.
410. Linehan, W.M., Robertson, C.N. and Rosenberg, S.A.: Clinical experience with adoptive immunotherapy in patients with renal cell carcinoma. In: Rouse, S.N. (ed.). 1989 Urology Annual, Norwalk: Appleton & Lange, 1989, pp. 131-137.
411. Jablons, D.M., Steinberg, S.M., Roth, J., Pittaluga, S., Rosenberg, S.A. and Pass, H.I.: Metastasectomy for soft tissue sarcoma: Further evidence for efficacy and prognostic indicators. J. Thorac. Cardiovas. Surg. 97:695-705, 1989.
412. Kawakami, Y., Custer, M.C., Rosenberg, S.A. and Lotze, M.T.: IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes. J. Immunol. 142:3452-3461, 1989.

413. Asher, A.L., Mulé, J.J. and Rosenberg, S.A.: Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2⁺ cells. Cancer Immunol. Immunother. 28:153-156, 1989.
414. Topalian, S.L., Solomon, D. and Rosenberg, S.A.: Tumor-specific cytotoxicity by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714-3725, 1989.
415. Denicoff, K.D., Durkin, T.M., Lotze, M.T., Quinlan, P.E., Davis, C.L., Listwak, S.J., Rosenberg, S.A. and Rubinow, D.R.: The neuroendocrine effects of interleukin-2 treatment. J. Clin. Endocrin. Metabol. 69:402-410, 1989.
416. Fox, B.A. and Rosenberg, S.A.: Heterogeneous lymphokine activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. Cancer Immunol. Immunother. 29:155-166, 1989.
417. Saris, S.C., Patronas, N.J., Rosenberg, S.A., Alexander, J., Frank, J., Schwartzentruber, D.T., Rubin, J.T., Barba, D. and Oldfield, E.H.: The effect of intravenous interleukin-2 on brain water content. J. Neurosurg. 71:169-174, 1989.
418. Rosenberg, S.A.: Clinical immunotherapy studies in the Surgery Branch, National Cancer Institute: Brief Review. Cancer Treat. Rev. 16:(Suppl. A), 115-121, 1989..E., White, D.E., Yang, J.C., Glatstein, E. and Rosenberg, S.A.: Functional and psychosocial effects of multimodality limb-sparing therapy in patients with soft tissue sarcomas. J. Clin. Oncol. 7:1217-1228, 1989.
421. Krosnick, J.A., Mulé, J.J., McIntosh, J.K. and Rosenberg, S.A.: Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 49:3729-3733, 1989.
422. Belldegrun, A., Kasid, A., Uppenkamp, M., Topalian, S. and Rosenberg, S.A.: Human tumor infiltrating lymphocytes: Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J. Immunol. 142:4520-4526, 1989.
423. Belldegrun, A. and Rosenberg, S.A.: Adoptive immunotherapy of urological tumors. Cancer Treat. Rep. 46:213-233, 1989.
424. Puri, R.K. and Rosenberg, S.A.: Combined effects of interferon- α and interleukin-2 on the induction of a vascular leak syndrome in mice. Cancer Immunol. Immunother. 28:267-274, 1989.
425. Yang, J.C. and Rosenberg, S.A.: Surgery for adult patients with soft tissue sarcomas. Semin. Oncol. 16:289-296, 1989.

426. Lotze, M.T., Kawakami, Y. and Rosenberg, S.A.: Immunotherapy protocols at the National Cancer Institute: Current status and future prospects. In: Fradelizi, D., Bertoglio, J. (eds.). Lymphokine Receptor Interactions, Germany: John Libbey Eurotext Ltd., 1989, 179:153-162.
427. Rosenberg, S.A., Longo, D.L. and Lotze, M.T.: Principles and applications of biologic therapy. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.): Cancer, Principles and Practices of Oncology, 3rd Edition, Philadelphia: J.B. Lippincott, 1989, pp. 301-348.
428. Chang, A.E., Rosenberg, S.A., Glatstein, E. and Antman, K.: Sarcomas of Soft tissues. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds.). Cancer, Principles and Practice of Oncology, 3rd Edition, Philadelphia: J.B. Lippincott, 1989, pp. 1342-1398.
429. Rosenberg, S.A.: Principles of Surgical Oncology. In: DeVita, V.T., Hellman, S., and Rosenberg, S.A. (eds.). Cancer, Principles and Practice of Oncology, 3rd Edition, Philadelphia: J.B. Lippincott, 1989, pp. 236-244.
430. Eisenthal, A. and Rosenberg, S.A.: Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin-2 . Cancer Res. 49:6953-6959, 1989.
431. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Aebersold, P.M., Linehan, W.M., Seipp, C.A. and White, D.E.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210:474-484, 1989.
432. Krosnick, J.A., McIntosh, J.K., Mulé, J.J. and Rosenberg, S.A.: Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor in normal and tumor-bearing mice. Cancer Immunol. Immunother. 30:133-138, 1989.
433. Lack, E.E., Steinberg, S.M., White, D.E., Kinsella, T., Glatstein, E., Chang, A.E. and Rosenberg, S.A.: Extremity soft tissue sarcomas. Analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. J. Surg. Oncol. 41:263-273, 1989.
434. Lotze, M.T., Jablons, D.M., Rubin, J.T., Chang, A.E. and Rosenberg, S.A.: Cytokine therapy of patients with cancer. Prog. Immunol. 7:1213-1220, 1989.
435. Barth, R.J., Mule, J.J., Bock, S. and Rosenberg, S.A.: Generation of rapidly proliferating tumor infiltrating lymphocytes with cytolytic specificity and therapeutic efficacy in mice. Surg. Forum 40:431-433, 1989.
436. Kasid, A., Director, E. and Rosenberg, S.A.: Regulation of interleukin-6 (IL-6) by IL-2 and TNF- α in human peripheral blood mononuclear cells. Annu. NY Acad. Sci., USA 557:564-566, 1989.

437. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Linehan, W.M., Seipp, C.A., Calabro, S., Karp, S.E., Sherry, R.M., Steinberg, S. and White, D.E.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7:1863-1874, 1989.
438. Chang, A.E. and Rosenberg, S.A.: Overview of interleukin-2 as an immunotherapeutic agent. Semin. Surg. Oncol. 5:385-390, 1989.
439. Griffith, K.D., Read, E.J., Carrasquillo, J.A., Carter, C.S., Yang, J.C., Fisher, B., Aebersold, P., Packard, B.S., Yu, M.Y. and Rosenberg, S.A.: In vivo distribution of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 81:1709-1717, 1989.
440. Rubin, J.T., Elwood, L.J., Rosenberg, S.A. and Lotze, M.T.: Immuno- histochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res. 49:7086-7092, 1989.
441. Fisher, B., Keenan, A.M., Garra, B.S., Steinberg, S.M., White, D.E., DiBisceglie, A.M., Hoofnagle, J.H., Yolles, P., Rosenberg, S.A. and Lotze, M.T.: Interleukin-2 induces profound reversible cholestasis: A detailed analysis in treated cancer patients. J. Clin. Oncol. 7:1852-1862, 1989.
442. Jablons, D.M., Mulé, J.J., McIntosh, J.K., Sehgal, P.B., May L.T., Huang, C.M., Rosenberg, S.A. and Lotze, M.T.: IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J. Immunol. 142:1542-1547, 1989.
443. Lotze, M.T., Tomita, S. and Rosenberg, S.A.: Human tumor antigens by cytotoxic and proliferative T cells. Human Tumor Antigens and Specific Tumor Therapy, 167-179, 1989.
444. McIntosh, J.K., Mulé, J.J., Jablons, D.M., Nordon, R.P., Rudikoff, S., Lotze, M.T. and Rosenberg, S.A.: The kinetics of interleukin-6 induction by the systemic administration of rhTNF-alpha in mice. Ann. NY Acad Sci., 557:572-575, 1989.
445. Kasid, A., Morecki, S., Aebersold, P., Cornetta, K., Culver, K., Freeman, S., Director, E., Lotze, M.T., Blaese, R.M., Anderson, W.F. and Rosenberg, S.A.: Human gene transfer: Characterization of human tumor infiltrating lymphocytes as vehicles for retroviral mediated gene transfer in man. Proc. Natl. Acad. Sci. 87:473-477, 1990.
446. Linehan, W.M., Robertson, C.N., and Rosenberg, S.A.: Adoptive immunotherapy of renal cell carcinoma using lymphokine activated killer cells and recombinant interleukin-2. In: Williams, R.D. (ed.) Advances in Urologic Oncology: Treatment Perspectives, New York: Pergamon Press, 1990, pp. 37-54.

447. Bock, N., Lee, R.E., Fisher, B., Rubin, J.T., Schwartzentruber, D., Wei, J.P., Callender, D.P.E., Yang, J.C., Lotze, M.T., Pizzo, P.A. and Rosenberg, S.A.: A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J. Clin. Oncol. 8:161-169, 1990.
448. Rosenberg, S.A.: Biologic therapy of cancer using recombinant cytokines: Current status and future possibilities. Editorial, Mediscript 11-18, 1990.
449. Cameron, R.B., Spiess, P.J. and Rosenberg, S.A.: Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin-2, and local tumor irradiation: Studies on the mechanism of action. J. Exp. Med. 171:249-263, 1990.
450. Haas, G.P., Solomon, D. and Rosenberg, S.A.: Tumor infiltrating lymphocytes from non-renal urologic malignancies. Cancer Immunol. Immunother. 30:342-350, 1990.
451. Barth, R.J., Bock, S.N., Mulé, J.J. and Rosenberg, S.A.: Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J. Immunol. 144:1531-1537, 1990.
452. Mulé, J.J., McIntosh, J.K., Jablons, D.M. and Rosenberg, S.A.: Antitumor activity of recombinant interleukin-6 in mice. J. Exp. Med. 171:629-636, 1990.
453. Rosenberg, S.A.: Adoptive immunotherapy for cancer. Sci. Am. 262:62-69, 1990.
454. Wiebke, E.A., Custer, M.C., Rosenberg, S.A. and Lotze, M.T.: Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-MHC restricted effectors reveals differential effects on natural and lymphokine-activated killing. J. Biol. Response Mod. 9:113-126, 1990.
455. Eisenthal, A., Cameron, R.B. and Rosenberg, S.A.: Induction of anti-body-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J. Immunol. 144:4463-4471, 1990.
456. Topalian, S.L., Kasid, A. and Rosenberg, S.A.: Immunoselection of a human melanoma resistant to specific lysis by autologous tumor infiltrating lymphocytes: Possible mechanisms for immunotherapeutic failures. J. Immunol. 144:4487-4495, 1990.
457. Hauser, G.J., McIntosh, J.K., Travis, W.D. and Rosenberg, S.A.: Manipulation of oxygen radical scavenging capacity in mice alters host sensitivity to the toxicity of recombinant human tumor necrosis factor toxicity, but does not interfere with its anti-tumor efficacy. Cancer Res. 50:3503-3508, 1990.
458. Jablons, D., Bolton, E., Mertins, S., Rubin, M., Pizzo, P., Rosenberg, S.A. and Lotze, M.T.: Interleukin-2 based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. J. Immunol. 144:3630-3636, 1990.

459. McIntosh, J.K., Mulé, J.J., Travis, W.D. and Rosenberg, S.A.: Studies of the effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res. 50:2463-2469, 1990.
460. Kragel, A.H., Travis, W.D., Feinberg, L., Pittalugia, S., Striker, L.M., Roberts, W.C., Lotze, M.T., Yang, J.J. and Rosenberg, S.A.: Pathologic findings associated with interleukin-2 based immunotherapy for cancer: A postmortem study of 19 patients. Hum. Pathol. 21:493-502, 1990.
461. Lotze, M.T., Custer, M.C., Bolton, E.S., Wiebke, E.A., Kawakami, Y. and Rosenberg, S.A.: Mechanisms of immunologic antitumor therapy: Lessons from the laboratory and clinical applications. Hum. Immunol. 28:198-207, 1990.
462. Topalian, S.L. and Rosenberg, S.A.: Cellular immunotherapy of cancer. Crit. Care Med. 18:S144, 1990.
463. Belldgrun, A., Kasid, A., Uppenkamp, M. and Rosenberg, S.A.: Lymphokine mRNA profile and functional analysis of a human CD4⁺ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid. Cancer Immunol. Immunother. 31:1-10, 1990.
464. Yang, J.C., Perry-Lalley, D. and Rosenberg, S.A.: An improved method for growing murine tumor infiltrating lymphocytes with in vivo antitumor activity. J. Biol. Response Mod. 9:149-159, 1990.
465. Huang, C.M., Elin, R.J., Rudel, M., Sliva, C., Elin, R.J., Lotze, M.T. and Rosenberg, S.A.: Changes in laboratory results for cancer patients treated with interleukin-2. Clin. Chem. 36:431-434, 1990.
466. Topalian, S.L. and Rosenberg, S.A.: Tumor infiltrating lymphocytes (TIL). Evidence for specific immune reactions against growing cancers in mice and humans. In: DeVita, V.T., Hellman, S., and Rosenberg, S.A. (eds.). Important Advances In Oncology, Philadelphia: J.B. Lippincott, 1990, pp. 19-41.
467. Skornick, Y., Topalian, S. and Rosenberg, S.A.: Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes and peripheral blood by repeated in vitro stimulation with autologous tumor. J. Biol. Response Mod. 9:431-438, 1990.
468. Knazek, R.A., Wu, Y.W., Aebersold, P.M. and Rosenberg, S.A.: Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. J. Immunol. Methods 127:29-37, 1990.

469. Rosenberg, S.A.: Immunotherapy with recombinant cytokines and activated lymphocytes in patients with advanced cancer: Review of Surgery Branch, NCI experience. In: Salmon, S.E. (ed.). Adjuvant Therapy of Cancer, Philadelphia: W.B. Saunders, 1990, pp. 33-38.
470. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topalian, S.L., Merino, M.J., Culver, K., Miller, A.D.E., Blaese, R.M. and Anderson, W.F.: Gene transfer into humans: Immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:570-578, 1990.
471. Morecki, S., Topalian, S., Myers, W.W., Okrongla, D., Okarma, T.B. and Rosenberg, S.A.: Separation and growth of human CD4⁺ and CD8⁺ tumor infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody coated flasks. J. Biol. Response Mod. 9:463-474, 1990.
472. Robertson, C.N., Linehan, W.M., Pass, H.I., Gomella, L.G., Haas, G.P., Berman, A., Merino, M. and Rosenberg, S.A.: Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus LAK cells. J. Urol. 144:614-618, 1990.
473. Alexander, R.B. and Rosenberg, S.A.: Long term survival of adoptively-transferred tumor infiltrating lymphocytes in mice. J. Immunol. 145:1615-1620, 1990.
474. Rosenberg, S.A.: The immunotherapy of human cancer: From laboratory to bedside. In: Lotze, M.T., Finn, O.J. (eds.). Cellular Immunity & the Immunotherapy of Cancer, New York: Wiley-Liss, 1990, pp. 383-393.
475. Mulé, J.J. and Rosenberg, S.A.: Murine sarcomas: Definition of elements responsible for successful immunotherapy. In: Lotze, M.T., Finn, O.J., (eds.). Cellular Immunity and the Immunotherapy of Cancer, New York: Wiley-Liss, 1990, pp. 223-234.
476. Kragel, A.H., Travis, W.D., Steis, R.G., Rosenberg, S.A. and Roberts, W.C.: Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66:1153-1516, 1990.
477. Hom, S.S., Topalian, S.L. and Rosenberg, S.A.: MHC class I antigen restriction of tumor recognition by lymphocytes infiltrating human melanomas. Surg. Forum 41:428-429, 1990.
478. Weber, J.S. and Rosenberg, S.A.: Effects of murine tumor I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J. Natl. Cancer Inst. 82:755-761, 1990.

479. Aebersold, P., Kasid, A. and Rosenberg, S.A.: Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: A case study. Hum. Gene Ther. 1:373-384, 1990.
480. Fox, B.A., Spiess, P.J., Kasid, A., Puri, R., Mulé, J.J., Weber, J.S. and Rosenberg, S.A.: In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J. Biol. Response Mod. 9:499-511, 1990.
481. Lefor, A.T. and Rosenberg, S.A.: The specificity of lymphokine-activated killer (LAK) cells in vitro: Fresh normal murine tissues are resistant to LAK-mediated lysis. J. Surg. Res. 50:15-23, 1991.
482. Rosenberg, S.A.: Biologics in diagnosis and treatment of human disease: Portents of things to come. In: Harrison, D.C., Osterweis, M., and Rubin, E.R. (eds.). Preparing for Science in the 21st Century, Washington: Assoc. of Academic Health Centers, 1991, pp. 34-39.
483. Morecki, S., Karson, E., Cornetta, K., Kasid, A., Aebersold, P., Blaese, R.M., Anderson, W.F. and Rosenberg, S.A.: Retrovirus-mediated gene transfer into CD4⁺ and CD8⁺ human T cell subsets derived from tumor infiltrating lymphocytes and peripheral blood mononuclear cells. Cancer Immunol. Immunother. 32:342-352, 1991.
484. Mulé, J.J., Jicha, D.L., Aebersold, P.M., Travis, W.D. and Rosenberg, A.: Disseminated human malignant melanoma in congenitally immune-deficient (Bg/Nu/Xid) mice. J. Natl. Cancer Inst. 83:350-355, 1991.
485. Barth, R.J., Mulé, J.J., Spiess, P.J. and Rosenberg, S.A.: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8⁺ tumor infiltrating lymphocytes. J. Exp. Med. 173:647-658, 1991.
486. Culver, K., Cornetta, K., Morgan, R., Morecki, S., Aebersold, P., Kasid, A., Lotze, M., Rosenberg, S.A., Anderson, W.F. and Blaese, R.M.: Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc. Natl. Acad. Sci. USA 88:3155-3159, 1991.
487. Wong, R.A., Alexander, R.B., Puri, R.K. and Rosenberg, S.A.: In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice. J. Immunol. 10:120-130, 1991.
488. Karpati, R.M., Banks, S.M., Malissen, B., Rosenberg, S.A., Sheard, M.A., Weber, J.S. and Hodes, R.J.: Phenotypic characterization of murine tumor-infiltrating T lymphocytes. J. Immunol. 146:2043-2051, 1991.
489. Rosenberg, S.A.: Development of adoptive cellular immunotherapies for the treatment of cancer. In: Broder, S. (ed.) Molecular Foundations of Oncology, Baltimore: Williams & Wilkins, 1991, pp 153-193.

490. Bock, S.N., Cameron, R.B., Kragel, P., Mulé, J.J. and Rosenberg, S.A.: Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice. Cancer Res. 51:2649-2654, 1991.
491. Asher, A.L., Mulé, J.J., Kasid, A., Restifo, N.P., Salo, J.C., Reichert, C., Jaffe, G., Fendly, B., Kriegler, M. and Rosenberg, S.A.: Murine tumor cells transduced with the gene for TNF-alpha: Evidence for paracrine immune effects of TNF against tumors. J. Immunol. 146:3227-3234, 1991.
492. Hom, S.S., Topalian, S.L., Simoni, S.T., Mancini, M.J. and Rosenberg, S.A.: Common expression of melanoma tumor-associated antigens recognized by human tumor-infiltrating lymphocytes: Analysis by HLA restriction. J. Immunother. 10:153-164, 1991.
493. Schwartzentruber, D.J., Topalian, S.L., Mancini, M.J. and Rosenberg, S.A.: Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor- α , and IFN- γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J. Immunol. 146:3674-3681, 1991.
494. Rosenberg, S.A.: The development of new approaches to the immunotherapy of cancer using recombinant cytokines and gene transfer. In Najarian, J.S. and Delaney, J.P. (eds.). Progress in Cancer Surgery, Philadelphia: J.B. Lippincott, 1991, pp. 1-6.
495. Aebbersold, P., Hyatt, C., Johnson, S., Hines, K., Korcak, L., Sanda, M., Lotze, M.T., Topalian, S.L., Yang, J.C. and Rosenberg, S.A.: Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: Association with clinical response. J. Natl. Cancer Inst., 83:13:932-937, 1991.
496. Barth, R.J., Mulé, J.J., Asher, A.L., Sanda, M.G. and Rosenberg, S.A.: Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. J. Immunol. Methods 140:269-279, 1991.
497. Pogrebniak, H.W., Roth, J.A., Steinberg, S.M., Rosenberg, S.A. and Pass, H.I.: Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma. Ann. Thorac. Surg. 52:197-203, 1991.
498. Rosenberg, S.A.: Immunotherapy and gene therapy of cancer. Cancer Res. (Suppl.) 51:5074s-5079s, 1991.
499. Restifo, N.P., Esquivel, F., Asher, A.L., Stotter, H., Barth, R.J., Bennink, J.R., Mulé, J.J., Yewdell, J.W. and Rosenberg, S.A.: Defective presentation of endogenous antigens by a murine sarcoma: Implications for the failure of an antitumor immune response. J. Immunol. 147:1453-1459, 1991.

500. Sherry, R.M., Rosenberg, S.A. and Yang, J.C.: Relapse after response to IL-2 based immunotherapy: Patterns of progression and response to retreatment. J. Immunother. 10:371-375, 1991.
501. Schwartzentruber, D.J., Topalian, S.L. and Rosenberg, S.A.: Characterization of lymphocytes infiltrating human breast carcinomas: Evidence of specific immune reactivity. Surg. Forum 42:480-482, 1991.
502. Karp, S.E., Salo, J.C., Jaffe, G., Mulé, J.J. and Rosenberg, S.A.: Regression of a nonimmunogenic murine tumor after retroviral-mediated insertion of the IL-2 gene. Surg. Forum 42:467-469, 1991.
503. Schwartzentruber, D.J., White, D.E., Zweig, M.H., Weintraub, B.D. and Rosenberg, S.A.: Thyroid dysfunction associated with immunotherapy of cancer patients. Cancer 68:2384-2390, 1991.
504. Alexander, R.B. and Rosenberg, S.A.: Adoptively transferred tumor infiltrating lymphocytes can cure established metastatic tumor in mice and persistent long term in vivo as functional memory T lymphocytes. J. Immunother. 10:389-397, 1991.
505. Pockaj, B.A. and Rosenberg, S.A.: Lack of antihypertensive effect of interleukin-2 administration in humans. J. Immunother. 10:456-459, 1991.
506. Stinson, S.F., Delaney, T.F., Greenberg, J., Yang, J.C., Lampert, M.H., Hicks, J.E., Venzon, D.E., Rosenberg, S.A. and Glatstein, E.J.: Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 21:1493-1499, 1991.
507. Rosenberg, S.A.: The immunotherapy and gene therapy of cancer. Origins of Human Cancer: A Comprehensive Review. Cold Spring Harbor Laboratory Press, 1991, pp. 865-883.
508. Jicha, D.L., Mulé, J.J. and Rosenberg, S.A.: Interleukin-7 generates antitumor CTL against murine sarcomas with efficacy in cellular adoptive immunotherapy. J. Exp. Med. 174:1511-1515, 1991.
509. Alexander, R.B. and Rosenberg, S.A.: Tumor necrosis factor: clinical applications. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp. 378-392.
510. Mulé, J.J. and Rosenberg, S.A.: Combination cytokine therapy: experimental and clinical trials. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp 393-416.

511. Mulé, J.J. and Rosenberg, S.A.: Interleukin-2: Preclinical trials. In: DeVita, V.T., Hellman, S., Rosenberg, S.A.(eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp. 142-158.
512. Lotze, M.T. and Rosenberg, S.A.: Interleukin-2: Clinical applications. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp. 159-177.
513. Topalian, S.L. and Rosenberg, S.A.: Adoptive cellular therapy: Basic principles. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp. 178-196.
514. Yang, J.C. and Rosenberg, S.A.: Adoptive cellular therapy: preclinical studies. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp. 197-213.
515. Rosenberg, S.A.: Adoptive cellular therapy: Clinical applications. In: DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.). Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott, 1991, pp. 214-236.
516. Weber, J.S., Yang, J.C., Topalian, S.L., White, D.E. and Rosenberg, S.A.: The use of interleukin-2 and LAK cells for the treatment of patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 10:33-40, 1991.
517. Weber, J.S. and Rosenberg, S.A.: Adoptive immunotherapy of cancer. Immunol. Allergy Clinics North Am. 11:381-400, 1991.
518. Yang, J.C., Schwarz, S.L., Perry-Lalley, D.M. and Rosenberg, S.A.: Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer. Lymphokine and Cytokine Res. 10:475-480, 1991.
519. Spencer, W.F., Linehan, W.M., Walther, M.M., Lotze, M.T., Topalian, S.L., Yang, J.C., Merino, M.J., Lange, J.R., Pockaj, B.A. and Rosenberg, S.A.: Immunotherapy with interleukin-2 and alpha interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study. J. Urol. 147:24-30, 1992.
520. Rosenberg, S.A.: The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10:180-199, 1992.
521. Kawakami, Y., Zakut, R., Topalian, S.L., Stotter, H. and Rosenberg, S.A.: Shared human melanoma antigens: Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J. Immunol. 148:638-643, 1992.

522. Linehan, W.M., Walther, M.M. and Rosenberg, S.A.: Metastatic renal cell carcinoma. In: Resnick, M.I., Kursh, R. (ed.). Current Therapy in Genitourinary Surgery, Hanover: Mosby, 1992, pp.31-34.
523. Rosenberg, S.A.: Gene therapy of Cancer. In: DeVita, V.T., Hellman, S., and Rosenberg, S.A. (eds.). Important Advances in Oncology, Philadelphia: J.B. Lippincott, 1992, pp. 17-38.
524. Sherry, R.M., Pass, H.I., Rosenberg, S.A. and Yang, J.C.: Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2 based immunotherapy. Cancer 69:1850-1855, 1992.
525. Choyke, P.L., Miller, D.L., Lotze, M.T., Whiteis, J., Ebbitt, B. and Rosenberg, S.A.: Delayed reactions to contrast media after interleukin-2 immunotherapy. Radiology 183:111-114, 1992.
526. Mulé, J.J., Custer, M.C., Travis, W.D. and Rosenberg, S.A.: Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J. Immunol. 148:2622-2629, 1992.
527. Jicha, D.L., Schwarz, S., Mulé, J.J. and Rosenberg, S.A.: Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL. Cell. Immunol. 141:71-83, 1992.
528. Alexander, R.B., Bolton, E.S., Koenig, S., Jones, G.M., Topalian, S.L., June, C.H. and Rosenberg, S.A.: Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. J. Immunol. Methods 148:131-141, 1992.
529. Restifo, N.P., Spiess, P.J., Karp, S.E., Mulé, J.J. and Rosenberg, S.A.: A nonimmunogenic sarcoma transduced with the cDNA for mIFN-gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175:1423-1431, 1992.
530. Sanda, M.G., Bolton, E., Mulé, J.J. and Rosenberg, S.A.: In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells. J. Immunother. 12:132-137, 1992.
531. Lichter, A.S., Lippman, M.E., Danforth, D.N., d'Angelo, T., Steinberg, S.M., deMoss, E., MacDonald, H.D., Reichert, C.M., Merino, M., Swain, S.M., Cowan, K., Gerber, L.H., Bader, J.L., Findlay, P.A., Schain, W., Gorrell, C.R., Straus, K., Rosenberg, S.A. and Glatstein, E.: Mastectomy versus breast conserving therapy in the treatment of Stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J. Clin. Oncol. 10:976-983, 1992.

532. Pogrebniak, H.W., Haas, G., Linehan, W.M., Rosenberg, S.A. and Pass, H.I.: Renal cell carcinoma: resection of solitary and multiple metastases. Ann. Thorac. Surg. 54:33-38, 1992.
533. Hwu, P., Schwarz, S. Custer, M., Smith, C.A., Mulé, J.J. and Rosenberg, S.A.: Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes. J. Immunol. Methods 151:139-147, 1992.
534. Mulé, J.J., Jicha, D.L. and Rosenberg, S.A.: The use of congenitally immunodeficient mice to study human tumor metastases and immuno- therapy. J. Immunother. 12:196-198, 1992.
535. Topalian, S.L., Hom, S.S., Kawakami, Y., Mancini, M., Schwartzentruber, D.J., Zakut, R. and Rosenberg, S.A.: Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J. Immunother. 12:203-206, 1992.
536. Karp, S.E., Hwu, P., Farber, A., Restifo, N.P., Kriegler, M., Mulé, J.J. and Rosenberg, S.A.: In vivo activity of TNF mutants: Secretory but not membrane bound TNF mediates the regression of retrovirally transduced murine tumor. J. Immunol. 149:2076-2081, 1992.
537. Sanda, M.G., Yang, J.C., Topalian, S.L., Groves, E.S., Childs, A., Belfort, R., deSmet, M.D., Schwartzentruber, D.J., White, D.E., Lotze, M.T. and Rosenberg, S.A.: Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: A phase I study. J. Clin. Oncol. 10:1643-1649, 1992.
538. Lange, J., Raubitschek, A., Pockaj, B., Spencer, W., Lotze, M., Topalian, S., Yang, J. and Rosenberg, S.A.: A pilot study of the combination of IL-2 based immunotherapy and radiation therapy. J. Immunother. 12:265-271, 1992.
539. Mulé, J.J., Marcus, S.G., Yang, J.C., Weber, J.S. and Rosenberg, S.A.: Clinical application of IL-6 in cancer therapy. Res. Immunol. 143:777-783, 1992.
540. Rosenberg, S.A.: Gene therapy for cancer. J. Am. Med. Assoc. 268:2416-2419, 1992.
541. Jicha, D.L., Yannelli, J.R., Custer, M., Colandrea, J., Taubenberger, J., Mulé, J.J. and Rosenberg, S.A.: The persistence of human peripheral lymphocytes, tumor infiltrating lymphocytes, and colon adenocarcinomas in immunodeficient mice. J. Immunother. 11:19-29, 1992.
542. Marincola, F.M., Venzon, D., White, D., Rubin, J.T., Lotze, M.T., Simonis, T.B., Balkissoon, J., Rosenberg, S.A. and Parkinson, D.R.: HLA association with response and toxicity in melanoma patients treated with interleukin-2 based immunotherapy. Cancer Res. 52:6561-6566, 1992.

543. Schwartzentruber, D.J., Solomon, D., Rosenberg, S.A. and Topalian, S.L.: Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12:1-12, 1992.
544. Hom, S.A., Rosenberg, S.A., and Topalian, S.L.: Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol. Immunother. 36:1-8, 1993.
545. Pockaj, B.A., Topalian, S.L., Steinberg, S.M., White, D.E. and Rosenberg, S.A.: Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J. Clin. Oncol. 11:136-147, 1993.
546. Hom, S.S., Schwartzentruber, D.J., Rosenberg, S.A. and Topalian, S.L.: Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J. Immunother. 13:18-30, 1993.
547. Yang, J.C., Shlasko, E., Ritchey, J.L., Landry, J.G., White, D.E. and Rosenberg, S.A.: Combination chemoimmunotherapy for metastatic colorectal cancer using 5-FU, leucovorin and interleukin-2. Eur. J. Cancer 29A:355-359, 1993.
548. Restifo, N.P., Esquivel, F., Kawakami, Y., Yewdell, J.W., Mulé, J.J., Rosenberg, S.A. and Bennink, J.R.: Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265-272, 1993.
549. Zakut, R., Topalian, S.L., Kawakami, Y., Mancini, M., Eliyahu, S. and Rosenberg, S.A.: Differential expression of MAGE-1, -2 and -3 mRNA in transformed and normal human cell lines. Cancer Res. 53:5-8, 1993.
550. Sindelar, W.F., Kinsella, T.J., Tepper, J.E., DeLaney, T.F., Maher, M.M., Smith, R., Rosenberg, S.A. and Glatstein, E.: Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am. J. Surg. 165:178-187, 1993.
551. Karp, S.E., Farber, A., Salo, J.C., Hwu, P., Jaffe, G., Asher, A.L., Shiloni, E., Restifo, N.P., Mulé, J.J. and Rosenberg, S.A.: Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol. 150:896-908, 1993.
552. Averbook, B.J., Wei, J.P., Perry-Lalley, D.M., Rosenberg, S.A. and Yang, J.C.: A tumor-elaborated supernatant factor chemotactic for IL-2 expanded tumor infiltrating T-lymphocytes. Lymphokine & Cytokine Res. 12:1-8, 1993.

553. Weber, J., Yang, J.C., Topalian, S.L., Parkinson, D.R., Schwartzentruber, D.S., Ettinghausen, S.E., Gunn, H., Mixon, A., Kim, H., Cole, D., Levin, R. and Rosenberg, S.A.: Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 11:449-506, 1993.
554. Rosenberg, S.A., Lotze, M.T., Yang, J.C., Topalian, S.L., Chang, A.E., Schwartzentruber, D.J., Aebersold, P., Leitman, S., Linehan, W.M., Seipp, C.A., White, D.E. and Steinberg, S.M.: Prospective randomized trial of high dose interleukin-2 alone or with lymphokine activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85:622-632, 1993.
555. Rosenberg, S.A.: The end of the beginning. Curr. Contents 18:8, 1993.
556. Rosenberg, S.A.: Newer approaches to cancer treatment: gene therapy of cancer. (In) DeVita, V., Hellman, S., Rosenberg, S.A. Principles and Practice of Oncology, 4th Edition. Philadelphia: J.B. Lippincott, 1993, pp. 2598-2613.
557. Rosenberg, S.A.: Principles and applications of biologic therapy. (In) DeVita, V.T., Hellman, S., Rosenberg, S.A. (eds.) Cancer, Principles and Practice of Oncology, 4th Edition, Philadelphia: J.B. Lippincott, 1993, pp. 293-324.
558. Rosenberg, S.A.: Principles of surgical oncology. (In) DeVita, V., Hellman, S. and Rosenberg, S.A. (eds.) Cancer: Principles and Practice of Oncology, 4th Edition, Philadelphia: J.B. Lippincott, 1993, pp. 238-247.
559. Yang, J.C., Rosenberg, S.A., Glatstein, E.J. and Antman, K.H.: Sarcomas of soft tissues. (In) DeVita, V., Hellman, S. and Rosenberg, S.A. Cancer: Principles and Practice of Oncology, 4th Edition, Philadelphia: J.B. Lippincott, 1993, pp. 1436-1488.
560. Hwu, P., Yannelli, J., Kriegler, M., Anderson, W.F., Perez, C., Chiang, Y., Schwarz, S., Cowherd, R., Delgado, C., Mulé, J. and Rosenberg, S.A.: Functional and molecular characterization of tumor infiltrating lymphocytes transduced with the tumor necrosis factor- α cDNA for the gene therapy of cancer in man. J. Immunol. 150:4104-4115, 1993.
561. Sindelar, W.F., Kinsella, T.J., Chen, P.W., DeLaney, T.F., Tepper, J.E., Rosenberg, S.A. and Glatstein, E.: Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch. Surg. 128:402-410, 1993.
562. Yannelli, J.R., Hyatt, C., Johnson, S., Hwu, P. and Rosenberg, S.A.: Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor- α or interleukin-2. J. Immunol. Meth. 161:77-90, 1993.

563. Marincola, F.M., Balkissoon, J., Schwartzentruber, D.J., Hom, S.S., Concepcion, R., Marcus, S.G., Yannelli, J., Topalian, S.L., Parkinson, D.R. and Rosenberg, S.A.: Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. J. Immunother. 12:282-288, 1993.
564. Hwu, P., Shafer, G.E., Treisman, J., Schindler, D.G., Gross, G., Cowherd, R., Rosenberg, S.A. and Eshhar, Z.: Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 178:361-366, 1993.
565. Alexander, R.B., Walther, M.M., Linehan, W.M. and Rosenberg, S.A.: Immunotherapy of renal cell carcinoma: Experience of the Surgery Branch, National Cancer Institute. In: Lytton, B., Catalona, W.J., Lipshultz, L.I., McGuire, E.J. (eds.). Adv. Urol., St. Louis, Mosby, 1993, pp.101-125.
566. O'Neil, B.H., Kawakami, Y., Restifo, N.P., Bennink, J.R., Yewdell, J.W. and Rosenberg, S.A.: Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol. 151:1410-1418, 1993.
567. Schwartzentruber, D.J., Stetler-Stevenson, M., Rosenberg, S.A. and Topalian, S.L.: Tumor infiltrating lymphocytes derived from select B cell lymphomas secrete GM-CSF and TNF- α in response to autologous tumor stimulation. Blood 82:1204-1211, 1993.
568. Kawakami, Y., Nishimura, I., Restifo, N.P., Topalian, S.L., O'Neil, B.H., Shilyansky, J., Yannelli, J.R. and Rosenberg, S.A.: T-cell recognition of human melanoma antigens. J. Immunother., 14:88-93, 1993.
569. Shiloni, E., Karp, S.E., Custer, M.C., Shilyansky, J., Restifo, N.P., Rosenberg, S.A. and Mulé, J.J.: Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunol. Immunother. 37:286-292, 1993.
570. Rosenberg, S.A., Anderson, W.F., Blaese, M., Hwu, P., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Ettinghausen, S.E., Parkinson, D.R., and White, D.E.: The development of gene therapy for the treatment of cancer. Ann. Surg. 218:455-464, 1993.
571. Kawakami, Y. and Rosenberg, S.A.: Immunotherapy and gene therapy for human cancer using T-lymphocytes. In: Kimura, K., Yamada, K., Carter, S.K., Longo, D.L. (eds.). Cancer Chemotherapy. Challenges for The Future. Tokyo:Excerpta Medica, 1993, pp. 39-44.

572. Cohen, P.A., Kim, H., Fowler, D.H., Gress, R.E., Jakobsen, M.K., Alexander, R.B., Mulé, J.J., Carter, C. and Rosenberg, S.A.: Use of interleukin-7, interleukin-2 and α -interferon to propagate CD4⁺ T cells in culture with maintained antigen-specificity. J. Immunother. 14:242-252, 1993.
573. Restifo, N.P., Kawakami, Y., Marincola, F., Shamamian, P., Taggarse, A., Esquivel, F. and Rosenberg, S.A.: Molecular mechanisms used by tumors to escape from immune recognition: immunogenethrapy and the cell biology of major histocompatibility complex Class I. J. Immunother. 14:182-190, 1993.
574. Marcus, S.G., Choyke, P.L., Reiter, R., Jaffe, G.S., Alexander, R.B., Linehan, W.M., Rosenberg, S.A. and Walther, M.M.: Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol. 150:463-466, 1993.
575. Marcus, S.G., Merino, M.J., Glatstein, E., DeLaney, T.F., Steinberg, S.M., Rosenberg, S.A. and Yang, J.C.: Long term outcome in 87 patients with low grade soft tissue sarcoma. Arch. Surg. 128:1336-1343, 1993.
576. Ogasawara, M. and Rosenberg, S.A.: Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Cancer Res. 53:3561-3568, 1993.
577. Shilyansky, J., Nishimura, M.I., Yang, J.C., Custer, M.C., Mulé, J.J. and Rosenberg, S.A.: Murine sarcoma-specific tumor-infiltrating lymphocyte (TIL) clone utilizing a unique T cell receptor rearrangement successfully treats established lung metastases. Surg. Forum 44:521-523, 1993.
578. Walther, M.M., Alexander, R.B., Weiss, G.I, Venzon, D., Berman, A., Pass, H.I., Linehan, W.M. and Rosenberg, S.A.: Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urol. 42:250-258, 1993.
579. Long, J.P., Walther, M.M., Alexander, R.B., Rosenberg, S.A. and Linehan, W.M.: The management of isolated renal recurrence of renal cell carcinoma following complete response to IL-2 based immunotherapy. J. Urol. 150:176-178, 1993.
580. Linehan, W.M., Walther, M.M., Alexander, R.B. and Rosenberg, S.A.: Adoptive immunotherapy of renal cell carcinoma: Surgery Branch, NCI. Semin. Urol. 11:41-43, 1993.
581. Ettinghausen, S.E. and Rosenberg, S.A.: Clinical trials of immunotherapy of cancer utilizing cytotoxic cells. (In) M. Sitkovsky and Henkart, P. (eds.) Cytotoxic Cells: Recognition Effector Function Generator and Methods, Boston: Birkhauser, 1993; 407-435.

582. Pockaj, B.A., Yang, J.C., Lotze, M.T., Lange, J.R., Spencer, W.F., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., White, D.E. and Rosenberg, S.A.: A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J. Immunother. 15:22-28, 1994.
583. Cole, D.J., Sanda, M.G., Yang, J.C., Schwartzentruber, D.J., Weber, J., Ettinghausen, S.E., Pockaj, B.A., Kim, H.I., Levin, R.D., Pogrebniak, H.W., Balkissoon, J., Fenton, R.M., DeBarge, L.R., Kaye, J., Rosenberg, S.A., Parkinson, D.R.: Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J. Natl. Cancer Inst. 86:39-45, 1994.
584. Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., Ettinghausen, S., Levitt, D. and Rosenberg, S.A.: A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J. Immunother. 15:292-302, 1994.
585. Marcus, S.G., Perry-Lalley, D., Mulé, J.J., Rosenberg, S.A., and Yang, J.C.: The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. J. Immunother. 15:105-112, 1994.
586. Cohen, P.A., Cohen, P.J., Rosenberg, S.A. and Mulé, J.J.: CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res. 54:1055-1058, 1994.
587. Rosenberg, S.A., Yang, J.C., Topalian, S., Schwartzentruber, D.J., Weber, J.S., Parkinson, D., Seipp, C.A., Einhorn, J.H. and White, D.E.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J. Am. Med. Assoc. 271:907-913, 1994.
588. Shilyansky, J., Nishimura, M.I., Yannelli, J.R., Kawakami, Y., Jacknin, L.S., Charmley, P. and Rosenberg, S.A.: T cell receptor usage by melanoma specific clonal and highly oligoclonal tumor infiltrating lymphocyte lines. Proc. Natl. Acad. Sci. 91:2829-2833, 1994.
589. Cohen, P.J., Cohen, P.A., Rosenberg, S.A., Katz, S.I. and Mulé, J.J.: Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol. 24:315-319, 1994.
590. Pockaj, B.A., Sherry, R., Wei, J., Yannelli, J.R., Carter, C.S., Leitman, S.F., Carrasquillo, J.R., White, D.E., Steinberg, S.M., Rosenberg, S.A., and Yang, J.C.: Localization of ¹¹¹Indium-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and association with response. Cancer 73:1731-1737, 1994.

591. Marincola, F.M., Ettinghausen, S., Cohen, P.A., Restifo, N.P., Mulé, J.J. and Rosenberg, S.A.: Treatment of established lung metastases with tumor infiltrating lymphocytes derived from a poorly immunogenic tumor transduced with the gene for hTNF- α . J. Immunol. 152:3501-3513, 1994.
592. Cole, D.J., Taubenberger, J.K., Pockaj, B.A., Yannelli, J.R., Carter, C.S., Carasquillo, J., Leitman, S., Steinberg, S.M., Rosenberg, S.A., and Yang, J.C.: Histopathologic analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor infiltrating lymphocytes. Cancer Immunol. Immunother. 38:299-303, 1994.
593. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Rivoltini, L., Topalian, S.L., Miki, T. and Rosenberg, S.A.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. 91:3515-3519, 1994.
594. Robbins, P.F., El-Gamil, M., Kawakami, Y., Stevens, E., Yannelli, J. and Rosenberg, S.A.: Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124-3126, 1994.
595. Pogrebniak, H.W., Witt, C.J., Terrill, R., Kranda, K., Travis, W., Rosenberg, S.A. and Pass, H.I.: Isolated lung perfusion with tumor necrosis factor: A swine model in preparation of human trials. Ann. Thorac. Surg. 57:1477-1483, 1994.
596. Topalian, S.L., Rivoltini, L., Mancini, M., Ng, J., Hartzman, R.J. and Rosenberg, S.A.: Melanoma-specific CD4⁺ T lymphocyte recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer, 58:69-79, 1994.
597. Bakker, A.B.H., Schreurs, M.W.J., de Boer, A.J., Kawakami, Y., Rosenberg, S.A., Adema, G.J. and Figdor, C.G.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J. Exp. Med. 179:1005-1009, 1994.
598. Schwartzentruber, D.J., Hom, S.S., Dadmarz, R., White, D.E., Yannelli, J.R., Steinberg, S.M., Rosenberg, S.A. and Topalian, S.L.: In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J. Clin. Oncol., 12:1475-1483, 1994.
599. Marincola, F.M., Shamamian, P., Simonis, T.B., Abati, A., Hackett, J., O'Dea, T., Fetsch, P., Yannelli, J., Restifo, N.P., Mulé, J.J. and Rosenberg, S.A.: Locus-specific analysis of human leukocyte antigen Class I expression in melanoma cell lines. J. Immunother. 16:13-23, 1994.
600. Kim, H., Rosenberg, S.A., Steinberg, S.M., Cole, D.J. and Weber, J.S.: A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J. Immunother. 16:60-65, 1994.

601. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P.F., Rivoltini, L., Yannelli, J.R., Appella, E. and Rosenberg, S.A.: Brief Definitive Report. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352, 1994.
602. Treisman, J., Hwu, P., Yannelli, J.R., Shafer, G.E., Cowherd, R., Samid, D. and Rosenberg, S.A.: Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell. Immunol. 156:448-457, 1994.
603. Marincola, F.M., Shamamian, P., Alexander, R.B., Gnarra, J.R., Turetskaya, R.L., Simonis, T.B., Hazen-Martin, D.J., Taubenberger, J.K., Yannelli, J., Mixon, A., Restifo, N.P., Herlyn, M. and Rosenberg, S.A.: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 153:1225-1237, 1994.
604. Weber, J., Salgaller, M., Samid, D., Johnson, B., Herlyn, M., Lassam, N., Treisman, J. and Rosenberg, S.A.: Expression of the MAGE-1 tumor antigen is upregulated by the demethylating agent 5 Azt 2' Deoxycytidine. Cancer Res. 54:1766-1771, 1994.
605. Salgaller, M.L., Weber, J.S., Koenig, S., Yannelli, J.R. and Rosenberg, S.A.: Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother. 39:105-116, 1994.
606. Hwu, P. and Rosenberg, S.A.: The use of gene modified TIL for cancer therapy. Ann. NY Acad. Sci. 716:188-199, 1994.
607. Yang, J.C., Topalian, S.L., Parkinson, D., Schwartzentruber, D.J., Weber, J.S., Ettinghausen, S.E. White, D.E., Steinberg, S.M., Cole, D.J., Kim, H.I., Levin, R., Guleria, A., MacFarlane, M.P., White, R.L., Einhorn, J.H., Seipp, C.A. and Rosenberg, S.A.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma - an interim report. J. Clin. Oncol. 12:1572-1576, 1994.
608. Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. and White, D.E.: Treatment of patients with metastatic melanoma using autologous tumor infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1159-1166, 1994.
609. Minev, B.R., Restifo, N.P., McFarland, B.J., Spiess, P.J. and Rosenberg, S.A.: Insertion signal sequence fused to a minimal peptide elicits specific CD8⁺T cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:4155-4161, 1994.

610. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Sakaguchi, K., Appella, E., Yannelli, J.R., Adema, G.J., Miki, T. and Rosenberg, S.A.: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91:6458-6462, 1994.
611. Rosenberg, S.A.: The gene therapy of cancer. Prev. Med. 23:624-626, 1994.
612. Wang, M.G., Zakut, R., Rosenberg, S.A. and McBride, O. W.: Localization of the gene for a human melanoma antigen MAGE-1 to chromosome Xq28. Cytogenet. Cell Genet. 67:116-119, 1994.
613. Shamamian, P., Mancini, M., Kawakami, Y., Restifo, N.P., Rosenberg, S.A., and Topalian, S.L.: Recognition of neuroectodermal tumors by melanoma-specific CTL: Evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunol. Immunother. 39:73-83, 1994.
614. Nishimura, M.I., Kawakami, Y., Charmley, P., O'Neil, B., Shilyansky, J., Yannelli, J.R., Rosenberg, S.A. and Hood, L.E.: T cell receptor repertoire in tumor infiltrating lymphocytes. Analysis of melanoma specific long term lines. J. Immunother. 16:85-94, 1994.
615. Topalian, S.L., Rivoltini, L., Mancini, M., Markus, N.R., Robbins, P.F., Kawakami, Y. and Rosenberg, S.A.: Human CD4⁺ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. 91:9461-9465, 1994.
616. Guleria, A.S., Yang, J.C., Topalian, S.L., Weber, J.S., Parkinson, D.R., MacFarlane, M.P., White, R.L., Steinberg, S.M., White, D.E., Einhorn, J.H., Seipp, C.A., Austin, H.A., Rosenberg, S.A. and Schwartzentruber, D.J.: Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 12:2714-2722, 1994.
617. Cole, D.J., Weil, D.P., Shamamian, P., Rivoltini, L., Kawakami, Y., Topalian, S., Jennings, C., Eliyahu, S., Rosenberg, S.A. and Nishimura, M.I.: Identification of MART-1 specific T-cell receptors: T-cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 54:5265-5268, 1994.
618. Ettinghausen, S.E. and Rosenberg, S.A.: Immunotherapy and gene therapy of cancer. Adv. Surg. 28:1994.
619. Marincola, F.M. and Rosenberg, S.A.: Melanoma. (In) DeVita, VT, Hellman, S, Rosenberg SA (eds.). Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott, 1995, pp 250-262.

620. Hwu, P. and Rosenberg, S.A.: Gene therapy using lymphocyte modification. (In) DeVita VT, Hellman S, Rosenberg SA (eds.). Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott, 1995, pp. 727-737.
621. Rosenberg, S.A.: Cell transfer therapy: Clinical applications. (In) DeVita VT, Hellman S, and Rosenberg SA (eds.). Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott, 1995, pp. 487-506.
622. Treisman, J., Hwu, P., Minamoto, S., Shafer, G.E., Cowherd, R. Morgan, R.A. and Rosenberg, S.A.: Interleukin-2 transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood, 85:139-145, 1995.
623. Thom, A.K., Alexander, H.R., Andrich, M.P., Barker, W.C., Rosenberg, S.A. and Fraker, D.L.: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon- γ and melphalan. J. Clin. Oncol., 13:264-273, 1995.
624. White, R.L., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D., Guleria, A., MacFarlane, M.P., Seipp, C.A., Einhorn, J.H., White, D.E. and Rosenberg, S.A.: The cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell cancer. Cancer 74:3212-3222, 1995.
625. Wang, R-F., Robbins, P.F., Kawakami, Y., Kang, X-Q. and Rosenberg, S.A.: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799-804, 1995.
626. Cole, D.J., Weil, D.P., Shilyansky, D.P., Custer, M., Kawakami, Y., Rosenberg, S.A. and Nishimura, M.I.: Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55:748-752, 1995.
627. MacFarlane, M.P., Yang, J.C., Guleria, A.S., White, R.L., Seipp, C.A., Einhorn, J.H., White, D.E. and Rosenberg, S.A.: The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell cancer. Cancer, 75:1030-1037, 1995.
628. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P.F., Marincola, F., Salgaller, M.L., Yannelli, J.R. and Rosenberg, S.A.: Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154:2257-2265, 1995.

629. Stevens, E., Jacknin, L., Robbins, P., Kawakami, Y., El-Gamil, M., Rosenberg, S.A. and Yannelli, J.R.: Generation of tumor specific CTLs from melanoma patients using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154:762-771, 1995.
630. Dadmarz, R., Sgagias, M.K., Rosenberg, S.A. and Schwartzentruber, D.J.: CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC Class II restricted fashion. Cancer Immunol. Immunother. 40:1-9, 1995.
631. Fyfe, G., Fisher, R., Rosenberg, S.A., Sznol, M., Parkinson, D., and Louie, A.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:688-696, 1995.
632. Alexander, R.B., Fitzgerald, E.B., Mixon, A., Carter, C.S., Jakobsen, M., Cohen, P.A. and Rosenberg, S.A.: Helper T cells infiltrating human renal cell carcinomas are activated memory-like T lymphocytes. J. Immunother. 17:39-46, 1995.
633. Sgagias, M.K., Gagneton, D.C., Rosenberg, S.A. and Danforth, D.N.: Cellular characterization and retroviral transduction of short-term breast cancer cells. J. Immunother. 17:88-97, 1995.
634. McCabe, B.J., Irvine, K.R., Nishimura, M.I., Yang, J.C., Spiess, P.J., Shulman, E.P., Rosenberg, S.A. and Restifo, N.P.: Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic anti-tumor cytolytic T lymphocyte responses. Cancer Res., 55:1741-1747, 1995.
635. Marincola, F.M., White, D. and Rosenberg, S.A.: Combination therapy with interferon- α -2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol. 13:1110-1122, 1995.
636. Restifo, N.P., Bacik, I., Irvine, K.R., Yewdell, J.W., McCabe, B.J., Anderson, R.W., Eisenlohr, L.C., Bennink, J.R., and Rosenberg, S.A.: Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:4414-4422, 1995.
637. Bronte, V., Tsung, K., Rao, J., Chen, P.W., Wang, M., Rosenberg, S.A. and Restifo, N.P.: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282-5292, 1995.
638. Wang, M., Bronte, V., Chen, P.W., Gritz, L., Panicali, D., Rosenberg, S.A. and Restifo, N.P.: Active immunotherapy of cancer with a non-replicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685-4692, 1995.

639. Koenig, S., Conley, A.J., Brewan, Y.A., Jones, G.M., Leath, S., Boots, L.J., Davey, V., Pantaleo, G., Demarest, J.F., Carter, C., Wannebo, C., Yannelli, J., Rosenberg, S.A., and Lane, H.C.: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nature Med. 1:330-336, 1995.
640. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E. and Rosenberg, S.A.: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968, 1995.
641. Irvine, K.R., McCabe, B.J., Rosenberg, S.A. and Restifo, N.P.: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 154:4651-4657, 1995.
642. Rosenberg, S.A.: Gene Therapy: Triumph of Discovery. 150th Anniversary issue. Sci. Am. New York: Henry Holt and Co, 1995, 1:104-109.
643. Ettinghausen, S.E., and Rosenberg, S.A.: Immunotherapy and Gene Therapy of Cancer. Adv. Surg. Chicago: Mosby - Year Book, Inc. 1995, 28:223-254.
644. Robbins, P.F., El-Gamil, M., Li, Y., Topalian, S.L., Rivoltini, L., Sakaguchi, K., Appella, E., Kawakami, Y. and Rosenberg, S.A.: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor-infiltrating lymphocytes. J. Immunol. 154:5944-5950, 1995.
645. Rivoltini, L., Barracchini, K.C., Viggiano, V., Kawakami, Y., Smith, A., Mixon, A., Restifo, N.P., Topalian, S.L., Simonis, T.B., Rosenberg, S.A., and Marincola, F.M.: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:3149-3157, 1995.
646. Rosenberg, S.A.: A New Perspective: The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1:89-100, 1995.
647. Fraker, D.L., Alexander, H.R., Andrich, M. and Rosenberg, S.A.: Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high dose tumor necrosis factor. Cancer J. Sci. Am. 1:122-130, 1995.
648. Hwu, P., Yang, J.C., Cowherd, R., Treisman, Shafer, G.E., and Rosenberg, S.A.: In vivo antitumor activity of T-cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 55:3369-3373, 1995.

649. Markus, N.R., Rosenberg, S.A. and Topalian, S.L.: Analysis of cytokine secretion by melanoma-specific CD4⁺ T lymphocytes. J. Interferon and Cytokine Res. 15:739-746, 1995.
650. Heywood, G.R., Rosenberg, S.A. and Weber, J.S.: Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high dose interleukin-2. J. Natl. Cancer Inst., 87:915-922, 1995.
651. Jakobsen, M.K., Restifo, N.P., Cohen, P.A., Marincola, F.M., Cheshire, L.B., Linehan, W.M., Rosenberg, S.A. and Alexander, R.B.: Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J. Immunother., 17:222-228, 1995.
652. Yang, J.C., Topalian, S.L., Schwartzentruber, D., Parkinson, D.R., Marincola, F.M., Weber, J.S., Seipp, C.A., White, D.E. and Rosenberg, S.A.: The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma: A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer, 76:687-694, 1995.
653. Kang, S., Kawakami, Y., El-Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J.R., Appella, E., Rosenberg, S.A. and Robbins, P.F.: Identification of a tyrosinase epitope recognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J. Immunol., 155:1343-1348, 1995.
654. Minamoto, S., Sugamura, K., Hankins, W.D. and Rosenberg, S.A.: Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors. Blood, 86:2281-2287, 1995.
655. Blaese, R.M., Culver, K.W., Miller, A.D., Carter, C., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., Greenblatt, J., Rosenberg, S., Klein, H., Berger, M., Mullen, C., Ramsey, J., Muul, L., Morgan, R.A., and Anderson, W.F.: T lymphocyte- directed gene therapy for ADA⁻ SCID: Initial trial results after 4 years. Science 270:475-480, 1995.
656. Salgaller, M.L., Afshar, A., Marincola, F.M., Rivoltini, L., Kawakami, Y. and Rosenberg, S.A.: Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972-4979, 1995.
657. Chen, P.C., Wang, M., Bronte, V., Zhai, Y., Rosenberg, S.A., and Restifo, N.P.: Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:224-231, 1996.

658. Rosenberg, S.A.: Secrecy in Medical Research. N. Engl. J. Med. 334:392-394, 1996.
659. Irvine, K.R., Rao, R.B., Rosenberg, S.A., and Restifo, N.P.: Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J. Immunol. 156:238-245, 1996.
660. Restifo, N.P., Marincola, F.M., Kawakami, Y., Taubenberger, J., Yannelli, J.R., and Rosenberg, S.A.: Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88:100-108, 1996.
661. Wang, M., Chen, P.W., Bronte, V., Rosenberg, S.A., and Restifo, N.P.: Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor antigen. J. Immunother. 18:139-146, 1995.
662. Bartels, C.J., Rosenberg, S.A. and Yang, J.C.: Adoptive cellular immunotherapy in mice using partially allogeneic T-cells. Ann. Surg. Oncol. 3:67-73, 1996.
663. Zhai, Y., Kawakami, Y., Wadsworth, S.C., Cardoza, L.M., Couture, L.A., Smith, A.E. and Rosenberg, S.A.: Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:700-710, 1996.
665. Yannelli, J.R., Hyatt, C., McConnell, S., Hines, K., Jacknin, L., Parker, L., Sanders, M. and Rosenberg, S.A.: Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int. J. Cancer 65:413-421, 1996.
666. Krouse, R.S., Royal, R.E., Heywood, G., Weintraub, B.D., White, D.E., Steinberg, S.M., Rosenberg, S.A. and Schwartzentruber, D.J.: Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J. Immunother. 18:272-278, 1996.
667. Rosenberg, S.A.: The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu. Rev. Med. 47:481-491, 1996.
668. Royal, R.E., Steinberg, S.M., White, D.E., Hwu, P., Marincola, F.M., Parkinson, D.R., Schwartzentruber, D.J., Topalian, S.L., Yang, J.C., and Rosenberg, S.A.: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J. Sci. Am. 2:91-98, 1996.
669. Kawakami, Y., Robbins, P.F., and Rosenberg, S.A.: Identification of human melanoma antigens recognized by T-cells and their use for immuno-gene therapy. In New Trends in Immunological Diseases eds, Academic Press, 123-131, 1996.

670. Rosenberg, S.A. and White, D.E.: Brief Report: Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 19:81-84, 1996.
671. Kim, C.J., Taubenberg, J.K., Simonis, T.B., White, D.E., Rosenberg, S.A., and Marincola, F.M.: Combination therapy with interferon- γ and interleukin-2 for the treatment of metastatic melanoma. J. Immunother. 19:50-58, 1996.
672. Wang, R-F., Parkhurst, M.R., Kawakami, Y., Robbins, P.F., and Rosenberg, S.A.: Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1131-1140, 1996.
673. Rao, J.B., Chamberlain, R.S., Bronte, V., Carroll, M.W., Irvine, K.R., Moss, B., Rosenberg, S.A., and Restifo, N.P.: Interleukin-12 is an effective adjuvant to recombinant vaccinia virus based tumor vaccines. J. Immunol. 156:3357-3365, 1996.
674. Robbins, P.F., El-Gamil, M., Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S.A.: A mutated β -catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185-1192, 1996.
675. Pass, H.I., Mew, D.J.Y., Kranda, K.C., Temeck, B.K., Donington, J.S., and Rosenberg, S.A.: Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann. Thorac. Surg. 61:1609-1617, 1996.
676. Kawakami, Y., Robbins, P.F., and Rosenberg, S.A.: Human melanoma antigens recognized by T lymphocytes. Keio. J. Med. 45:100-108, 1996.
677. Chamberlain, R.S., Carroll, M.W., Bronte, V., Hwu, P., Warren, S., Yang, J.C., Nishimura, M., Moss, B., Rosenberg, S.A., and Restifo, N.P.: Costimulation enhances the active immunotherapy effect of model recombinant anticancer vaccines. Cancer Res. 56:2832-2836, 1996.
678. Rosenberg, S.A.: Secrecy in Medical Research. FASEB Newsletter 29:2-3, 1996.
679. Wang, R-F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S.A.: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216, 1996.
680. Topalian, S.L., Gonzales, M.I., Parkhurst, M., Li, Y.F., Southwood, S., Sette, A., Rosenberg, S.A., and Robbins, P.F.: Melanoma-specific CD4⁺ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965-1971, 1996.

681. Marincola, F.M., Hijazi, Y.M., Fetsch, P., Salgaller, M.L., Rivoltini, L., Corminer, J., Simonis, T.B., Duray, P.H., Herlyn, M., Kawakami, Y., and Rosenberg, S.A.: Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. 19:192-205, 1996.
682. Lam, J.S., Reeves, M.E., Cowherd, R., Rosenberg, S.A., and Hwu, P.: Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum. Gene Therapy 17:1415-1422, 1996.
683. Mulé, J.J., Custer, M., Averbook, B., Yang, J.C., Weber, J.S., Goeddel, D.V., Rosenberg, S.A., and Schall, T.J.: RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations. Hum. Gene Therapy 7:1545-1553, 1996.
684. Rosenberg, S.A.: Secrecy in Research: Cooperation and Costimulation in Immunology. Curr. Opin. Immunol. 8:611-612, 1996.
685. Parkhurst, M.R., Salgaller, M.L., Southwood, S., Robbins, P.F., Sette, A., Rosenberg, S.A., and Kawakami, Y.: Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0210 binding residues. J. Immunol. 157:2539-2548, 1996.
686. Marincola, M.F., Rivoltini, L., Salgaller, M.L., Player, M., and Rosenberg, S.A.: Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J. Immunother. 19:266-277, 1996.
687. Kawakami, Y., and Rosenberg, S.A.: T-cell recognition of self peptides as tumor rejection antigens. Immunol. Res. 15:179-190, 1996.
688. Wang, R-F., and Rosenberg, S.A.: Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J. Leukoc. Biol. 60:296-309, 1996.
689. Rosenberg, S.A.: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88:1635-1644, 1996.
690. Rosenberg, S.A., Kawakami, Y., Robbins, P.F. and Wang, R-F.: Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy. Adv. Cancer Res. 70:145-177, 1996.
691. Reeves, M.E., Royal, R.E., Lam, J.S., Rosenberg, S.A., and Hwu, P.: Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672-5677, 1996.

692. Kang X., Robbins, P.F., Fitzgerald, E.B., Wang, R-F., Rosenberg, S.A., and Kawakami, Y.: Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Cancer Res. 57:202-205, 1997.
693. Salgaller, M.I., Marincola, F.M., Cormier, J.N., and Rosenberg, S.A.: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749-4757, 1996.
694. Alexander, M., Salgaller, M.L., Celis, E., Sette, A., Barnes, W.A., Rosenberg, S.A., and Steller, M.A.: Generation of tumor specific cytolytic T-lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175:1586-1593, 1996.
695. Bloom, M.B., Perry-Lalley, D., Robbins, P.F., Li, Y., El-Gamil. M., Rosenberg, S.A., and Yang, J.C.: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453-459, 1997.
696. Kawakami, Y., and Rosenberg, S.A.: Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Intern. Rev. Immunol. 14:173-192, 1997.
697. Carroll, M.W., Ovwijk, W.W., Chamberlain, R.S., Rosenberg, S.A., Moss, B., and Restifo, N.P.: Highly attenuated modified vaccinia virus ankara (MVA) as a recombinant vector for cancer immunotherapy. Vaccine 15:387-394, 1997.
698. Rosenberg, S.A.: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175-182, 1997.
699. Zhai, Z., Yang, J.C., Spiess, P., Nishimura, M.I., Overwijk, W.W., Roberts, B., Restifo, N.P., and Rosenberg, S.A.: Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART-1 and gp100. J. Immunother. 20:15-25, 1997.
700. Cormier, J.N., Salgaller, M.L., Prevette, T., Barracchini, K.C., Rivoltini, L., Restifo, N.P., Rosenberg, S.A., and Marincola, F.M.: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/melan A. Cancer J. Sci. Am. 3:37-44, 1997.
701. Adams, D.H., Yannelli, J.R., Newman, W., Lawley, T., Ades, E., Rosenberg, S.A., and Shaw, S.: Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br. J. Cancer 75:1421-1431, 1997.

702. Kawakami, Y., Battles, J.K., Kobayashi, T., Wang, X., Tupesis, J.L., Marincola, F.M., Robbins, P.F., Hearing, V.J., Gonda, M.A., and Rosenberg, S.A.: Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1. J. Immunol. Methods 202:13-25, 1997.
703. Irvine, K.R., Chamberlain, R.S., Shulman, E.P., Rosenberg, S.A., and Nicholas, P.R.: Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J. Natl. Cancer Inst. 89:390-392, 1997.
704. Shilyansky, J., Yang, J.C., Custer, M.C., Spiess, P., Mixon, A., Cole D.J., Mulé, J.J., Rosenberg, S.A., and Nishimura, M.I.: Identification of a T-cell receptor from a therapeutic murine T-cell clone. J. Immunother. 20:247-255, 1997.
705. Kim, C.J., Prevette, P., Cormier, J., Overwijk, W., Gritz, L., Maxxara, G.P., Restifo, N.P., Rosenberg, S.A., and Marincola, F.M.: Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother. 20:276-286, 1997.
706. Cormier, J.N., Hurst, R., Vasselli, J., Lee, D., Kim, C.J., McKee, M., Venzon, D., White, D., Marincola, F.M., and Rosenberg, S.A.: Prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2. J. Immunother. 20:292-300, 1997.
707. Walther, M.M., Yang, J.C., Pass, H.I., Linehan, W.M., and Rosenberg, S.A.: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol. 158:1675-1678, 1997.
708. Specht, J.M., Wang, G., Do, M.T., Lam, J.S., Royal, R.E., Reeves, M.E., Rosenberg, S.A., and Hwu, P.: Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213-1221, 1997.
709. Kawakami, Y., and Rosenberg, S.A.: Human tumor antigens recognized by T-cells. Immunol. Res. 16:313-339, 1997.
710. Yang, J.C., Chang, A.E., Baker, A.R., Sindelar, W.F., Danforth, D.N., Toplaian, S.L., Delaney, T., Glatstein, E., Steinberg, S.M., Merino, M.J. and Rosenberg, S.A.: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 16:197-203, 1998.
711. Yang, J.C., and Rosenberg, S.A.: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Am. 3:S79-S84, 1997.

712. Rosenberg, S.A.: Keynote Address: Perspectives on the use of interleukin-2 in cancer treatment. Cancer J. Sci. Am. 3:S1-S6, 1997.
713. Cormier, J.N., Abati, A., Fetsch, P., Hijazi, Y.M., Rosenberg, S.A., Marincola, F., and Topalian, S.L.: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother. 21:27-31, 1998.
714. Cormier, J.N., Huazi, Y.M., Abati, A., Fetsch, P., Bettinotti, M., Steinberg, S.M., Rosenberg, S.A., and Marincola, F.M.: Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer 75:517-524, 1998.
715. Wang, G, Chopra, R.K., Royal, R.E., Yang, J.C., Rosenberg, S.A., and Hwu, P.: A T-cell independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc- γ chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat. Med. 4:168-172, 1998.
716. Rosenberg, S.A., Yang, J.C., Schwarzentruher, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhorn, J.H., and White, D.E.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327, 1998.
717. Czerniecki, B.J., Carter, C., Rivoltini, L., Koski, G.K., Kim, H.I., Weng, D.E., Roros, J.G., Hijazi, Y.M., Xu, S., Rosenberg, S.A., and Cohen, P.A.: Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J. Immunol. 159:3823-3827, 1997.
718. Wang, R-F., Johnston, S.L., Southwood, S., Sette, A., and Rosenberg, S.A.: Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J.Immunol. 160:890-897, 1998.
719. Lee, D.S., White, D.E., Hurst, R., Rosenberg, S.A. and Yang, J.C.: Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2 based immunotherapy. Cancer J. Sci. Am. 4:86-93, 1998.
720. Irvine, K.R., Chamberlain, R.S., Shulman, E.P., Surman, D.R., Rosenberg, S.A., and Restifo, N.P.: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst. 89:1595-1601, 1997.
721. Bronte, V., Carroll, M.W., Goletz, T.J., Wang, M., Overwijk, W.W., Marincola, F., Rosenberg, S.A., Moss, B., and Restifo, N.P.: Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. 94:3183-3188, 1997.

722. Robbins, P.F., El-Gamil, M., Li, Y.F., Fitzgerald, E., Kawakami, Y., and Rosenberg, S.A.: The intronic region of an incompletely-spliced gp100 transcript encodes an epitope recognized by melanoma-reactive tumor infiltrating lymphocytes. J. Immunol. 159:303-308, 1998.
723. Walther, M.M., Jennings, S.B., Choyke, P.L., Andrich, M., Hurley, K., Linehan, W.M., Rosenberg, S.A. and Alexander, R.B.: Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J. Urol. 14:S2-S7, 1996.
724. Walther, M.M., Johnson, B., Culley, D., Shah, R., Weber, J., Venzon, D., Yang, J.C., Linehan, W.M., and Rosenberg, S.A.: Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J. Urol. 159:718-722, 1998.
725. Kawakami, Y., Robbins, P.F., Wang, R-F., Parkhurst, M., Kang, X., and Rosenberg, S.A.: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer, Tumor Antigens Recognized by T Cells, The use of Melanosomal Proteins in the Immunotherapy of Melanoma. J. Immunother. 21:237-246, 1998.
726. Alexander, H.R., Bartlett, D.L., Libutti, S.K., Fraker, D.L., Moser, T., and Rosenberg, S.A.: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16:1479-1489, 1998.
727. Rosenberg, S.A.: Vaccines for treatment of patients with metastatic melanoma. The Melanoma Letter 16:4-5, 1998.
728. Overwijk, W.W., Tsung, A., Irvine, K.R., Parkhurst, M.R., Goletz, T.J., Tsung, K., Carroll, M.W., Liu, C., Moss, B., Rosenberg, S.A., and Restifo, N.P.: gp100/pmel 17 is a Murine tumor rejection antigen: Induction of "Self" -reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286, 1998.
729. Surman, D.R., Irvine, K.R., Shulman, E.P., Rosenberg, S.A., and Restifo, N.P.: Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J. Immunol. Meths. 214:51-62, 1998.
730. Kammula, U.S., White, D.E., and Rosenberg, S.A.: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797-805, 1998.
731. Wang, R-F., Wang, X., Johnston, S.L., Robbins, P.F., and Rosenberg, S.A.: Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res. 58:3519-3525, 1998.

732. Pass, H.A., Schwarz, S.L., Wunderlich, J.R., and Rosenberg, S.A.: Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the elispot assay. Cancer J. Sci. Am. 4:316-323, 1998.
733. Nishimura, M.I., Custer, M.C., Schwarz, S.L., Parker, L.L., Mixon, A., Clay, T.M., Yannelli, J.R., and Rosenberg, S.A.: T cell-receptor V gene use by CD4⁺ melanoma-reactive clonal and oligoclonal T-cell lines. J. Immunotherapy. 21:352-362, 1998.
734. Rosenberg, S.A., Yang, J.C., White, D.E., and Steinberg, S.M.: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann. of Surg. 228:307-319, 1998.
735. Irvine, K.R., Chamberlain, R.S., Shulman, E.P., Rosenberg, S.A., and Restifo, N.P.: Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J. Natl. Cancer Inst. 89:390-392, 1998.
736. Zaks, T.Z., and Rosenberg, S.A.: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58:4902-4908, 1998.
737. Parkhurst, M.R., Fitzgerald, E.B., Southwood, S., Sette, A., Rosenberg, S.A., and Kawakami, Y.: Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58:4895-4901, 1998.
738. Bronte, V., Wang, M., Overwijk, W.W., Surman, D.R., Pericle, F., Rosenberg, S.A., and Restifo, N.P.: Apoptotic death of CD8⁺ T lymphocytes after immunization: Induction of a suppressive population of Mac-1⁺/Gr-1⁺ cells. J. Immunol. 161:5313-5320, 1998.
739. Rosenberg, S.A., Zhai, Y., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Seipp, C.A., Einhorn, J.H., Roberts, B., and White, D.E.: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigen. J. Natl. Cancer Inst. 90:1894-1900, 1998.
740. Kawakami, Y., Robbins, P.F., Wang, X., Tupesis, J.P., Parkhurst, M.R., Kang, X., Sakaguchi, K., Appella, E., and Rosenberg, S.A.: Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J. Immunol. 161:6985-6995, 1998.
741. Lee, K-H., Panelli, M.C., Kim, C.J., Riker, A.I., Bettinotti, M.P., Roden, M.M., Fetsch, P., Abati, A., Rosenberg, S.A. and Marincola, F.M.: Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J. Immunol. 161:4183-4194, 1998.

742. Chappell, D.B., Zaks, T.Z., Rosenberg, S.A., and Restifo, N.P.: Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59:59-62, 1999.
743. Zeh, H.J., Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C.: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989-994, 1999.
744. Clay, T., Custer, M., McKee, M., Parkhurst, M., Robbins, P., Kerstann, K., Wunderlich, J., Rosenberg, S.A., and Nishimura, M.: Changes in the fine specificity of gp100₍₂₀₉₋₂₁₇₎-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162:1749-1755, 1999.
745. Restifo, N.P., and Rosenberg, S.A.: Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11:50-57, 1999.
746. Rosenberg, S.A.: 200 years after Jenner: Progress in the search for a cancer vaccine. Accomplishments in Cancer 1997. 180-185, 1998.
747. Rosenberg, S.A., Yang, J.C., Schwarzentruer, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Seipp, C.A., Einhorn, J.H., White, D.E., and Steinberg, S.M.: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and alpha interferon. J. Clin. Oncol. 17:968-975, 1999.
748. Wang, R-F., Johnston, S.L., Zeng, G., Topalian, S.L., Schwarzentruer, D.J., and Rosenberg, S.A.: A breast and melanoma-shared tumor antigenic peptides translated from different open reading frames. J. Immunol. 161:3596-3606, 1998.
749. Pieper, R., Christian, R.E., Gonzales, M.I., Nishimura, M.I., Gupta, G., Settlage, R.E., Shabanowitz, J., Rosenberg, S.A., Hunt, D.F., and Topalian, S.L.: Biochemical identification of a mutated human melanoma antigen recognized by CD4⁺ T cells. J. Exp. Med. 189:757-766, 1999.
750. Lee, L., Wang, R-F., Wang, X., Mixon, A., Johnson, B.E., Rosenberg, S.A. and Schrumpp, D.S.: NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J. Sci. Am. 5:20-26, 1999.
751. Rosenberg, S.A.: Guest Editorial A new era of cancer immunotherapy: converting theory to performance. Cancer J. Clin. 49:70-73, 1999.
752. Zaks, L.T., Chappell, D.B., Rosenberg, S.A., and Restifo, N.P.: Fas-mediated suicide of tumor-reactive T cells following activated by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162:3273-3279, 1999.

753. Marincola, F.M., and Rosenberg, S.A.: The development of cancer vaccines for the treatment of metastatic melanoma. Progress in Anti-Cancer Chemotherapy Part V:201-218, 1999.
754. Overwijk, W.W., Lee, D.S., Surman, D.R., Irvine, K.R., Touloukian, C.E., Chan, C-C., Carroll, M.W., Moss, B., Rosenberg, S.A., Restifo, N.P.: Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4⁺ T lymphocytes. Proc. Natl. Acad. Sci. 96:2982-2987, 1999.
755. Rosenberg, S.A.: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287, 1999.
756. McKee, M.D., Clay, T.M., Rosenberg, S.A., and Nishimura, M.I.: Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. J. Immunother. 22:93-102, 1999.
757. Wang, R-F., Wang, X., and Rosenberg, S.A.: Identification of a novel major histocompatibility complex class-II-restricted tumor antigen resulting from chromosomal rearrangement recognized by CD4⁺ T cells. J. Exp. Med. 189:1659-1667, 1999.
758. Wagner, J.R., Walther, M.M., Linehan, W.M., White, D.E., Rosenberg, S.A., and Yang, J.C.: Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with kidney in place. J. Urol. 162:43-45, 1999.
759. Wang, R-F., Wang, X., Atwood, A.L., Topalian, S.L., and Rosenberg, S.A.: Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351-1354, 1999.
760. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Sznol, M., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Seipp, C.A., Einhorn, J.H., Rogers-Freezer, L., White, D.E.: Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163:1690-1695, 1999.
761. Atkins, M.B., Lotze, M.T., Dutcher, J.P., Fisher, R.I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Kunkel, L., and Rosenberg, S.A.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated from 1985-1993. J. Clin. Oncol. 17:2105-2116, 1999.
762. Irvine, K.R., Parkhurst, M.R., Shulman, E.P., Tupesis, J.P., Custer, M., Touloukian, C.E., Robbins, P.F., Yafal, A.G., Greenhalgh, P., Suttmuller, R.P.M., Offringa, R., Rosenberg, S.A., and Restifo, N.P.: Recombinant virus vaccination against “self” antigens using anchor-fixed immunogens. Cancer Res. 59:2536-2540, 1999.

763. Fraker, D.L., Alexander, H.R., Andrich, M., and Rosenberg, S.A.: Treatment of patients with metastatic melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 14:479-489, 1996.
764. H., Steinberg, S., Rosenberg, S.A. and Marincola, F.: Immune selection after antigen-specific immunotherapy of melanoma. Surg. 126:112-120, 1999.
765. Dudley, M.E., Nishimura, M.I., Holt, A.K.C., and Rosenberg, S.A.: Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J. Immunother. 22:288-298, 1999.
766. Rosenberg, S.A.: New opportunities for the development of cancer immunotherapies. Cancer J. Sci. Am. Supplement 4:S1-S4, 1998.
767. Hurst, R., White, D., Heiss, J., Lee, D., Rosenberg, S.A., and Schwartzentruber, D.: Brain metastasis after immunotherapy in patients with melanoma or renal cell cancer: Is craniotomy indicated? J. Immunother. 22:356-362, 1998.
768. Kim, C.J., Chan, C-C., and Rosenberg, S.A.: Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens. J. Immunother. 22:182-183, 1999.
769. Riker, A.I., Kammula, U.S., Ohnmacht, G.A., Steinberg, S.M., Rosenber, S.A., and Marincola, F.M.: Threshold levels of gene expression of the melanoma antigen, gp100, determine tumor cell recognition b cytotoxic T lymphocytes. Surg. Forum L:295-297, 1999.
770. Lee, K-H., Wang, E., Nielsen, M-B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S.M., Rosenberg, S.A., and Marincola, F.M.: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:6292-6300, 1999.
771. Wang, R-F., and Rosenberg, S.A.: Human tumor antigens for cancer vaccine development. Immunol. Rev. 170:85-100, 1999.
772. Robbins, P.F., Wang, R-F., and Rosenberg, S.A.: VII. Medical Applications of cytotoxic lymphocytes: Tumor antigens recognized by cytotoxic lymphocytes. In: Sitkovsky, M.V., Henkart, P.A. (eds): Cytotoxic Cells: Basic Mechanisms and Medical Applications, Philadelphia: J.B. Lippincott, 2000, pp 363-383.

773. Nishimura, M.I., Avichezer, D., Custer, M.C., Lee, C.S., Chen, C., Parkhurst, M.R., Diamond, R.A., Robbins, P.F., Schwartzentruber, D.J., and Rosenberg, S.A.: MHC class I restricted recognition of a melanoma antigen by a human CD4⁺ tumor infiltrating lymphocyte. Cancer Res. 59:6230-6238, 1999.
774. Touloukian, C.E., and Rosenberg, S.A.: A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. Cancer J. Sci. Am. 5:269-274, 1999.
775. Panelli, M.C., Riker, A., Kammula, U., Wang, E., Lee, K-L., Rosenberg, S.A., and Marincola, F.M.: Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J. Immunol. 164:495-504, 2000.
776. Touloukian, C.E., Leitner, W.W., Topalian, S.L., Li, Y.F., Robbins, P.F., Rosenberg, S.A., and Restifo, N.P.: Identification of an MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J. Immunol. 164:3535-3542, 2000.
777. Kammula, U.S., Lee, K-H., Riker, A.I., Wang, E., Ohnmacht, G.A., Rosenberg, S.A., and Marincola, F.M.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163:6867-6875, 1999.
778. Panelli, M.C., Bettinotti, M.P., Lally, K., Li, Y., Ohnmacht, G.A., Robins, P., Riker, A., Rosenberg, S.A., and Marincola, F.M.: A tumor infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 164:4382-4392, 2000.
779. Riker, A.I., Panelli, M.C., Kammula, U.S., Wang, E., Wunderlich, J., Abati, A., Fetsch, P., Rosenberg, S.A., and Marincola, F.M.: Development and characterization of melanoma cell lines established by fine needle aspiration biopsy: Advances in monitoring patients with metastatic melanoma. Cancer Prev. Detect. 23:387-396, 1999.
780. Kaufman, H.L., Rao, J.B., Irvine, K.R., Bronte, V., Rosenberg, S.A., and Restifo, N.P.: Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J. Immunother. 22:489-496, 1999.
781. Rosenberg, S.A.: Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am. 6:S2-S7, 2000.
782. Rosenberg, S.A.: Identification of cancer antigens: Impact on the development of cancer immunotherapies. Cancer J. Sci. Am. 6:S200-S207, 2000.
783. Dudley, M.E., Ngo, L.T., Westwood, J., Wunderlich, J.R., and Rosenberg, S.A.: T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J. Sci. Am. 6:69-77, 2000.

784. Kawakami, Y., Dang, N., Wang, X., Tupesis, J., Robbins, P.F., Wang, R-F., Wunderlich, J.R., Yannelli, J.R., and Rosenberg, S.A.: Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23:17-27, 2000.
785. Rosenberg, S.A.: Identification of cancer antigens: Impact on development of cancer vaccines. Cancer J. Sci. Am. 6:S141-S149, 2000.
786. Lindsey, K.R., Rosenberg, S.A., and Sherry, R.M.: Impact of the number of treatment courses on the clinical response of patients who received high-dose bolus interleukin-2. J. Clin. Oncol. 18:1954-1959, 2000.
787. Zeng, G., Touloukian, C.E., Wang, X., Restifo, N.P., Rosenberg, S.A., and Wang, R-F.: Identification of CD4⁺ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165:1153-1159, 2000.
788. McKee, M.D., Clay, T.M., Diamond, R.A., Rosenberg, S.A., and Nishimura, M.I.: Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: Dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture. J. Immunother. 23:419-429, 2000.
789. Marroquin, C.E., White, D.E., Steinberg, S.M., Rosenberg, S.A., and Schwartzentruber, D.J.: Decreased tolerance to interleukin-2 (IL-2) with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer. J. Immunother. 23:387-392, 2000.
790. Panelli, M.C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S.A., and Marincola, F.M.: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 23:487-498, 2000.
791. Kammula, U.S., Marincola, F.M., and Rosenberg, S.A.: Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92:1336-1344, 2000.
792. Fritsch, M., Rosenberg, S.A., and Duray, P.H.: Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine. J. Immunother. 23:557-569, 2000.
793. Parker, L.L., Do, M.T., Westwood, J.A., Wunderlich, J.R., Dudley, M.E., Rosenberg, S.A., and Hwu, P.: Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Human Gene Therapy 11:2377-2387, 2000.

794. Bownds, S., Tong-On, P., Rosenberg, S.A. and Parkhurst, M.: Induction of tumor-reactive Cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J. Immunother. 24:1-9, 2001.
795. Chang, E., and Rosenberg, S.A.: Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2 based therapy. J. Immunother. 24:88-90, 2001.
796. Clay, T.M., Custer, M.C., Sachs, J., Hwu, P., Rosenberg, S.A., and Nishimura, M.I.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163:507-513, 1999.
797. Harada, M., Li, Y.F., El-Gamil, M., Rosenberg, S.A. and Robbins, P.F.: Use of an *in vitro* immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. Cancer Res. 61:1089-1094, 2001.
798. Kawakami, Y., Wang, X., Shofuda, T., Sumimoto, H., Tupesis, J.P., Fitzgerald, E., and Rosenberg, S.A.: Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J. Immunol. 166:2871-2877, 2001.
799. Ohnmacht, G.A., Mavroukakis, S.A., Steinberg, S.M., Witebsky, F.G., McIntyre, L.S., Goodwin, R.S., Muehlbauer, P.M., Morton, K.E., Rogers-Freezer, L.J., Seipp, C.A., Rosenberg, S.A., and Marincola, F.M.: A prospective randomized double-blind, placebo controlled trial evaluating the impact of nystatin on the development of oral irritation in patients receiving high dose intravenous interleukin-2. J. Immunother. 24:188-192, 2001.
800. Weiser, T.S., Guo, S., Ohnmacht, G.A., Parkhurst, M.L., Tong-On, P., Marincola, F.M., Fischette, M.R., Yu, X., Chen, A., Hong, J.A., Stewart, J.H., Nguyen, D.M., Rosenberg, S.A., and Schrumpp, D.S.: Sequential 5-Aza-2'-deoxycytidine-Depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24:151-161, 2001.
801. Zeng, G., Wang, X., Robbins, P.F., Rosenberg, S.A., and Wang, R-F.: CD4⁺ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. 98:3964-3969, 2001.
802. Overwijk, W.W., and Rosenberg, S.A.: 200 years after jenner: The search for a cancer vaccine. Frontiers in Biomedicine, edited: Dr. Goldstein. New York: Kluwer Academic, pp. 279-289, 2001.

803. Monsurro, V., Nielsen, M., Perez-Diez, A., Dudley, M.E., Wang, E., Rosenberg, S.A., and Marincola, F.M.: Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol. 166:5817-5825, 2001.
804. Riley, J.P., Rosenberg, S.A., and Parkhurst, M.R.: Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. J. Immunother. 24:212-220, 2001.
805. Rosenberg, S.A.: Progress in human tumour immunology and immunotherapy. Nature 411:380-384, 2001.
806. Phan, G.Q., Attia, P., Steinberg, S.M., White, D.E., and Rosenberg, S.A.: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19:3477-3482, 2001.
807. Ladanyi, A., Nishimura, M.I., Rosenberg, S.A., and Yang, J.C.: Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide. J. Immunother. 23:36-47, 2000.
808. Vasselli, J.R., Yang, J.C., Linehan, W.M., White, D.E., Rosenberg, S.A., and Walther, M.M.: Lack of retroperitoneal lymphadenopathy predicts survival and response to IL-2 in patients with metastatic renal cell carcinoma. J. Urol. 66:68-72, 2001.
809. Leitner, W.W., Ying, H., Driver, D.A., Dubensky, T.W., Rosenberg, S.A., and Restifo, N.P.: Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60:51-55, 2000.
810. Dudley, M.E., Wunderlich, J., Nishimura, M.I., Yu, D., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Sherry, R., Leitman, S., and Rosenberg, S.A.: Adoptive transfer of cloned, melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. 24:363-373, 2001.
811. Harada, M., Li, Y.F., El-Gamil, M., Ohnmacht, G.A., Rosenberg, S.A., and Robbins, P.F.: Melanoma reactive CD⁺ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J. Immunother. 24:323-333, 2001.
812. Liu, K., and Rosenberg, S.A.: Transduction of an interleukin-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167:6356-6365, 2001.
813. Mocellin, S., Fetsch, P., Abati, A.B., Phan, G., Wang, E., Provenzano, M., Stroncek, D., Rosenberg, S.A., and Marincola, F.M.: Laser scanning cytometer evaluation of MART-1, gp100 and HLA-A2 expression in melanoma metastases. J. Immunother. 24:447-458, 2001.

814. Touloukian, C.E., Leitner, W.W., Robbins, P.F., Rosenberg, S.A., and Restifo, N.P.: Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. Cancer Res. 61:8100-8104, 2001.
815. Rosenberg, S.A.: Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250:462-475, 2001.
816. Nielsen, M.B., Monsurro, V., Migueles, S.A., Wang, E., Perez-Diez, A., Lee, K.H., Kammula, U., Rosenberg, S.A., and Marincola, F.M.: Status of activation of circulating vaccine-elicited CD8⁺ T cells. J. Immunol. 165:2287-2296, 2000.
817. Stewart, J.H., Rosenberg, S.A.: Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine. J. Immunother. 23:401-404, 2000.
818. Rosenberg, S.A.: Cellular therapy: an introduction. Cancer J.Supplement. 2:S51-52, 2001.
819. Ohnmacht, G.A., Wang, E., Mocellin, S., Abati, A., Filie, A., Fetsch, P., Riker, A.I., Kammula, U.S., Rosenberg, S.A., and Marincola, F.M.: Short-term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167:1809-1820, 2001.
820. McKee, M.D., Cecco, S.A., Niemela, J.E., Cormier, J., Kim, C.J., Steinberg, S.M., Rehak, N.N., Elin, R.J., and Rosenberg, S.A.: Effects of interleukin 2 therapy on lymphocyte magnesium levels. J. Lab. Clin. Med. 139:5-12, 2002.
821. Monsurro, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M.E., Rosenberg, S.A., Marincola, F.M.: Functional heterogeneity of vaccine-induced CD8(+) T cells. J. Immunol. 168:5933-5942, 2002.
822. Thurber, S.E., Khong, H.T., Kammula, U.S., and Rosenberg, S.A.: Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using quantitative real-time PCR. J. Immunother. 25:63-71, 2002.
823. Guirguis, L.M., Yang, J.C., White, D.E., Steinberg, S.M., Liewehr, D.J., Rosenberg, S.A., and Schwartzentruber, D.J.: Safety and efficacy of high dose IL-2 therapy in patients with brain metastases. J. Immunother. 25:82-87, 2002.
824. Toso, J.F., Gill, V.J., Witebsky, W.G., Hwu, P., Marincola, F.M., Restifo, N.P., Schwartzentruber, D.J., Sherry, R.M., Topalian, S.L., Yang, J.C., Freezer, L.J., Morton, K.E., Seipp, C., Haworth, L., Mavroukakis, S., White, D.E., Sznol, M., and Rosenberg, S.A.: Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20:142-152, 2002.

825. Rosenberg, S.A., Tong-On, P., Li, Y., Riley, J.P., El-Gamil, M., Parkhurst, M.R., and Robbins, P.F.: Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. J. Immunol. 168:2402-2407, 2002.
826. Khong, H.T., and Rosenberg, S.A.: Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol. 168:951-956, 2002.
827. Weinreich, D., and Rosenberg, S.A.: Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low dose interleukin-2. J. Immunother. 25:185-187, 2002.
828. Rosenberg, S.A., Spiess, P.J., and Kleiner, D.E.: Antitumor effects in mice of the intravenous injection of attenuated salmonella typhimurium. J.Immunother. 25:218-225, 2002.
829. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R.M., Marincola, F.M., Leitman, S.F., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., Nahvi, A., Mavroukakis, S.A., White, D.E., and Rosenberg, S.A.: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:243-251, 2002.
830. Seiter, S., Monsurro, V., Nielsen MB, Wang, E., Provenzano, M., Wunderlich, J.R., Rosenberg, S.A., and Marincola, F.M.:Frequency of MART-1/MelanA and gp100/PMel17-Specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J. Immunother. 25:252-263, 2002.
831. Marroquin, C.E., Westwood, J.A., Lapointe, R., Mixon, A., Wunderlich, J.R., Caron, D., Rosenberg, S.A., and Hwu, P. Mobilization of dendritic cell precursors in patients with cancer by Flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother. 25:278-288, 2002.
832. Khong, H.T., and Rosenberg, S.A.: The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 62:3020-3023, 2002.
833. Wang, E., Miller, L.D., Ohnmacht, G.A., Mocellin, S., Perez-Diez, A., Petersen, D., Zhao, Y., Simon, R., Powell, J.I., Asaki, E., Alexander, R., Duray, P.H., Herlyn, M., Restifo, N.P., Liu, E.T., Rosenberg, S.A., Marincola, F.M. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62:3581-3586, 2002.

834. Zeng, G., Li, Y., El-Gamil, M., Sidney, J., Sette, A., Wang, R., Rosenberg, S.A., and Robbins, P.F. Generation of NY-ESO-1-specific CD4⁺ and CD8⁺ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62(13): 3630-3635, 2002.
835. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M., Robinson, M.R., Raffeld, M., Duray, P., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., Mavroukakis, S.A., White, D.E., and Rosenberg, S.A.: Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. Science. 298:850-854, 2002.
836. Touloukian, C.E., Leitner, W.W., Robbins, P.F., Li, Y.F., Lapointe, R., Hwu, P., Rosenberg, S.A. and Restifo, N.P.: Expression of a “self-“ antigen by human tumor cells enhance tumor antigen-specific CD4(+) T-cell function. Cancer Res. 62:5144-5147, 2002.
837. Javia, L.R., and Rosenberg, S.A.: CD4⁺CD25⁺ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26:85-93, 2003.
838. Robbins, P.F., El-Gamil, M., Li, Y.F., Zeng, G., Dudley, M., and Rosenberg, S.A.: Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. 169:6036-6047, 2002.
839. Attia, P., Phan, G.Q., Duray, P.H., Rosenberg, S.A.: Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma. Am. J. Clin. Oncol. 26:42-45, 2003.
840. Heimann, D.M., Rosenberg, S.A.: Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. J. Immunother. 26:179-180, 2003.
841. Liu, K. and Rosenberg, S.A.: Interleukin-2 independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation-dependent. J. Immunother. 26:190-201, 2003.
842. Barrett, J.C., Bennett, L.M., Fleming, L.K., Linehan, W.M., Liotta, L.A., Pastan, I., Rosenberg, S.A., Staudt, L.M., Thompson, T.E., Yang, J.C.: Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin. Adv. Hematol. Oncology. 1:302-306, 2003.

843. Rosenberg, S.A., Yang, J.C. Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Restifo, N.P., Haworth, L.R., Seipp, C.A., Freezer, L.J., Morton, K.E., Mavroukakis, S.A., and White, D.E.: Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum. Gene Ther. 14:709-714, 2003.
844. Phan, G. Q., Touloukian, C.E., Yang, J.C., Restifo, N.P., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Seipp, C.A., Freezer, L.J., Morton, K.E., Mavroukakis, S.A., White, D.E., Rosenberg, S.A.: Immunization of patients with metastatic melanoma using both class I and class II restricted peptides from melanoma-associated antigens. J. Immunother. 26:349-356, 2003.
845. Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Restifo, N.P., Haworth, L.R., Seipp, C.A., Freezer, L.J., Morton, K.E., Mavroukakis, S.A., Duray, P.H., Steinberg, S.M., Allison, J.P., Davis, T.A. and Rosenberg, S.A.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. 100:8372-8377, 2003.
846. Touloukian, C.E., Leitner, W.W., Schnur, R.E., Robbins, P.F., Li Y., Southwood, S., Sette A., Rosenberg, S.A., Restifo, N.P.: Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J. Immunol. 170:1579-85, 2003.
847. Riley, J.P., Rosenberg, S.A., and Parkhurst, M.R.: Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities. J. Immunol Methods. 276:103-19, 2003.
848. Parkhurst, M.R., DePan C., Riley, J.P., Rosenberg, S.A., and Shu, S.: Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol. 170:5317-25, 2003.
849. Dudley, M.E., Wunderlich, J.R., Shelton, T.E., Even, J., and Rosenberg, S.A.: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26:332-342, 2003.
850. Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., and Rosenberg, S.A.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:427-434, 2003.

851. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Topalian, S.L., Sherry, R.M., Restifo, N.P., Wunderlich, J.R., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., Mavroukakis, S.A., Gritz, L., Panicali, D.L., and White, D.E.: Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate anti-tumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 9:2973-2980, 2003.
852. Nagorsen, D., Panelli, M., Dudley, M.E., Finkelstein, S.E., Rosenberg, S.A., and Marincola, F.M.: Biased epitope selection by recombinant vaccinia-virus (rVV)-Infected mature or immature dendritic cells. Gene Ther. 10:1754-1765, 2003.
853. Rosenberg, S.A., Yang, J.C., Robbins, P.F., Wunderlich, J.R., Hwu, P., Sherry, R.M., Schwartzentruber, D.J., Topalian, S.L., Restifo, N.P., Filie, A., Chang, R., and Dudley, M.E.: Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 26:385-393, 2003.
854. Yang, J.C., Sherry, R.M., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., White, D.E., Liewehr, D.J., Merino, M.J., and Rosenberg, S.A.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21:3127-3132, 2003.
855. Overwijk, W.W., Theoret, M.R., Finkelstein, S.E., Surman, D.R., de Jong, L.A., Vyth-Dreese, F.A., Dellemljn, T.A., Antony, P.A., Spiess, P.J., Palmer, D.C., Heimann, D.M., Klebanoff, C.A., Yu, Z., Hwang, L.N., Feigenbaum, L., Kruisbeek, A.M., Rosenberg, S.A., and Restifo, N.P.: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8⁺ T cells. J. Exp. Med. 198:569-580, 2003.
856. Morgan, R.A., Dudley, M.E., Yu, Y.Y.L., Zheng, Z., Robbins, P.F., Theoret, M.R., Wunderlich, J.R., Hughes, M.S., Restifo, N.P., and Rosenberg, S.A.: High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171:3287-3295, 2003.
857. Maccalli, C., Li, Y.F., El-Gamil, M., Rosenberg, S.A., and Robbins, P.F.: Identification of a colorectal tumor associated antigen (COA-1) recognized by CD4⁺ T lymphocytes. Cancer Res. 63:6735-6743, 2003.
858. Dudley, M.E., and Rosenberg, S.A.: Adoptive cell transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer. 3:666-675, 2003.
859. Parkhurst, M.R., Riley, J.P., Robbins, P.F., and Rosenberg, S.A.: Induction of CD4⁺ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J. Immunother. 27:79-91, 2004.

860. Powell, D.J. and Rosenberg, S.A.: Phenotypic and functional maturation of tumor antigen-reactive CD8⁺ T lymphocytes in patients undergoing multiple course peptide vaccination. J. Immunother. 27:36-47, 2004.
861. Rosenberg, S.A.: Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350:1461-1463, 2004.
862. Rosenberg, S.A.: Development of effective immunotherapy for the treatment of patients with cancer. J. Am. Coll. Surg. 198:685-696, 2004
863. Khong, H.T., Wang, Q.J., and Rosenberg, S.A.: Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother. 27:184-190, 2004.
864. Klebanoff, C.A., Finkelstein, S.E., Surman, D.R., Lichtman, M.K., Gattinoni, L., Theoret, M.R., Grewal, N., Spiess, P.J., Antony, P.A., Palmer, D.C., Tagaya, Y., Rosenberg, S.A., Waldmann, T.A., and Restifo, N.P.: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8⁺ T cells. Proc. Natl. Acad. Sci. 101:1969-1974, 2004.
865. Huang, J., El-Gamil, M., Dudley, M.E., Li, Y.F., Rosenberg, S.A., and Robbins, P.F.: T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J. Immunol. 172:6057-6064, 2004.
866. Rosenberg, S.A. and Dudley, M.E.: The immunotherapy of patients with metastatic melanoma by inducing clonal repopulation with antitumor lymphocytes. Progress in Oncology. Massachusetts: Jones and Bartlett, pp. 254-268, 2004.
867. Parkhurst, M.R., Riley, J.P., Igarashi, T., Li, Y., Robbins, P.F., and Rosenberg, S.A.: Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumor endogenously expressing telomerase. Clin. Cancer Res. 10:4688-4698, 2004.
868. Finkelstein, S.E., Heimann, D.M., Klebanoff, C.A., Antony, P.A., Gattinoni, L., Hinrichs, C.S., Hwang, L.N., Palmer, D.C., Spiess, P.J., Surman, D.R., Wrzesinski, C., Yu, Z., Rosenberg, S.A., and Restifo, N.P.: Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J. Leukoc. Biol. 76:333-337, 2004.
869. Finkelstein, S.E., Carrasquillo, J.A., Hoffman, J.M., Galen, B., Choyke, P., White, D.E., Rosenberg, S.A., and Sherry, R.M.: A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann. Surg. Oncol. 11:731-738, 2004.

870. Rosenberg, S.A., Yang, J.C., and Restifo, N.P.: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-915, 2004.
871. Rosenberg, S.A., Dudley, M.E.: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. 101:14639-14645, 2004.
872. Rosenberg, S.A., Yang, J.C., and Restifo, N.P.: Reply to "Cancer vaccines: Pessimism in check". Nat. Med. 10:1279-1280, 2004.
873. Elaraj, D.M., White, D.E., Steinberg, S.M., Haworth, L., Rosenberg, S.A., Yang, J.C.: A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J. Immunother. 27:259-264, 2004.
874. Khong, H.T., Yang, J.C., Topalian, S.L., Sherry, R.M., Mavroukakis, S.A., White, D.E., and Rosenberg, S.A.: Immunization of HLA-A*0201 and/or HLA-DP β 1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27:472-477, 2004.
875. Robinson, M.R., Chan, C-C., Yang, J.C., Rubin, B.J., Gracia, G.J., Sen, H.N., Csaky, K.G., and Rosenberg, S.A.: Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J. Immunother. 27:478-479, 2004.
876. Powell, D.J., Dudley, M.E., Robbins, P.F., and Rosenberg, S.A.: Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105:241-250, 2004.
877. Zhou, J., Dudley, M.E., Rosenberg, S.A., and Robbins, P.F.: Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J. Immunol. 173:7622-7629, 2004.
878. Robbins, P.F., Dudley, M.E., Wunderlich, J., El-Gamil, M., Li, Y.F., Zhou, J., Huang, J., Powell, D.J., and Rosenberg, S.A.: Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173:7125-7130, 2004.
879. Restifo, N.P., Rosenberg, S.A.: Use of standard criteria for assessment of cancer vaccines. Lancet Oncol. 6:3-4, 2005.
880. Rosenberg, S.A.: Cell transfer and other immunotherapeutic strategies. Clin Adv. Hematol. Oncol. 3:28-29, 2005.

881. Zhou, J., Dudley, M.E., Rosenberg, S.A., and Robbins, P.F.: Persistence of multiple tumor-specific T cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28:53-62, 2005.
882. Charo, J., Finkelstein, S.E., Grewal, N., Restifo, N.P., Robbins, P.F., and Rosenberg, S.A.: Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65:2001-2008, 2005.
883. Rosenberg, S.A.: Cancer immunotherapy comes of age. Nat. Clin. Pract.Oncol. 2:115, 2005.
884. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L. Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., Jones, S.A., Mangiameli, D.P., Pelletier, M.M., Gea-Banacloche, J., Robinson, M.R., Berman, D.M., Filie, A.C., Abati, A., and Rosenberg, S.A.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23:2346-2357, 2005.
885. Rosenberg, S.A.: The emergence of modern cancer immunotherapy. Ann.Surg. Oncol. 12:1-4, 2005.
886. Antony, P.A., Piccirillo, C.A., Akpinarli, A., Finkelstein, S.E., Speiss, P.J., Surman, D.R., Palmer, D.C., Chan, C.C., Klebanoff, C.A., Overwijk, W.W., Rosenberg, S.A., and Restifo, N.P.: CD8⁺ T cell immunity against a tumor/self-antigen is augmented by CD4⁺ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174:2591-2601, 2005.
887. Zhao, Y., Zheng, Z., Robbins, P.F., Khong, H.T., Rosenberg, S.A., and Morgan, R.A.: Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor celllines. J. Immunol. 174:4415-4423, 2005.
888. Huang, J., Khong, H.T., Dudley, M.E., El-Gamil, M., Li, Y.F., Rosenberg, S.A., and Robbins, P.F.: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28:258-267, 2005.
889. Ahmadzadeh, M., and Rosenberg, S.A.: TGF- β 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174:5215-5223, 2005.
890. Hughes, M.S., Yu, Y.Y.L., Dudley, M.E., Zheng, Z., Robbins, P.F., Li, Y., Wunderlich, J., Hawley, R.G., Moayeri, M., Rosenberg, S.A., and Morgan, R.A.: Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16:457-472, 2005.

891. Gattinoni, L., Klebanoff, C.A., Palmer, D.C., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S.E., Theoret, M.R., Rosenberg, S.A., and Restifo, N.P.: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8⁺ T cells. J. Clin. Invest. 115:1616-1626, 2005.
892. Attia, P., Phan, G.Q., Maker, A.V., Robinson, M.R., Quezado, M.M., Yang, J.C., Sherry, R.M., Topalian, S.L., Kammula, U.S., Royal, R.E., Restifo, N.P., Haworth, L.R., Levy, C., Mavroukakis, S.A., Nichol, G., Yellin, M.J., and Rosenberg, S.A.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23:6043-6053, 2005.
893. Powell, D.J., Parker, L.L., and Rosenberg, S.A.: Large scale depletion of CD25⁺ regulatory T cells from patient leukapheresis samples. J. Immunother. 28:403-411, 2005.
894. Aisner, D.L., Maker, A., Rosenberg, S.A., and Berman, D.M.: Loss of S100 antigenicity in metastatic melanoma. Hum. Pathol. 36:1016-1019, 2005.
895. Klebanoff, C.A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A.R., Finkelstein, S.E., Palmer, D.C., Antony, P.A., Hwang, S.T., Rosenberg, S.A., Waldmann, T.A., and Restifo, N.P.: Central memory self/tumor-reactive CD8⁺ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. 102:9571-9576, 2005.
896. Gattinoni, L., Finkelstein, S.E., Klebanoff, C.A., Antony, P.A., Palmer, D.C., Spiess, P.J., Hwang, L.N., Yu, Z., Wrzesinski, C., Heimann, D.M., Surh, C.D., Rosenberg, S.A., and Restifo, N.P.: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8⁺ T cells. J. Exp. Med. 202:907-912, 2005.
897. Rosenberg, S.A., Sherry, R.M., Morton, K.E., Sharfman, W.H., Yang, J.C., Topalian, S.L., Royal, R.E., Kammula, U., Restifo, N.P., Hughes, M.S., Schwartzentruber, D., Berman, D.M., Schwarz, S.L., Ngo, L.T., Mavroukakis, S.A., White, D.E., Steinberg, S.M.: Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8⁺ T cells in patients with melanoma. J. Immunol. 175:6169-6176, 2005.
898. Cohen, C.J., Zheng, Z., Bray, R., Zhao, Y., Sherman, L.A., Rosenberg, S.A., and Morgan, R.A.: Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175:5799-5808, 2005.
899. Blansfield, J.A., Beck, K.E., Tran, K., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Topalian, S.L., Haworth, L.R., Levy, C., and Rosenberg, S.A.: Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28:593-598, 2005.

900. Hinrichs, C.S., Palmer, D.C., Rosenberg, S.A., and Restifo, N.P.: Glucocorticoids do not inhibit antitumor activity of activated CD8⁺ T cells. J. Immunother. 28:517-524, 2005.
901. Attia, P., Maker, A.V., Haworth, L.R., Rogers-Freezer, L., and Rosenberg, S.A.: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB₃₈₉IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28:582-592, 2005.
902. Zhou, J., Shen, X., Hodes, R.J., Rosenberg, S.A., Robbins, P.: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175:7046-7052, 2005.
903. Maker, A.V., Phan, G.Q., Attia, P., Yang, J.C., Sherry, R.M., Topalian, S.L., Kammula, U.S., Royal, R.E., Haworth, L.R., Levy, C., Kleiner, D., Mavroukakis, S.A., Yellin, M., and Rosenberg, S.A.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann. Surg. Oncol. 12:1005-1016, 2005.
904. Maker, A.V., Attia, P., and Rosenberg, S.A.: Analysis of the cellular mechanism of anti-tumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175:7746-7754, 2005.
905. Hsu, C., Hughes, M.S., Zheng, Z., Bray, R.B., Rosenberg, S.A., and Morgan, R.A.: Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J. Immunol. 175:7226-7234, 2005.
906. Ahmadzadeh, M., and Rosenberg, S.A.: IL-2 administration increases CD4⁺CD25^{hi}Foxp3⁺ regulatory T cells in cancer patients. Blood. 107:2409-2414, 2006.
907. Jaber, S.H., Cowen, E.W., Haworth, L.R., Boohar, S.L., Berman, D.M., Rosenberg, S.A., and Hwang, S.T.: Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142:166-172, 2006.
908. Attia, P., Powell, D.J., Maker, A.V., Kreitman, R.J., Pastan, I., and Rosenberg, S.A.: Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J. Immunother. 29:208-214, 2006.
909. Rosenberg, S.A., Sherry, R.M., Morton, K.E., Yang, J.C., Topalian, S.L., Royal, R.E., Kammula, U., Restifo, N.P., Hughes, M.S., Schwarz, S.L., Ngo, L.T., Mavroukakis, S.A., and White, D.E.: Altered CD8⁺ T cell responses when immunizing with multiepitope peptide vaccines. J. Immunother. 29:224-231, 2006.

910. Romeo, M.J., Wunderlich, J., Ngo, L., Rosenberg, S.A., Steinberg, S.M., Berman, D.M.: Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray. Clin. Cancer Res. 12:2463-2467, 2006.
911. Lindsey, K.R., Gritz, L., Sherry, R., Abati, A., Fetsch, P.A., Goldfeder, L.C., Gonzales, M.I., Zinnack, K.A., Rogers-Freezer, L., Haworth, L., Mavroukakis, S.A., White, D.E., Steinberg, S.M., Restifo, N.P., Panicali, D.L., Rosenberg, S.A., and Topalian, S.L.: Evaluation of prime/boost regimens using recombinant foxxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res. 12:2526-2537, 2006.
912. Gattinoni, L., Powell, D.J., Rosenberg, S.A., Restifo, N.P.: Adoptive immunotherapy for cancer: Building on success. Nat. Rev. Immunology . 6:383-393, 2006.
913. Liu, S., Riley, J., Rosenberg, S., and Parkhurst, M.: Comparison of common γ -chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 29:284-293, 2006.
914. Rosenberg, S.A., Sportes, C., Ahmadzadeh, M., Fry, T.J., Ngo, L.T., Schwarz, S.L., Stetler-Stevenson, M., Morton, K.E., Mavroukakis, S.A., Morre, M., Buffet, R., Mackall, C.L., Gress, R.E.: IL-7 administration to humans leads to expansion of CD8⁺ and CD4⁺ cells but a relative decrease of CD4⁺ T regulatory cells. J. Immunother. 29:313-319, 2006.
915. Shafer-Weaver, K., Rosenberg, S., Strobl, S., Alvord, W.G., Baseler, M., and Malyguine, A.: Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J. Immunother. 29:328-335, 2006.
916. Zhao, Y., Zheng, Z., Khong, H.T., Rosenberg, S.A., and Morgan, R.A.: Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4⁺ lymphocytes. J. Immunother. 29:398-406, 2006.
917. Rosenberg, S.A., Restifo, N.P.: Response to comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8⁺ T cells in patients with melanoma". J. Immunol. 176:4511-4512, 2006.
918. Zhao, Y., Zheng, Z., Cohen, C.J., Gattinoni, L., Palmer, D.C., Restifo, N.P., Rosenberg, S.A., Morgan, R.A.: High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13:151-159, 2006.
919. Rosenberg, S.A.: Response to comment on "Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 176:5136, 2006.

920. Maker, A.V., Yang, J.C., Sherry, R.M., Topalian, S.L., Kammula, U.S., Royal, R.E., Hughes, M., Yellin, M.J., Haworth, L.R., Levy, C., Allen, T., Mavroukakis, S.A., Attia, P., and Rosenberg, S.A.: Inpatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29:455-463, 2006.
921. Beck, K.E., Blansfield, J.A., Tran, K.Q., Feldman, A.L., Hughes, M.S., Royal, R.E., Kammula, U.S., Topalian, S.L., Sherry, R.M., Kleiner, D., Quezado, M., Lowy, I., Yellin, M., Rosenberg, S.A., and Yang, J.C.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24:2283-2289, 2006.
922. Huang, J., Kerstann, K.W., Ahmadzadeh, M., Li, Y.F., El-Gamil, M., Rosenberg, S.A., and Robbins, P.F.: Modulation by IL-2 of CD70 and CD27 expression on CD8⁺ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J. Immunol. 176:7726-7735, 2006.
923. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., de Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., and Rosenberg, S.A.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129, 2006.
924. Cohen, C.J., Zhao, Y., Zheng, Z., Rosenberg, S.A., and Morgan, R.A.: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66:8878-8886, 2006.
925. Grover, A., Kim, G.J., Lizee, G., Tschoi, M., Wang, G., Wunderlich, J.R., Rosenberg, S.A., Hwang, S.T., and Hwu, P.: Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin. Cancer Res. 12:5801-5808, 2006.
926. Powell, D.J., Dudley, M.E., Hogan, K.A., Wunderlich, J.R., and Rosenberg, S.A.: Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J. Immunol. 177:6527-6539, 2006.
927. Johnson, L.A., Heemskerk, B., Powell, D.J., Cohen, C.J., Morgan, R.A., Dudley, M.E., Robbins, P.F., and Rosenberg, S.A.: Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177:6548-6559, 2006.
928. Lotem, M., Zhao, Y., Riley, J., Hwu, P., Morgan, R.A., Rosenberg, S.A., and Parkhurst, M.A.: Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J. Immunother. 29:616-627, 2006.

929. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., Chen, C.C., Yang, J.C., Rosenberg, S.A., and Hwu, P.: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12:6106-6115, 2006.
930. Muranski, P., Boni, A., Wrzesinski, C., Citrin, D.E., Rosenberg, S.A., Childs, R., and Restifo, N.P.: Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go?. Nat. Clin. Pract. Oncol. 3:668-681, 2006.
931. Smith, F.O., Goff, S.L., Klapper, J.A., Levy, C., Allen, T., Mavroukakis, S.A., and Rosenberg, S.A.: Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J. Immunother. 1:130, 2007.
932. Shen, X., Zhou, J., Hathcock, K.S., Robbins, P., Powell, D.J. Jr., Rosenberg, S.A., and Hodes, R.J., Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 1:123-129, 2007.
933. Gattinoni, L., Ranganathan, A., Surman, D.R., Palmer, D.C., Antony, P.A. Theoret, M.R., Heimann, D.M., Rosenberg, S.A., Restifo, N.P.: CTLA-4 dysregulation of self/tumor-reactive CD8+ T cell function is CD4+ T cell-dependent. Blood 108:3818-3823, 2006.
934. Wrzesinski, C., Paulos, C.M., Gattinoni, L., Palmer, D.C., Kaiser, A., Yu, Z., Rosenberg, S.A., and Restifo, N.P.: Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin Invest. 117:492-501, 2007.
935. Zhao, Y., Parkhurst, M.R., Zheng, Z., Cohen, C.J., Riley, J.P., Gattinoni, L., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A.: Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via notch signaling. Cancer Res. 67:2425-2429, 2007.
936. Ahmadzadeh, M., Antony, P., and Rosenberg, S.A.: IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J. Immunother. 30:294-302, 2007.
937. Powell Jr., D.J., de Vries, C.R., Allen, T., Ahmadzadeh, M., and Rosenberg, S.A.: Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J. Immunother. 30:438-447, 2007.
938. Hsu, C., Jones, S.A., Cohen, C.J., Zheng, Z., Kerstann, K., Zhou, J., Robbins, P.F., Peng, P.D., Shen, X., Gomes, T.J., Dunbar, C.E., Munroe, D.J., Stewart, C., Cornetta, K., Wangsa, D., Ried, T., Rosenberg, S.A., and Morgan, R.A.: Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109:5168-5177, 2007.

939. Paulos, C.M., Wrzesinski, C., Kaiser, A., Hinrichs, C.S., Chieppa, M., Cassard, L., Palmer, D.C., Boni, A., Muranski, P., Yu, Z., Gattinoni, L., Antony, P.A., Rosenberg, S.A. and Restifo, N.P.: Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8⁺ T cells via TLR4 signaling. J. Clin. Invest. 117:2197-2204, 2007.
940. Rosenberg, S.A.: Interleukin 2 for patients with renal cancer. Nat. Clin. Pract. Oncol. 4:497, 2007.
941. Cohen, C.J., Li, Y.F., El-Gamil, M., Robbins, P.F., Rosenberg, S.A., and Morgan, R.A.: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67:3898-3903, 2007.
942. Paulos, C.M., Kaiser, A., Wrzesinski, C., Hinrichs, C.S., Cassard, L., Boni, A., Muranski, P., Sanchez-Perez, L., Palmer, D.C., Yu, Z., Antony, P.A., Gattinoni, L., Rosenberg, S.A., and Restifo, N.P.: Toll-like receptors in tumor immunotherapy. Clin. Cancer Res. 13:5280-5289, 2007.
943. Zhao, Y., Bennett, A.D., Zheng, Z., Wang, Q.J., Robbins, P.F., Yu, L.Y.L., Li, Y., Molloy, P.E., Dunn, S.M., Jakobsen, B.K., Rosenberg, S.A., and Morgan, R.A.: High-affinity TCRs generated by phage display provide CD4⁺ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179:5845-5854, 2007.
944. Downey, S.G., Klapper, J.A., Smith, F.O., Yang, J.C., Sherry, R.M., Royal, R.E., Kammula, U.S., Hughes, M.S., Allen, T.E., Levy, C.L., Yellin, M., Nichol, G., White, D.E., Steinberg, S.M., and Rosenberg, S.A.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13:6681-6688, 2007.
945. Dudley, M.E. and Rosenberg, S.A.: Adoptive cell transfer therapy. Semin Oncol. 34:524-531, 2007.
946. Yang, J.C., Hughes, M., Kammula, U., Royal, R., Sherry, R.M., Topalian, S.L., Suri, K.B., Levy, C., Allen, T., Mavroukakis, S., Lowy, I., White, D.E., and Rosenberg, S.A.: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30:825-830, 2007.
947. Rosenberg, S.A.: Why perform sentinel-lymph-node biopsy in patients with melanoma? Nat. Clin. Pract. Oncol. 5:1, 2008.
948. Abad, J.D., Wrzensinski, C., Overwijk, W., De Witte, M.A., Jorritsma, A., Hsu, C., Gattinoni, L., Cohen, C.J., Paulos, C.M., Palmer, D.C., Haanen, J.B.A.G., Schumacher, T.N.M., Rosenberg, S.A., Restifo, N.P., and Morgan, R.A.: T-cell receptor gene therapy of established tumors in a murine melanoma model. J. Immunother. 31:1-6, 2008.

949. Powell Jr., D.J., Attia, P., Ghetie, V., Schindler, J., Vitetta, E.S., and Rosenberg, S.A.: Partial reduction of human Foxp3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J. Immunother. 31:189-198, 2008.
950. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., and Dudley, M.E.: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8:299-308, 2008.
951. Robbins, P.F., Li, Y.F., El-Gamil, M., Zhao, Y., Wargo, J.A., Zheng, Z., Xu, H., Morgan, R.A., Feldman, S.A., Johnson, L.A., Bennett, A.D., Dunn, S.M., Mahon, T.M., Jakobsen, B.K., and Rosenberg, S.A.: Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180:6116-6131, 2008.
952. Heemskerk, B., Liu, K., Dudley, M.E., Johnson, L.A., Kaiser, A., Downey, S., Zheng, Z., Shelton, T.E., Matsuda, K., Robbins, P.F., Morgan, R.A., and Rosenberg, S.A.: Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 19:496-510, 2008.
953. Restifo, N.P., Robbins, P.F., and Rosenberg, S.A.: Tumor Immunology. In: Paul, W.E. (ed.) Fundamental Immunology, 6th edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1489-1522, 2008.
954. Restifo, N.P., Robbins, P.F., and Rosenberg, S.A.: Principles of Immunology. In: DeVita, V.T., Lawrence, T.S., Rosenberg, S.A. (eds.) Cancer: Principles & Practice of Oncology, 8th edition, Lippincott Williams & Wilkins, Philadelphia, PA, 351-368, 2008.
955. Slingluff Jr., C.L., Flaherty, K., Rosenberg, S.A., and Read, P.W.: Cutaneous Melanoma. In: DeVita, V.T., Lawrence, T.S., Rosenberg, S.A. (eds.) Cancer: Principles & Practice of Oncology, 8th edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1897-1951, 2008.
956. Rosenberg, S.A., and Dudley, M.E.: Cancer Immunotherapy. In: DeVita, V.T., Lawrence, T.S., Rosenberg, S.A. (eds.) Cancer: Principles & Practice of Oncology, 8th edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2979-2989, 2008.
957. Palmer, D.C., Chan, C-C., Gattinoni, L., Wrzesinski, C., Paulos, C.M., Hinrichs, C.S., Powell Jr., D.J., Klebanoff, C.A., Finkelstein, S.E., Fariss, R.N., Yu, Z., Nussenblatt, R.B., Rosenberg, S.A., and Restifo, N.P.: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl. Acad. Sci. 105:8061-8066, 2008.
958. Klapper, J.A., Downey, S.G., Smith, F.O., Yang, J.C., Hughes, M.S., Kammula, U.S., Sherry, R.M., Royal, R.E., Steinberg, S.M., and Rosenberg, S.A.: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer 113:293-301, 2008.

959. Breunis, W.B., Tarazona-Santos, E., Chen, R., Kiley, M., Rosenberg, S.A., Chanock, S.J.: Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J. Immunother. 31:586-590, 2008.
960. Hinrichs, C.S., Spolski, R., Paulos, C.M., Gattinoni, L., Kerstann, K.W., Palmer, D.C., Klebanoff, C.A., Rosenberg, S.A., Leonard, W.J., and Restifo, N.P.: IL-2 and IL-21 confer opposing differentiation programs to CD8⁺ T cells for adoptive immunotherapy. Blood 111:5326-5333, 2008.
961. Rosenberg, S.A.: Overcoming obstacles to the effective immunotherapy of human cancer. Proc. Natl. Acad. Sci. 105:12643-12644, 2008.
962. Smith, F.O., Downey, S.G., Klapper, J.A., Yang, J.C., Sherry, R.M., Royal, R.E., Kammula, U.S., Hughes, M.S., Restifo, N.P., Levy, C.L., White, D.E., Steinberg, S.M., and Rosenberg, S.A.: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14:5610-5618, 2008.
963. Powell, D.J., Jr., Felipe-Silva A., Merino, M.J., Ahmadzadeh, M., Allen, T., Levy, C., White, D.E., Mavroukakis, S., Kreitman, R.J., Rosenberg, S.A., Pastan, I.: Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179:4919-4928, 2007.
964. Rosenberg, S.A., Dudley, M.E., Restifo, N.P.: Cancer Immunotherapy. N. Engl. J. Med., 359:1072, 2008.
965. Tran, K.Q., Zhou, J., Durflinger, K.H., Langan, M.M., Shelton, T.E., Wunderlich, J.R., Robbins, P.F., Rosenberg, S.A., Dudley, M.E.: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 31: 742-751, 2008.
966. Yang, S., Rosenberg, S.A., and Morgan, R.A.: Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother. 31:830-839, 2008.
967. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F. Wunderlich, J., Restifo, N.P., Thomasian, A., Downey, S.G., Smith, F.O., Klapper, J., Morton, K., Laurencot, C., White, D.E., and Rosenberg, S.A.: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233-5239, 2008.

968. Boni, A., Muranski, P., Cassard, L., Wrzesinski, C., Paulos, C.M., Palmer, D.C., Gattinoni, L., Hinrichs, C.S., Chan, C.C., Rosenberg, S.A., and Restifo, N.P.: Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 112:4746-4754, 2008.
969. Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D.J., Jr., Wunderlich, J.R., Merino, M.J., and Rosenberg, S.A.: FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112:4953-4960, 2008.
970. Theoret, M.R., Cohen, C.J., Nahvi, A.Z., Ngo, L.T., Suri, K.B., Powell, Jr., D.J., Dudley, M.E., Morgan, R.A., and Rosenberg, S.A.: Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum. Gene Ther. 19:1219-1232, 2008.
971. Wargo, J.A., Robbins, P.F., Li, Y., Zhao, Y., El-Gamil, M., Caragacianu, D., Zheng, Z., Hong, J.A., Downey, S., Schrumpp, D.S., Rosenberg, S.A., and Morgan, R.A.: Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58:383-394, 2009.
972. Parkhurst, M.R., Joo, J., Riley, J.P., Yu, Z., Li, Y., Robbins, P.F., and Rosenberg, S.A.: Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 15:169-180, 2009.
973. Solomon, D.A., Kim, J.S., Cronin, J.C., Sibenaller, Z., Ryken, T., Rosenberg, S.A., Ransom, H., Jean, W., Bigner, D., Yan, H., Samuels, Y., Waldman, T.: Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res. 68:10300-10306, 2008.
974. Yang, S., Cohen, C.J., Peng, P.D., Zhao, Y., Cassard, L., Yu, Z., Zheng, Z., Jones, S., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A.: Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15:1411-1423, 2008.
975. Rosenberg, S.A.: Effective immunotherapy for patients with metastatic melanoma. The Melanoma Letter. 26:1-4, 2008.
976. Rosenberg, S.A. and Dudley, M.E.: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21:233-240, 2009
977. Jones, S., Peng, P.D., Yang, S., Hsu, C., Cohen, C.J., Zhao, Y., Abad, J., Zheng, Z., Rosenberg, S.A., and Morgan, R.: Lentiviral vector design for optimal TCR gene expression in the transduction of PBL and TIL. Hum. Gene Ther. 20:630-640, 2009.

978. Palavalli, L.H., Prickett, T.D., Wunderlich, J.R., Wei, X., Burrell, A.S., Porter-Gill, P., Davis, S., Wang, C., Cronin, J.C., Agrawal, N.S., Lin, J.C., Westbroek, W., Hoogstraten-Miller, S., Molinolo, A.A., Fetsch, P., Filie, A.C., O'Connell, M.P., Banister, C.E., Howard, J.D., Buckhaults, P., Weeraratna, A.T., Brody, L.C., Rosenberg, S.A., and Samuels, Y.: Analysis of the matrix metalloproteinase family reveals the MMP8 is often mutated in melanoma. Nat. Genet. 41:518-520, 2009.
979. Yeh, S., Karne, N.K., Kerkar, S.P., Heller, C.K., Palmer, D.C., Johnson, L.A., Li, Z., Bishop, R.J., Wong, W.T., Sherry, R.M., Yang, J.C., Dudley, M.E., Restifo, N.P., and Rosenberg, S.A., Nussenblatt, R.N.: Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 116:981-989.e1, 2009.
980. Klapper, J.A., Thomasian, A.A., Smith, D.M., Gorgas, G.C., Wunderlich, J.R., Smith, F.O., Hampson, B.S., Rosenberg, S.A., and Dudley, M.D.: Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J. Immunol. Methods 345:90-99, 2009.
981. Kochenderfer, J.N., Feldman, S.A., Zhao, Y., Xu, H., Black, M.A., Morgan, R.A., Wilson, W.H., and Rosenberg, S.A.: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32:689-702, 2009.
982. Cronin, J.C., Wunderlich, J., Loftus, S.K., Prickett, T.D., Wei, X., Ridd, K., Vemula, S., Burrell, A.S., Agrawal, N.S., Lin, J.C., Banister, C.E., Buckhaults, P., Rosenberg, S.A., Bastian, B.C., Pavan, W.J., and Samuels, Y.: Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res. 22:435-444, 2009.
983. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., Lee, C-C. R., Restifo, N.P., Schwarz, S.L., Cogdill, A.P., Bishop, R.J., Kim, H., Brewer, C.C., Rudy, S.F., VanWaes, C., Davis, J.L., Mathur, A., Ripley, R.T., Nathan, D.A., Laurencot, C.M., and Rosenberg, S.A.: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546, 2009.
984. Peng, P.D., Cohen, C.J., Yang, S., Hsu, C., Jone, S., Zhao, Y., Zheng, Z., Rosenberg, S.A., and Morgan, R.A.: Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 16:1042-1049, 2009.
985. Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., and Rosenberg, S.A.: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544, 2009.

986. Smith, F.O., Klapper, J.A., Wunderlich, J.R., Rosenberg, S.A., and Dudley, M.E.: Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J. Immunother. 32:870-874, 2009.
987. Goff, S.L., Robbins, P.F., El-Gamil, M., and Rosenberg, S.A.: No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma. J. Immunother. 32:884-885, 2009.
988. Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, J.R., Cronin, J.C., Cruz, P., Rosenberg, S.A., and Samuels, Y.: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41:1127-1132, 2009.
989. Hinrichs, C.S., Borman, Z.A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z., Sanchez-Perez, L., Muranski, P., Kern, S.J., Logun, C., Palmer, D.C., Ji, Y., Reger, R.N., Leonard, W.J., Danner, R.L., Rosenberg, S.A., and Restifo, N.P.: Adoptively transferred effector cells derived from naive rather than central memory CD8⁺ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. 106:17469-17474, 2009.
990. Burns, W.R., Zheng, Z., Rosenberg, S.A., and Morgan, R.A.: Lack of specific (-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114:2888-2899, 2009.
991. Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S.A., and Morgan, R.A.: A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183:5563-5574, 2009.
992. Ripley, R.T., Davis, J.L., Klapper, J.A., Mathur, A., Kammula, U., Royal, R.E., Yang, J.C., Sherry, R.M., Hughes, M.S., Libutti, S.K., White, D.E., Steinberg, S.M., Dudley, M.E., Rosenberg, S.A., and Avital, I.: Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann. Surg. Oncol. 17:163-170, 2010.
993. Wrzesinski, C., Paulos, C.M., Kaiser, A., Muranski, P., Palmer, D.C., Gattinoni, L., Yu, Z., Rosenberg, S.A., and Restifo, N.P.: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T. cells. J. Immunother. 33:1-7, 2010.
994. Kerkar, S.P., Kemp, C.D., Duffy, A., Kammula, U.S., Schrupp, D.S., Kwong, K.F., Quezado, M., Goldspiel, B.R., Venkatesan, A., Berger, A., Walker, M., Toomey, M.A., Steinberg, S.M., Giaccone, G., Rosenberg, S.A., and Avital, I.: The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 10:121, 2009.

995. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and Rosenberg, S.A.: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18:843-851, 2010.
996. Burns, W.R., Zhao, Y., Frankel, T.L., Hinrichs, C.S., Zheng, Z., Xu, H., Feldman, S.A., Ferrone, S., Rosenberg, S.A., and Morgan, R.A.: A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70:3027-3033, 2010.
997. Frankel, T.L., Burns, W.R., Peng, P.D., Yu, Z., Chinnasamy, D., Wargo, J.A., Zheng, Z., Restifo, N.P., Rosenberg, S.A. and Morgan, R.A.: Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 184:5988-5998, 2010.
998. Cárdenas-Navia, L.I., Cruz, P., Lin, J.C., NISC Comparative Sequencing Program, Rosenberg, S.A., and Samuels, Y.: Novel somatic mutations in heterotrimeric G proteins in melanoma. Cancer Biol. Ther. 10:1-5, 2010.
999. Prieto, P.A., Durflinger, K.H., Wunderlich, J.R., Rosenberg, S.A., and Dudley, M.E.: Enrichment of CD8⁺ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J. Immunother. 33:547-556, 2010.
1000. Rosenberg, S.A., Yang, J.C., Kammula, U.S., Hughes, M.S., Restifo, N.P., Schwarz, S.L., Morton, K.E., Laurencot, C.M., and Sherry, R.M.: Different adjuvanticity of Incomplete Freund's Adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J. Immunother. 33:626-629, 2010.
1001. Yang, S., Dudley, M.E., Rosenberg, S.A., and Morgan, R.A.: A simplified method for the clinical-scale generation of central memory-like CD8⁺ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. J. Immunother. 33:648-658, 2010.
1002. Kalbasi, A., Shrimali, R.K., Chinnasamy, D., and Rosenberg, S.A.: Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 33:672-683, 2010.
1003. Shrimali, R.K., Yu, Z., Theoret, M.R., Chinnasamy, D., Restifo, N.P., and Rosenberg, S.A.: Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70:6171-6180, 2010.

1004. Lopez, G.Y., Reitman, Z.J., Solomon, D., Waldman, T., Bigner, D.D., McLendon, R.E., Rosenberg, S.A., Samuels, Y., and Yan H.: IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem. Biophys. Res. Commun. 398:585-587, 2010.
1005. Morgan, R.A., Dudley, M.E., and Rosenberg, S.A.: Adoptive cell therapy: Genetic modification to redirect effector cell specificity. Cancer J. 16:336-341, 2010.
1006. Davis, J.L., Ripley, R.T., Frankel, T.L., Maric, I., Lozier, J.N., and Rosenberg, S.A.: Paraneoplastic granulocytosis in metastatic melanoma. Melanoma Res. 20:326-329, 2010.
1007. Ray, S., Chhabra, A., Chakraborty, N.G., Hedge, U., Dorsky, D.I., Chodon, T., von Euw, E., Comin-Anduiz, B., Koya, R.C., Ribas, A., Economou, J.S., Rosenberg, S.A., and Mukherji, B.: MHC-I-restricted melanoma antigen specific TCR-engineered human CD4⁺ T cells exhibit multifunctional effector and helper responses, in vitro. Clin. Immunol. 136:338-347, 2010.
1008. Kerkar, S.P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D.C., Reger, R.N., Borman, Z.A., Zhang, L., Morgan, R.A., Gattinoni, L., Rosenberg, S.A., Trinchieri, G., and Restifo, N.P.: Tumor-specific CD8⁺ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70:6725-6734, 2010.
1009. Royal, R.E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U.S., Sherry, R.M., Topalian, S.L., Yang, J.C., Lowy, I., and Rosenberg, S.A.: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33:828-833, 2010.
1010. Goff, S.L., Smith, F.O., Klapper, J.A., Sherry, R., Wunderlich, J.R., Steinberg, S.M., White, D., Rosenberg, S.A., Dudley, M.E., and Yang, J.C.: Tumor infiltrating lymphocyte therapy for metastatic melanoma: Analysis of tumors resected for TIL. J. Immunother. 33:840-847, 2010.
1011. Goff, S.L., Johnson, L.A., Black, M.A., Xu, H., Zheng, Z., Cohen, C.J., Morgan, R.A., Rosenberg, S.A., and Feldman, S.A.: Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1 reactive T cell receptor following a rapid expansion. Cancer Immunol. Immunother. 59:1551-1560, 2010.
1012. Frankel, T.L., Burns, W., Riley, J., Morgan, R.A., Davis, J.L., Hanada, K., Quezado, M., Rosenberg, S.A., and Royal, R.E.: Identification and characterization of a tumor infiltrating CD56⁺/CD16⁻ NK cell subset with specificity for pancreatic and prostate cancer cell lines. Cancer Immunol. Immunother. 59:1757-1769, 2010.

1013. Hong, J.J., Rosenberg, S.A., Dudley, M.E., Yang, J.C., White, D.E., Butman, J.A., and Sherry, R.A.: Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 16:4892-4898, 2010.
1014. Rosenberg, S.A.: Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 18:1744-1755, 2010.
1015. Inozume, T., Hanada, K., Wang, Q.J., Ahmadzadeh, M., Wunderlich, J.R., Rosenberg, S.A., and Yang, J.C.: Selection of CD8⁺PD-1⁺ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33:956-964, 2010
1016. Klapper, J.A., Davis, J.L., Ripley, R.T., Smith, F.O., Nguyen, D.M., Kwong, K.F., Mercedes, L., Kemp, C.D., Mathur, A., White, D.E., Dudley, M.E., Wunderlich, J.R., Rosenberg, S.A., and Schrumpp, D.S.: Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience. J. Thorac. Cardiovasc. Surg. 140:1276-1282, 2010.
1017. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., Morgan, R.A., and Rosenberg, S.A.: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-4102, 2010.
1018. Chinnasamy, D., Yu, Z., Theoret, M.R., Zhao, Y., Shrimali, R.K., Morgan, R., Feldman, S.A., Restifo, N.P., and Rosenberg, S.A.: Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120:3953-3968, 2010.
1019. Wei, X., Prickett, T.D., Vilorio, C.G., Molinolo, A., Line, J.C., Cardenas-Navia, I., Cruz, P., NISC Comparative Sequencing Program, Rosenberg, S.A., Davies, M.A., Gershenwald, J.E., López-Otin, C., and Samuels, Y.: Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol. Cancer Res. 8:1513-1525, 2010.
1020. Davis, J.L., Theoret, M.R., Zheng, Z., Lamers, C.H., Rosenberg, S.A. and Morgan, R.A.: Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16:5852-5861, 2010.
1021. Chinnasamy, N., Wargo, J.A., Yu, Z., Rao, M., Frankel, T.L., Riley, J.P., Hong, J.J., Parkhurst, M.R., Feldman, S.A., Schrumpp, D.S., Restifo, N.P., Robbins, P.F., Rosenberg, S.A., and Morgan, R.A.: A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186:685-696, 2011.

1022. Hinrichs, C.S., Borman, Z.A., Gattinoni, L., Yu, Z., Burns, W.R., Huang, J., Klebanoff, C.A., Johnson, L.A., Kerkar, S.P., Yang, S., Muranski, P., Palmer, D.C., Scott, C.D., Morgan, R.A., Robbins, P.F., Rosenberg, S.A., and Restifo, N.P.: Human effector CD8⁺ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117:808-814, 2011.
1023. Parkhurst, M.R., Yang, J.C., Langan, R.C., Dudley, M.E., Nathan, D.N., Feldman, S.A., Davis, J.L., Morgan, R.A., Merino, M.J., Sherry, R.M., Hughes, M.S., Kammula, U.S., Phan, G.Q., Lim, R.M., Wank, S.A., Restifo, N.P., Robbins, P.F., Laurencot, C.M., and Rosenberg, S.A.: T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19:620-626, 2011.
1024. Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., Wunderlich, J.R., Nahvi, A.Z., Helman, L.J., Mackall, C.L., Kammula, U.S., Hughes, M.S., Restifo, N.P., Raffeld, M., Lee, C.C., Levy, C.L., Li, Y.F., El-Gamil, M., Schwarz, S.L., Laurencot, C., and Rosenberg, S.A.: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29:917-924, 2011.
1025. Zhang, L., Kerkar, S.P., Yu, Z., Zheng, Z., Yang, S., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A.: Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19:751-759, 2011.
1026. Kerkar, S.P., Sanchez-Perez, L., Yang, S., Borman, Z.A., Muranski, P., Ji, Y., Chinnasamy, D., Kaiser, A.D., Hinrichs, C.S., Klebanoff, C.A., Scott, C.D., Gattinoni, L., Morgan, R.A., Rosenberg, S.A., and Restifo, N.P.: Genetic engineering of murine CD8⁺ and CD4⁺ cells for preclinical adoptive immunotherapy studies. J. Immunother. 34:343-352, 2011.
1027. Langan, R.C., Prieto, P.A., Sherry, R.M., Zlott, D., Wunderlich, J., Csako, G., Costello, R., White, D.E., Rosenberg, S.A., and Yang, J.C.: Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J. Immunother. 34:397-402, 2011.
1028. Huang, J., Wang, Q.J., Yang, S., Li, Y.F., El-Gamil, M., Rosenberg, S.A., and Robbins, P.F.: Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J. Immunother. 34:327-335, 2011.
1029. Wei, X., Walia, V., Lin, J.C., Teer, J.K., Prickett, T.D., Gartner, J., Davis, S., NISC Comparative Sequencing Program, Stemke-Hale, K., Davies, M.A., Gershenwald, J.E., Robinson, S., Rosenberg, S.A., and Samuels, Y.: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43:442-446, 2011.

1030. Ertl, H.C., Zaia, J., Rosenberg, S.A., June, C.H., Dotti, G., Kahn, J., Cooper, L.J., Corrigan-Curay, J., and Strome, S.E.: Considerations for the clinical application of chimeric antigen receptor T cells: Observations from a Recombinant DNA Advisory Committee symposium held June 15, 2010. Cancer Res. 71:3175-3181, 2011.
1031. Schwartzentruber, D.J., Lawson, D.H., Richards, J.M., Conry, R.M., Miller, D.M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., Kendra, K.L., White, R.L., Gonzalez, R., Kuzel, T.M., Curti, B., Leming, P.D., Whitman, E.D., Balkissoon, J., Reintgen, D.S., Kaufman, H., Marincola, F.M., Merino, M.J., Rosenberg, S.A., Choyke, P., Vena, D., and Hwu, P.: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364:2119-2127, 2011.
1032. Rosenberg, S.A.: Surgical oncology: General issues. DeVita, V.T., Lawrence, T.S., Rosenberg, S.A. (eds.). Cancer: Principles and Practice of Oncology, Philadelphia: Lippincott, Williams & Wilkins, 268-276, 2011.
1033. Rosenberg, S.A., Robbins, P.F., and Restifo, N.P.: Cancer immunotherapy. DeVita, V.T., Lawrence, T.S., Rosenberg, S.A. (eds.). Cancer: Principles and Practice of Oncology, Philadelphia: Lippincott, Williams & Wilkins, 332-344, 2011.
1034. Wei, X., Moncada-Pazos, A., Cal S., Soria-Valles, C., Gartner, J., Rudloff, U., Lin, J.C., NISC Comparative Sequencing Program, Rosenberg, S.A., López-Otin, C., and Samuels, Y.: Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. Hum. Mutat. 32:E2148-2175, 2011.
1035. Yang, S., Gattinoni, L., Liu, F., Ji, Y., Yu, Z., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A.: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol. Immunother. 60:739-749, 2011.
1036. Lonser, R.R., Song, D.K., Klapper, J., Hagan, M., Suh, S., Kerr, P.B., Citrin, D.E., Heiss, J.D., Camphausen, K., and Rosenberg, S.A.: Surgical management of melanoma brain metastases in patients treated with immunotherapy. J.Neurosurg. 115:30-36, 2011.
1037. Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., Citrin, D.E., Restifo, N.P., Robbins, P.F., Wunderlich, J.R., Morton, K.E., Laurencot, C.M., Steinberg, S.M., White, D.E., and Dudley, M.E.: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17:4550-4557, 2011.
1038. Kohn, D.B., Dotti, G., Brentjens, R., Savoldo, B., Jensen, M., Cooper, L.J., June, C.H., Rosenberg, S., Sadelain, M., and Heslop, H.E.: Cars on track in the clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy, May 18, 2010. Mol. Ther. 19:432-438, 2011.

1039. Dalet, A., Robbins, P.F., Stroobant, V., Vigneron, N., Li, Y.F., El-Gamil, M., Hanada, K., Yang, J.C., Rosenberg, S.A., and Van den Eynde, B.J.: An antigenic peptide produced by reverse splicing and double asparagines deamidation. Proc. Natl. Acad. Sci. 108:E323-331, 2011.
1040. Solomon, D.A., Kim, T., Diaz-Martinez, L.A., Fair, J., Elkahouloun, A.G., Harris, B.T., Toretsky, J.A., Rosenberg, S.A., Shukla, N., Ladanyi, M., Samuels, Y., James, C.D., Yu, H., Kim, J.S., and Waldman, T.: Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science, 333:1039-1043, 2011.
1041. Yang, S., Liu, F., Wang, Q.J., and Rosenberg, S.A.: The Shedding of CD62L (L-Selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 6:e22560, 2011.
1042. Klebanoff, C.A., Gattinoni, L., Palmer, D.C., Muranski, P., Ji, Y., Hinrichs, C.S., Borman, Z.A., Kerkar, S.P., Scott, C.D., Finkelstein, S.E., Rosenberg, S.A., and Restifo, N.P.: Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17:5343-5352, 2011.
1043. Parkhurst, M.R., Riley, J.P., Dudley, M.E. and Rosenberg, S.A.: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17:6287-6297, 2011.
1044. Prickett, T.D., Wei, X., Cardenas-Navia, I., Teer, J.K., Lin, J.C., Walia, C., Gartner, J., Jiang, J., Cherukuri, P.F., Molinolo, A., Davies, M.A., Gershenwald, J.E., Stemke-Hale, K., Rosenberg, S.A., Margulies, E.H., and Samuels, Y.: Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43:1119-1126, 2011.
1045. Turcotte, S., Rosenberg, S.A.: Immunotherapy for metastatic solid cancers. Adv. Surg. 45:341-360, 2011.
1046. Friedman, K.M., Devillier, L.E., Feldman, S.A., Rosenberg, S.A., and Dudley, M.E.: Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J. Immunother. 34:651-661, 2011.
1047. Rosenberg, S.A., Kochenderfer, J.N.: Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. Mol. Ther. 19:1928-1930, 2011.
1048. Rosenberg, S.A.: Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know. Nat. Rev. Clin. Oncol. 8:577-585, 2011.
1049. Kochenderfer, J.N. and Rosenberg, S.A.: Chimeric antigen receptor-modified T cells in CLL (Letter to the Editor). N.Engl. J. Med. 365:1937-1938, 2011.

1050. Kerkar, S.P., Goldszmid, R.S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R.N., Leonardi, A.J., Morgan, R.A., Wang, E., Marincola, F.M., Trinchieri, G., Rosenberg, S.A., Restifo, N.P.: IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin Invest. 121:4746-4757, 2011.
1051. Bear, A.S., Morgan, R.A., Cornetta, K., June, C.H., Binder-Scholl, G., Dudley, M.E., Feldman, S.A., Rosenberg, S.A., Shurtleff, S.A., Rooney, C.M., Heslop, H.E., and Dotti, G.: Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol. Ther. 20:246-249, 2012.
1052. Jin, J., Sabatino, M., Somerville, R., Wilson, J.R., Dudley, M.E., Stronck, D.F., and Rosenberg, S.A.: Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J. Immunother. 35:283-292, 2012.
1053. Rosenberg, S.A.: Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4:127ps8, 2012.
1054. Restifo, N.P., Dudley, M.E. and Rosenberg, S.A.: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12:269-281, 2012.
1055. Chinnasamy, D., Yu, Z., Kerkar, S.P., Zhang, L., Morgan, R.A., Restifo, N.P., and Rosenberg, S.A.: Local delivery of interleukin-2 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18:1672-1683, 2012.
1056. Prieto, P.A., Yang, J.C., Sherry, R.M., Hughes, M.S., Kammula, U.S., White, D.E., Levy, C.L., Rosenberg, S.A., and Phan, G.Q.: CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18:2039-2047, 2012.
1057. Somerville, R.P., Devillier, L., Parkhurst, M.R., Rosenberg, S.A. and Dudley, M.E.: Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J. Transl. Med. 10:69, 2012.
1058. Friedman, K.M., Prieto, P.A., Devillier, L.E., Gross, C.A., Yang, J.C., Wunderlich, J.R., Rosenberg, S.A., and Dudley, M.E.: Tumor-specific CD4⁺ melanoma tumor-infiltrating lymphocytes. J. Immunother. 35:400-408, 2012.
1059. Zhang, L., Feldman, S.A., Zheng, Z., Chinnasamy, N., Xu, H., Nahvi, A.V., Dudley, M.E., Rosenberg, S.A., and Morgan, R.A.: Evaluation of γ -retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J. Immunother. 35:430-439, 2012.

1060. Lai, J.P., Robbins, P.F., Raffeld, M., Aung, P.P., Tsokos, M., Rosenberg, S.A., Miettinen, M.M., and Lee, C.C.: NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod. Pathol. 25:854-858, 2012.
1061. DeVita, V.T., and Rosenberg, S.A.: Two hundred years of cancer research. N. Engl. J. Med. 366:2207-2214, 2012.
1062. Yang, S., Karne, N.K., Goff, S.L., Black, M.A., Xu, H., Bischof, D., Cornetta, K., Rosenberg, S.A., Morgan, R.A., and Feldman, S.A.: A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes. Hum. Gene Ther. Methods 23:73-83, 2012.
1063. Kvistborg, P., Shu, C.J., Heemskerk, B., Frankhauser, M., Thrue, C.A., Toebe, M., van Rooij, N., Linnemann, C., van Buuren, M.M., Urbanus, J.H., Beltman, J.B., Thor Straten, P., Li, Y.F., Robbins, P.F., Besser, M.J., Schachter, J., Kenter, G.G., Dudley, M.E., Rosenberg, S.A., Haanen, J.B., Hadrup, S.R., and Schumacher, T.N.: TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1:409-418, 2012.
1064. June, C., Rosenberg, S.A., Sadelain, M., and Weber, J.S.: T-cell therapy at the threshold. Nat. Biotechnol. 30:611-614, 2012.
1065. Parks, T.S., Rosenberg, S.A., Morgan, R.A.: Treating cancer with genetically engineered T cells. Trends Biotechnol. 29:550-557, 2011.
1066. Yao, X., Ahmadzadeh, M., Lu, Y.C., Liewehr, D.J., Dudley, M.E., Liu, F., Schrumpp, D.S., Steinberg, S.M., Rosenberg, S.A., and Robbins, P.F.: Levels of peripheral CD4⁺FoxP3⁺ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119:5688-5696, 2012.
1067. Bergamaschi, C., Bear, J., Rosati, M., Beach, R.K., Alicea, C., Sowder, R., Chertova, E., Rosenberg, S.A., Felber, B.K., and Pavlakis, G.N.: Circulating IL-15 exists as heterodimeric complex with soluble IL-15R α in human and mouse serum. Blood 120:e1-e8, 2012.
1068. Wang, A., Chandran, S., Shah, S.A., Chiu, Y., Paria, B.C., Aghamolla, T., Alvarez-Downing, M.M., Lee, C-C.R., Singh, S., Li, T., Dudley, M.E., Restifo, N.P., Rosenberg, S.A., and Kammula, U.S.: The stoichiometric production of IL-2 and IFN- γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci. Transl. Med. 4:149ra120, 2012.

1069. Seaman, B.J., Guardiani, E.A., Brewer, C.C., Zalewski, C.K., King, K.A., Rudy, S., Van Waes, C., Morgan, R.A., Dudley, M.E., Yang, J.C., and Rosenberg, S.A.: Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg. 147:744-749, 2012.
1070. Zhu, S., Van den Eynde, B.J., Coulie, P.G., Li, Y.F., El-Gamil, M., Rosenberg, S.A., and Robbins, P.F.: Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12. J. Immunother. 35:680-688, 2012.
1071. Morgan, R.A., Johnson, L.A., Davis, J.L., Zheng, Z., Woolard, K.D., Reap, E.A., Feldman, S.A., Chinnasamy, N., Kuan, C.T., Song, H., Zhang, W., Fine, H.A., and Rosenberg, S.A.: Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23:1043-1053, 2012.
1072. Gros, A., Turcotte, S., Wunderlich, J.R., Ahmadzadeh, M., Dudley, M.E., and Rosenberg, S.A.: Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin. Cancer Res. 18:5212-5223, 2012.
1073. Parker, S.C., Gartner, J., Cardenas-Navia, I., Wei, X., Ozel Abaan, H., Ajay, S.S., Hansen, N.F., Song, L., Bhanot, U.K., Killian, J.K., Gindin, Y., Walker, R.L., Meltzer, P.S., Mullikin, J.C., Furey, T.S., Crawford, G.E., Rosenberg, S.A., Samuels, Y., and Margulies, E.H.: Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes. PLoS Genet. 8:e1002871, 2012.
1074. Somerville, R.P., Devillier, L., Parkhurst, M.R., Rosenberg, S.A. and Dudley, M.E.: Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J. Transl. Med. 10:69, 2012.
1075. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., Yang, J.C., Kammula, U.S., Devillier, L., Carpenter, R., Nathan, D.A., Morgan, R.A., Laurencot, C., Rosenberg, S.A.: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720, 2012.
1076. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., Phan, G.Q., Hughes, M.S., Kammula, U.S., Miller, A.D., Hessman, C.J., Stewart, A.A., Restifo, N.P., Quezado, M.M., Alimchandani, M., Rosenberg, A.Z., Nath, A., Wang, T., Bielekova, B., Wuest, S.C., Akula, N., McMahon, F.J., Wilde, S., Mosetter, B., Schendel, D.J., Laurencot, C.M., and Rosenberg, S.A.: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36:133-151, 2013.

1077. Kochenderfer, J.N. and Rosenberg, S.A.: Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10:267-276, 2013.
1078. Uccellini, L., De Giorgi, V., Zhao, Y., Tumaini, B., Erdenebileg, N., Dudley, M.E., Tomei, S., Bedognetti, D., Ascierto, M.L., Liu, Q., Simon R., Kottyan, L., Kaufman, K.M., Harley, J.B., Wang, E., Rosenberg, S.A., Marincola, F.M.: IRF5 gene polymorphisms in melanoma. J. Transl. Med. 10:170, 2012.
1079. Gartner, J.J., Davis, S., Wei, X., Lin, J.C., Trivedi, N.S., NISC Comparative Sequencing Program, Meltzer, P.S., Rosenberg, S.A., Samuels, Y.: Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics 13:505, 2012.
1080. Zhong, S., Malecek, K., Johnson, L.A., Yu, Z., Vega-Saenz de Miera, E., Darvishian, F., McGary, K., Huang, K., Boyer, J., Corse, E., Shao, Y., Rosenberg, S.A., Restifo, N.P., Osman, I., and Krogsaard, M.: T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110:6973-6978, 2013.
1081. Chinnasamy, D., Tran, E., Yu, Z., Morgan, R.A., Restifo, N.P., and Rosenberg, S.A.: Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res. 73:3371-3380, 2013.
1082. Tran, E., Chinnasamy, D., Yu, Z., Morgan, R.A., Lee, C.C., Restifo, N.P., and Rosenberg, S.A.: Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J.Exp. Med. 210:1125-1135, 2013.
1083. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Clifton, P., Tycksen, E., Samuels, Y., and Rosenberg, S.A.: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19:747-752, 2013.
1084. Dudley, M.E., Gross, C.A., Somerville, R.P., Hong, Y., Schaub, N.P., Rosati, S.F., White, D.E., Nathan, D., Resito, N.P., Steinberg, S.M., Wunderlich, J.R., Kammula, U.S., Sherry, R.M., Yang, J.C., Phan, G.Q., Hughes, M.S., Laurencot, C.M., and Rosenberg, S.A.: Randomized selection design trial evaluating CD8⁺-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncology. 31:2152-2159, 2013.
1085. Lu, Y.C., Yao, X., Li, Y.F., El-Gamil, M., Dudley, M.E., Yang, J.C., Almeida, J.R., Douek, D.C., Samuels, Y., Rosenberg, S.A., and Robbins, P.F.: Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. 190:6034-6042, 2013.

1086. Yang, S., Ji, Y., Gattinoni, L., Zhang, L., Yu, Z., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A.: Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother. 62:727-36, 2013.
1087. Malecek, K., Zhong, S., McGary, K., Yu, C., Huang, K., Johnson, L.A., Rosenberg, S.A., and Krogsaard, M.: Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. J. Immunol. Methods 392:1-11, 2013.
1088. Alvarez-Downing, M.M., Inchauste, S.M., Dudley, M.E., White, D.E., Wunderlich, J.R., Rosenberg, S.A., and Kammula, U.S.: Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World J. Surg. Oncol. 10:113, 2012.
1089. Zhang, L., Yu, Z., Muranski, P., Palmer, D.C., Restifo, N.P., Rosenberg, S.A., and Morgan, R.A.: Inhibition of TGF- β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 20:575-580, 2013.
1090. Kerkar, S.P., Leonardi, A.J., van Panhuys, N., Zhang, L., Yu, Z., Crompton, J.G., Pan, J.H., Palmer, D.C., Morgan, R.A., Rosenberg, S.A., and Restifo, N.P.: Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol. Ther. 21:1369-1377, 2013.
1091. Gartner, J.J., Parker, S.C.J., Prickett, T.D., Dutton-Regeister, K., Stitzel, M.L., Lin, J.C., Davis, S., Simhadri, V.L., Jha, S., Katagiri, N., Gotea, V., Teer, J.K., Wei, X., Morken, M.A., Bhanot, U.K., NISC Comparative Sequencing Program, Chen, G., Elnitski, L.L., Davies, M.A., Gershenwald, J.E., Carter, H., Karchin, R., Robinson, W., Robinson, S., Rosenberg, S.A., Collins, F.S., Parmigiani, G., Komar, A.A., Kimchi-Sarfaty, C., Hayward, N.K., Margulies, E.H., and Samuels, Y.: Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc. Natl. Acad. Sci. USA 110:13481-13486, 2013.
1092. Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C.S., Wunderlich, J.R., Dudley, M.E., and Rosenberg, S.A.: Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J. Immunol. 191:2217-2225, 2013.
1093. Abate-Daga, D., Hanada, K., Davis, J.L., Yang, J.C., Rosenberg, S.A., and Morgan, R.A.: Expression in profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 122:1399-1410, 2013.
1094. Phan, G.Q. and Rosenberg, S.A.: Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 20:289-297, 2013.

1095. Beard, R.E., Abate-Daga, D., Rosati, S.F., Zheng, Z., Wunderlich, J.R., Rosenberg, S.A., and Morgan, R.A.: Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin. Cancer Res. 19:4941-4950, 2013.
1096. Chen, S., Li, Y., Depontieu, F.R., McMiller, T.L., English, A.M., Shabanowitz, J., Kos, F., Sidney, J., Sette, A., Rosenberg, S.A., Hunt, D.F., Mariuzza, R.A., and Topalian, S.L.: Structure-based design of altered MHC Class II-restricted peptide ligands with heterogeneous immunogenicity. J. Immunol. 191:5097-5106, 2013.
1097. Bedognetti, D., Spivey, T.L., Zhao, Y., Uccellini, L., Tomei, S., Dudley, M.E., Ascierto, M.L., De Giorgi, V., Liu, Q., Delogu, L.G., Sommariva, M., Sertoli, M.R., Simon, R., Wang, E., Rosenberg, S.A., and Marincola, F.M.: CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer 109:2412-2423, 2013.
1098. Casati, A., Varghaei-Nahvi, A., Feldman, S.A., Assenmacher, M., Rosenberg, S.A., Dudley, M.E., and Scheffold, A.: Clinical-scale selection and viral transduction of human naïve and central memory CD8⁺ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 62:1563-1573, 2013.
1099. Kochenderfer, J.N., Dudley, M.E., Carpenter, R.O., Kassim, S.H., Rose, J.J., Telford, W.G., Hakim, F.T., Halverson, D.C., Fowler, D.H., Hardy, N.M., Mato, A.R., Hickstein, D.D., Gea-Banacloche, J.C., Pavletic, S.Z., Sportes, C., Maric, I., Feldman, S.A., Hansen, B.G., Wilder, J.S., Blacklock-Schuver, B., Jena, B., Bishop, M.R., Gress, R.E., and Rosenberg, S.A.: Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:4129-4139, 2013.
1100. Turcotte, S., Gros, A., Tran, E., Lee, C-C R., Wunderlich, J.R., Robbins, P.F., and Rosenberg, S.A.: Tumor-reactive CD8⁺ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin. Cancer Res. 20:331-343, 2014.
1101. Liu, B., Zhong, S., Malecek, K., Johnson, L.A., Rosenberg, S.A., Zhu, C., and Krogsgaard, M.: 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. Eur. J. Immunol. 44:239-250, 2014.
1102. Aung, P.P., Liu, Y.C., Ballester, L.Y., Robbins, P.F., Rosenberg, S.A., and Lee, C.C.: Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum. Pathol. 45:259-267, 2014.
1103. Hinrichs, C.S., Rosenberg, S.A.: Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 257:56-71, 2014.

1104. Rosenberg, S.A.: Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther. 21:45-47, 2014.
1105. Rosati, S.F., Parkhurst, M.R., Hong, Y., Zheng, Z., Feldman, S.A., Rao, M., Abate-Daga, D., Beard, R.E., Xu, H., Black, M.A., Robbins, P.F., Schrupp, D.A., Rosenberg, S.A., and Morgan, R.A.: A novel murine T-cell receptor targeting NY-ESO-1. J. Immunother. 37:135-146, 2014.
1106. Abate-Daga, D., Speiser, D.E., Chinnasamy, N., Zheng, Z., Xu, H., Feldman, S.A., Rosenberg, S.A., and Morgan, R.A.: Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One 9:e93321, 2014.
1107. Prickett, T.D., Zerlanko, B., Gartner, J.J., Parker, S.C., Dutton-Regester, K., Lin, J.C., Teer, J.K., Wei, X., Jiang, J., NISC Comparative Sequencing Program, Chen, G., Davies, M.A., Gershenwald, J.E., Robinson, W., Robinson, S., Hayward, N.K., Rosenberg, S.A., Margulies, E.H., and Samuels, Y.: Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. J. Invest. Dermatol. 134:452-460, 2014.
1108. Tseng, J., Citrin, D.E., Waldman, M., White, D.E., Rosenberg, S.A., and Yang, J.C.: Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer 120:1426-1432, 2014.
1109. Liu, Q., Tomei, S., Ascierto, M.L., De Giorgi, V., Bedognetti, D., Dai, C., Uccellini, L., Spivey, T., Pos, Z., Thomas, J., Reinboth, J., Murtas, D., Zhang, Q., Chouchane, L., Weiss, G.R., Slingsluff, C.L., Jr., Lee, P.P., Rosenberg, S.A., Alter, H., Yao, K., Wang, E., and Marincola, F.M.: Melanoma NOS1 expression promoted dysfunctional IFN signaling. J. Clin. Invest. 124:2147-2159, 2014.
1110. Yang, J.C., Sherry, R.M. and Rosenberg, S.A.: Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma?. Nat. Rev. Clin. Oncol. 11:245-246, 2014.
1111. Bartlett, E.K., Fetsch, P.A., Filie, A.C., Abati, A., Steinberg, S.M., Wunderlich, J.R., White, D.E., Stephens, D.J., Marincola, F.M., Rosenberg, S.A., and Kammula, U.S.: Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. Clin.Cancer Res. 20:2607-2616, 2014.
1112. Gros, A., Robbins, P.F., Yao, X., Li, Y.F., Turcotte, S., Tran, E., Wunderlich, J.R., Mixon, A., Farid, S., Dudley, M.E., Hanada, K., Almeida, J.R., Darko, S., Douek, D.C., Yang, J.C., and Rosenberg, S.A.: PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124:2246-2259, 2014.

1113. Tran, E., Turcotte, S., Gros, A., Robbins, P.F., Lu, Y.C., Dudley, M.E., Wunderlich, J.R., Somerville, R.P., Hogan, K., Hinrichs, C.S., Parkhurst, M.R., Yang, J.C., and Rosenberg, S.A.: Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science 344:641-645, 2014.
1114. Rosenberg, S.A.: IL-2: The first effective immunotherapy for human cancer. J. Immunol. 192:5451-5458, 2014.
1115. Dutton-Regester, K., Gartner, J.J., Emmanuel, R., Qutob, N., Davies, M.A., Gershenwald, J.E., Robinson, W., Robinson, S., Rosenberg, S.A., Scolyer, R.A., Mann, G.J., Thompson, J.F., Hayward, N.K., and Samuels, Y.: A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget 5:2912-2917, 2014.
1116. Beane, J.D., Yang, J.C., White, D., Steinberg, S.M., Rosenberg, S.A., and Rudloff, U.: Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann. Surg. Oncol. 21:2484-2489, 2014.
1117. Lu, Y.C., Yao, X., Crystal, J.S., Li, Y.F., El-Gamil, M., Gross, C., Davis, L., Dudley, M.E., Yang, J.C., Samuels, Y., Rosenberg, S.A., and Robbins, P.F.: Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin. Cancer Res. 20:3401-3410, 2014.
1118. Tran, E. and Rosenberg, S.A.: T-cell therapy against cancer mutations. Oncotarget 5:4579-4580, 2014.
1119. Corrigan-Curay, J., Kiem, H.P., Baltimore, D., O'Reilly, M., Brentjens, R.J., Cooper, L., Forman, S., Gottschalk, S., Greenberg, P., Junghans, R., Heslop, H., Jensen, M., Mackall, C., June, C., Press, O., Powell, D., Ribas, A., Rosenberg, S., Sadelain, M., Till, B., Patterson, A.P., Jambou, R.C., Rosenthal, E., Gargiulo, L., Montgomery, M., and Kohn, D.B.: T-cell immunotherapy: looking forward. Mol. Ther. 22:1564-1574, 2014.
1120. Sampson, J.H., Choi, B.D., Sanchez-Perez, L., Suryadevara, C.M., Snyder, D.J., Flores, C.T., Schmittling, R.J., Nair, S.K., Reap, E.A., Norberg, P.K., Herndon, J.E., Kuan, C.T., Morgan, R.A., Rosenberg, S.A., and Johnson, L.A.: EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin. Cancer Res. 20:972-984, 2014.
1121. Feldman, S.A., Xu, H., Black, M.A., Park, T.S., Robbins, P.F., Kochenderfer, J.N., Morgan, R.A., and Rosenberg, S.A.: Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating gamma-retroviral vectors. Hum. Gene Ther. Methods 25:253-260, 2014.

1122. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S., and Mackall, C.L.: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517-528, 2015.
1123. Rosenberg, S.A.: Decade in review-cancer immunotherapy: Entering the mainstream of cancer treatment. Nat. Rev. Clin. Oncol. 11:630-632, 2014.
1124. Prickett, T.D., Zerlanko, B.J., Hill, V.K., Gartner, J.J., Qutob, N., Jiang, J., Simaan, M., Wunderlich, J., Gutkind, J.S., Rosenberg, S.A., and Samuels, Y.: Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex foundation. J. Invest. Dermatol. 134:2390-2398, 2014.
1125. Malecek, K., Grigoryan, A., Zhong, S., Gu, W.J., Johnson, L.A., Rosenberg, S.A., Cardozo, T., and Krogsgaard, M.: Specific increase in potency via structure-based design of a TCR. J. Immunol. 193:2587-2599, 2014.
1126. Walia, V., Prickett, T.D., Kim, J.S., Lin, J.C., Zhou, M., Rosenberg, S.A., Elble, R.C., Solomon, D.A., Waldman, T., and Samuels, Y.: Mutational and functional analysis of the tumor-suppressor PTPRD in human-melanoma. Hum. Mutat. 35:1301-1310, 2014.
1127. Conlon, K.C., Lugli, E., Welles, H.C., Rosenberg, S.A., Fojo, A.T., Morris, J.C., Fleisher, T.A., Dubois, S.P., Perera, L.P., Stewart, D.M., Goldman, C.K., Bryant, B.R., Decker, J.M., Chen, J., Worthy, T.A., Figg, W.D. Sr., Peer, C.J., Sneller, M.C., Lane, H.C., Yovandich, J.L., Creekmoore, S.P., Roederer, M., and Waldmann, T.A.: Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33:74-82, 2015.
1128. Crompton, J.G., Sukumar, M., Roychoudhuri, R., Clever, D., Gros, A., Eil, R.L., Tran, E., Hanada, K., Yu, Z., Palmer, D.C., Kerkar, S.P., Michalek, R.D., Upham, T., Leonardi, A., Acquavella, N., Wang, E., Marincola, F.M., Gattinoni, L., Muranski, P., Sundrud, M.S., Klebanoff, C.A., Rosenberg, S.A., Fearon, D.T., and Restifo, N.P.: Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 75:296-305, 2015.
1129. Chandran, S.S., Paria, B.C., Srivastava, A.K., Rothermel, L.D., Stephens, D.J., Dudley, M.E., Somerville, R., Wunderlich, J.R., Sherry, R.M., Yang, J.C., Rosenberg, S.A., and Kammula, U.S.: Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin. Cancer Res. 21:534-543, 2015.

1130. Robbins, P.F., Kassim, S.H., Tran, T.L., Crystal, J.S., Morgan, R.A., Feldman, S.A., Yang, J.C., Dudley, M.E., Wunderlich, J.R., Sherry, R.M., Kammula, U.S., Hughes, M.S., Restifo, N.P., Raffeld, M., Lee, C.C., Li, Y.F., El-Gamil, M., and Rosenberg, S.A.: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response. Clin. Cancer Res. 21:1019-1027, 2015.
1131. Rosenberg, S.A., Restifo, N.P.: Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348:62-68, 2015.
1132. Zhang, L., Morgan, R.A., Beane, J.D., Zheng, Z., Dudley, M.E., Kassim, S.H., Nahvi, A.V., Ngo, L.T., Sherry, R.M., Phan, G.Q., Hughes, M.S., Kammula, U.S., Feldman, S.A., Toomey, M.A., Kerkar, S.P., Restifo, N.P., Yang, J.C., and Rosenberg, S.A.: Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21:2278-2288, 2015.
1133. Stevanovic, S., Draper, L.M., Langan, M.M., Campbell, T.E., Kwong, M.L., Wunderlich, J.R., Dudley, M.E., Yang, J.C., Sherry, R.M., Kammula, U.S., Restifo, N.P., Rosenberg, S.A., and Hinrichs, C.S.: Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33:1543-1550, 2015.
1134. Topalian, S.L., Wolchok, J.D., Chan, T.A., Mellman, I., Palucka, K., Banchereau, J., Rosenberg, S.A., and Wittrup, K.D.: Immunotherapy: The path to win the war on cancer? Cell 161:186-186, 2015.
1135. Liu, L., Patel, B., Ghanem, M.H., Bundoc, V., Zheng, Z., Morgan, R.A., Rosenberg, S.A., Dey, B., and Berger, E.A.: Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J. Virol. 89:6685-6694, 2015.
1136. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., Raffeld, M., Feldman, S., Lu, L., Li, Y.F., Ngo, L.T., Goy, A., Feldman, T., Spaner, D.E., Wang, M.L., Chen, C.C., Kranick, S.M., Nath, A., Nathan, D.A., Morton, K.E., Toomey, M.A., and Rosenberg, S.A.: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33:540-549, 2015.
1137. Abate-Daga, D., Lagisetty, K.H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W.R., Miermont, A.M., Teper, Y., Rudloff, U., Restifo, N.P., Feldman, S.A., Rosenberg, S.A., and Morgan, R.A.: A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum. Gene Ther. 25:1003-1012, 2014.

1138. Beane, J.D., Lee, G., Zheng, Z., Mendel, M., Abate-Daga, D., Bharathan, M., Black, M., Gandhi, N., Yu, Z., Chandran, S., Giedlin, M., Ando, D., Miller, J., Paschon, D., Guschin, D., Rebar, E.J., Reik, A., Holmes, M.C., Gregory, P.D., Restifo, N.P., Rosenberg, S.A., Morgan, R.A., and Feldman, S.A.: Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma. Mol. Ther. 23:1380-1390, 2015.
1139. Feldman, S.A., Assadipour, Y., Kriley, I., Goff, S.L., and Rosenberg, S.A.: Adoptive cell therapy-tumor-infiltrating lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Semin. Oncol. 42:626-639, 2015.
1140. Cohen, C.J., Gartner, J.J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan K., Bliskovsky, V.V., Parkhurst, MR., Ankri, C., Prickett, T.D., Crystal, J.S., Li Y.F., El-Gamil, M., Rosenberg, S.A., and Robbins, P.F.: Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125:3981-3991, 2015.
1141. Draper, L.M., Kwong, M.L., Gros, A., Stevanovic, S., Tran, E., Kerkar, S., Raffeld, M., Rosenberg, S.A., and Hinrichs, C.S.: Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin. Cancer Res. 21:4431-4439, 2015.
1142. Arafteh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahlon, A., Wilmott, J.S., Gartner, J.J., Di Pizio, A., Winograd-Katz, S., Sindiri, S., Rotkopf, R., Dutton-Regester, K., Johansson, P., Pritchard, A.L., Waddell, N., Hill, V.K., Lin, J.C., Hevroni, Y., Rosenberg, S.A., Khan, J., Ben-Dor, S., Niv, M.Y., Ulitsky, I., Mann, G.J., Scolyer, R.A., Hayward, N.K., and Samuels, Y.: Recurrent inactivating RASA2 mutations in melanoma. Nat. Genet. 47:1408-1410, 2015.
1143. Tran, E., Ahmadzadeh, M., Lu, Y.C., Gros, A., Turcotte, S., Robbins, P.F., Gartner, J.J., Zheng, Z., Li, Y.F., Ray, S., Wunderlich, J.R., Somerville, R.P., and Rosenberg, S.A.: Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350:1387-1390, 2015.
1144. Park, T.S., Groh, E.M., Patel, K., Kerkar, S.P., Lee, CC., and Rosenberg, S.A.: Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers. J. Immunother. 39:1-7, 2016.
1145. Rosenberg, S.A.: CCR 20th Anniversary Commentary: Autologous T cells – The ultimate personalized drug for the immunotherapy of human cancer. Clin. Cancer Res. 21:5409-5411, 2015.

1146. Klebanoff, C.A., Scott, C.D., Leonardi, A.J., Yamamoto, T.N., Cruz, A.C., Ouyang, C., Ramaswamy, M., Roychoudhuri, R., Ji, Y., Eil, R.L., Sukumar, M., Crompton, J.G., Palmer, D.C., Borman, Z.A., Clever, D., Thomas, S.K., Patel, S., Yu, Z., Muranski, P., Liu, H., Wang, E., Marincola, F.M., Gros, A., Gattinoni, L., Rosenberg, S.A., Siegel, R.M., and Restifo, N.P.: Memory T cell-driven differentiation of naïve cells impairs adoptive immunotherapy. J. Clin. Invest. 126:318-334, 2016.
1147. Klebanoff, C.A., Rosenberg, S.A., and Restifo, N.P.: Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22: 26-36, 2016.
1148. Brudno, J.N., Somerville, R.P., Shi, V., Rose, J.J., Halverson, D.C., Fowler, D.H., Gea-Banacloche, J.C., Pavletic, S.Z., Hickstein, D.D., Lu, T.L., Feldman, S.A., Iwamoto, A.T., Kurlander, R., Maric, I., Goy, A., Hansen, B.G., Wilder, J.S., Blacklock-Schuver, B., Hakim, F.T., Rosenberg, S.A., Gress, R.E., and Kochenderfer, J.N.: Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34:1112-1121, 2016.
1149. Kalaora, S., Barnea, E., Merhavi-Shoham, E., Qutob, N., Teer, J.K., Shimony, N., Schachter, J., Rosenberg, S.A., Besser, M.J., Admon, A., and Samuels, Y.: Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7:5110-5117, 2016.
1150. Jaigirdar, A., Rosenberg, S.A., and Parkhurst, M.: A high-avidity WT1-reactive T-cell receptor mediates recognition of peptide and processed antigen but not naturally occurring WT1-positive tumor cells. J. Immunotherapy 39:105-116, 2016.
1151. Yang, J.C. and Rosenberg, S.A.: Adoptive T-cell therapy for cancer. Adv. Immunol. 130:279-294, 2016.
1152. Gros, A., Parkhurst, M.R., Tran, E., Pasetto, A., Robbins, P.F., Ilyas, S., Prickett, T.D., Gartner, J.J., Crystal, J.S., Roberts, I.M., Trebska-McGowan, K., Wunderlich, J.R., Yang, J.C., and Rosenberg, S.A.: Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22:433-438, 2016.
1153. Kerkar, S.P., Wang, Z.F., Lasota, J., Park, T., Patel, K., Groh, E., Rosenberg, S.A., and Miettinen, N.M.: MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases. J. Immunother. 39:181-187, 2016.
1154. Yao, X., Lu, Y.C., Parker, L.L., Li, Y.F., El-Gamil, M., Black, M.A., Xu, H., Feldman, S.A., van der Bruggen, P., Rosenberg, S.A., and Robbins, P.F.: Isolation and characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-cell receptor for cancer. J. Immunother. 39:191-201, 2016.

1155. Deniger, D.C., Pasetto, A., Tran, E., Parkhurst, M.R., Cohen, C.J., Robbins, P.F., Cooper, L.J., and Rosenberg, S.A.: Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the Sleeping Beauty transposon/transposase system. Mol. Ther. 24:1078-1089, 2016.
1156. Goff, S.L., Dudley, M.E., Citrin, D.E., Somerville, R.P., Wunderlich, J.R., Danforth, D.N., Zlott, D.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Klebanoff, C.A., Hughes, M.S., Restifo, N.P., Langan, M.M., Shelton, T.E., Lu, L., Kwong, M.L., Ilyas, S., Klemen, N.D., Payabyab, E.C., Morton, K.E., Toomey, M.A., Steinberg, S.M., White, D.E., and Rosenberg, S.A.: Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34:2389-2397, 2016.
1157. Prickett, T.D., Crystal, J.S., Cohen, C.J., Pasetto, A., Parkhurst, M.R., Gartner, J.J., Yao, X., Wang, R., Gros, A., Li, Y.F., El-Gamil, M., Trebska-McGowan, K., Rosenberg, S.A., and Robbins, P.F.: Durable complete responses from metastatic melanoma after transfer of autologous T-cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4:669-678, 2016.
1158. Pasetto, A., Gros, A., Robbins, P.F., Deniger, D.C., Prickett, T.D., Matus-Nicodemus, R., Douek, D.C., Howie, B., Robins, H., Parkhurst, M.R., Gartner, J., Trebska-McGowan, K., Crystal, J.S., and Rosenberg, S.A.: Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol. Res. 4:734-743, 2016.
1159. Tran, E., Robbins, P.F., Lu, Y.C., Prickett, T.D., Gartner, J.J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E.M., Kriley, I.R., and Rosenberg, S.A.: T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375:2255-2262, 2016.
1160. Lu, T.L., Pugach, O., Somerville, R.P., Rosenberg, S.A., Kochenderfer, J.N., Better, M., and Feldman, S.A.: A rapid cell expansion process for production of engineered autologous CAR-T cell therapies. Hum. Gene Ther. Methods 27:209-218, 2016.
1161. Klemen, N.D., Feingold, P.L., Goff, S.L., Hughes, M.S., Kammula, U.S., Yang, J.C., Schrumpp, D.S., Rosenberg, S.A., and Sherry, R.M.: Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann. Surg. Oncol. 24:135-141, 2017.
1162. Deniger, D.C., Kwong, M.L., Pasetto, A., Dudley, M.E., Wunderlich, J.R., Langan, M.M., Lee, C.R., and Rosenberg, S.A.: A pilot trial of the combination of vemurafenib with adoptive cell therapy in patients with metastatic melanoma. Clin. Cancer Res. 23:351-362, 2017.

1163. Tran, E., Robbins, P.F., and Rosenberg, S.A.: 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 18:255-262, 2017.
1164. Rosenberg, S.A., Tran, E., and Robbins, P.F.: T-cell transfer therapy targeting mutant KRAS. N. Engl. J. Med. 376:e11, 2017 (Authors Reply Letter to the Editor).
1165. Park, T.S., Phan, G.Q., Yang, J.C., Kammula, U., Hughes, M.S., Trebeska-McGowan, K., Morton, K.E., White, D.E., Rosenberg, S.A., and Sherry, R.M.: Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg. Oncol. 24:947-951, 2017.
1166. Kochenderfer, J.N., Somerville, R.P., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S.L., Yang, J.C., Sherry, R.M., Klebanoff, C.A., Kammula, U.S., Sherman, M., Perez, A., Yuan, C.M., Feldman, T., Friedberg, J.W., Roschewski, M.J., Feldman, S.A., McIntyre, L., Toomey, M.A., and Rosenberg, S.A.: Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35:1803-1813, 2017.
1167. Assadipour, Y., Zacharakis, N., Crystal, J.S., Prickett, T.D., Gartner, J.J., Somerville, R.P., Xu, H., Black, M.A., Jia, L., Chinnasamy, H., Kriley, I., Lu, L., Wunderlich, J.R., Zheng, Z., Lu, Y-C., Robbins, P.F., Rosenberg, S.A., Goff, S.L., and Feldman, S.A.: Characterization of an immunogenic mutation in a patient with metastatic triple negative breast cancer. Clin. Cancer Res. 23:4347-4353, 2017
1168. Stevanovic, S., Pasetto, A., Helman, S.R., Gartner, J.J., Prickett, T.D., Howie, B., Robins, H.S., Robbins, P.F., Klebanoff, C.A., Rosenberg, S.A., and Hinrichs, C.S.: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 355:200-205, 2017.
1169. Chandran, S.S., Somerville, R.P., Yang, J.C., Sherry, R.M., Klebanoff, C.A., Goff, S.L., Wunderlich, J.R., Danforth, D.N., Zlott, D., Paria, B.C., Sabesan, A.C., Srivastava, A.K., Xi, L., Pham, T.H., Raffeld, M., White, D.E., Toomey, M.A., Rosenberg, S.A. and Kammula, U.S.: Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 18:792-802, 2017.
1170. Kochenderfer, J.N., Somerville, R.P.T., Lu, T., Yang, J.C., Sherry, R.M., Feldman, S.A., McIntyre, L., Bot, A., Rossi, J., Lam, N., and Rosenberg, S.A.: Long-duration complete remissions of diffuse large B-cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25:2245-2253, 2017.

1171. Lu, Y.C., Parker, L.L., Lu, T., Zheng, Z., Toomey, M.A., White, D.E., Yao, X., Li, Y.F., Robbins, P.F., Feldman, S.A., van der Bruggen, P., Klebanoff, C.A., Goff, S.L., Sherry, R.M., Kammula, U.S., Yang, J.C., and Rosenberg, S.A.: Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J. Clin. Oncol. 35:3322-3329, 2017.
1172. Xi, L., Pham, T.H., Payabyab, E.C., Sherry, R.M., Rosenberg, S.A., and Raffeld, M.: Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. Clin. Cancer Res. 22:5480-5486, 2016.
1173. Arafeh, R., Flores, K., Keren-Paz, A., Maik-Rachline, G., Gutkind, N., Rosenberg, S.A., Seger, R., and Samuels, Y.: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. Sci. Rep. 7:16345, 2017.
1174. Qiao, G., Qin, J., Kunda, N., Calata, J.F., Mahmud, D.L., Gann, P., Fu, Y.X., Rosenberg, S.A., Prabhakar, B.S., and Maker, A.V.: LIGHT elevation enhances immune eradication of colon cancer metastases. Cancer Res. 77:1880-1891, 2017.
1175. Slaney, C.Y., von Scheidt, B., Davenport, A.J., Beavis, P.A., Westwood, J.A., Mardiana, S., Tschärke, D.C., Ellis, S., Prince, H.M., Trapani, J.A., Johnstone, R.W., Smyth, M.J., Teng, M.W., Ali, A., Yu, Z., Rosenberg, S.A., Restifo, N.P., Neeson, P., Darcy, P.K., and Kershaw, M.H.: Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin. Cancer Res. 23:2478-2490, 2017.
1176. Parkhurst, M., Gros, A., Pasetto, A., Prickett, T., Crystal, J.S., Robbins, P., Rosenberg, S.A.: Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin. Cancer Res. 23:2491-2505, 2017.
1177. Qutob, N., Masuho, I., Alon, M., Emmanuel, R., Cohen, I., Di Pizio, A., Madore, J., Elkahoul, A., Ziv, T., Levy, R., Gartner, J.J., Hill, V.K., Lin, J.C., Hevroni, Y., Greenberg, P., Brodeur, A., Rosenberg, S.A., Kosloff, M., Hayward, N.K., Admon, A., Niv, M.Y., Scolyer, R.A., Martemyanov, K.A., and Samuels, Y.: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. Sci. Rep. 8:653, 2018.
1178. Lu, Y.C., Zheng, Z., Robbins, P.F., Tran, E., Prickett, T.D., Gartner, J.J., Li, Y.F., Ray, S., Franco, Z., Bliskovsky, V., Fitzgerald, P.C., and Rosenberg, S.A.: An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors. Mol. Ther. 26:379-389, 2018.

1179. Mehta, G.U., Malekzadeh, P., Shelton, T., White, D.E., Butman, J.A., Yang, J.C., Kammula, U.S., Goff, S.L., Rosenberg, S.A., and Sherry, R.M.: Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases. J. Immunother. 41:241-247, 2018.
1180. Jin, B.Y., Campbell, T.E., Draper, L.M., Stevanovic, S., Weissbrich, B., Yu, Z., Restifo, N.P., Rosenberg, S.A., Trimble, C.L., and Hinrichs, C.S.: Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in murine model. JCI Insight 3:e99488, 2018.
1181. Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y.C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., Gartner, J., Jia, L., Trebska-McGowan, K., Somerville, R.P., Robbins, P.F., Rosenberg, S.A., Goff, S.L., and Feldman, S.A.: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24:724-730, 2018.
1182. Rossi, J., Paczkowski, P., Shen, Y.W., Morse, K., Flynn, B., Kaiser, A., Ng, C., Gallatin, K., Fan, R., Mackay, S., Heath, J.R., Rosenberg, S.A., Kochenderfer, J.N., Zhou, J., and Bot, A.: Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood 132:804-814, 2018.
1183. Cornetta, K., Duffy, L., Feldman, S.A., Mackall, C.L., Davila, M.L., Curran, K.J., Junghans, R.P., Tang, J.Y., Kochenderfer, J.N., O’Ceardbhaill, R., Archer, G., Kiem, H.P., Shah, N.N., Delbrook, C., Kaplan, R., Brentjens, R.J., Rivière, I., Sadelain, M., and Rosenberg, S.A.: Screening clinical cell products for replication competent retrovirus: The National Gene Vector Biorepository experience. Mol. Ther. Methods Clin. Dev. 10:371-378, 2018.
1184. Deniger, D.C., Pasetto, A., Robbins, P.F., Gartner, J.J., Prickett, T.D., Paria, B.C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M.M., Wunderlich, J.R., Danforth, D.N., Somerville, R.P.T., and Rosenberg, S.A.: T-cell responses to TP53 “Hotspot” mutations and unique neoantigens expressed by human ovarian cancers. Clin. Cancer Res. 24:5562-5573, 2018.
1185. Kalaora, S., Wolf, Y., Feferman, T., Barnea, E., Greenstein, E., Reshef, D., Tirosh, I., Reuben, A., Patkar, S., Levy, R., Quinkhardt, J., Omokoko, T., Qutob, N., Golani, O., Zhang, J., Mao, X., Song, X., Bernatchez, C., Haymaker, C., Forget, M.A., Creasy, C., Greenberg, P., Carter, B.W., Cooper, Z.A., Rosenberg, S.A., Lotem, M., Sahin, U., Shakhar, G., Ruppin, E., Wargo, J.A., Friedman, N., Admon, A., and Samuels, Y.: Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8:1366-1375, 2018.

1186. Yossef, R., Tran, E., Deniger, D.C., Gros, A., Pasetto, A., Parkhurst, M.R., Gartner, J.J., Prickett, T.D., Cafri, G., Robbins, P.F., and Rosenberg, S.A.: Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 10:122467, 2018.
1187. Stevanovic, S., Helman, S.R., Wunderlich, J.R., Dorn, S.L., Langan, M.M., Kwong, M.L.M., Somerville, R.P.T., Klebanoff, C.A., Kammula, U., Sherry, R.M., Yang, J.C., Rosenberg, S.A., and Hinrichs, C.S.: A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin. Cancer Res. 25:1486-1493, 2019.
1188. Malekzadeh, P., Pasetto, A., Robbins, P.F., Parkhurst, M.R., Paria, B.C., Jia, L., Gartner, J.J., Hill, V., Yu, Z., Restifo, N.P., Sachs, A., Tran, E., Lo, W., Somerville, R.P.T., Rosenberg, S.A., and Deniger, D.C.: Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J. Clin. Invest. 129:1109-1114, 2019.
1189. Lo, W., Parkhurst, M., Robbins, P.F., Tran, E., Lu, YC., Jia, L., Gartner, J.J., Pasetto, A., Deniger, D., Malekzadeh, P., Shelton, T.E., Prickett, T., Ray, S., Kivitz, S., Paria, B.C., Kriley, I., Schrumpp, D.S., and Rosenberg, S.A.: Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol. Res. 7:534-543, 2019.
1190. Goff, S.L. and Rosenberg, S.A.: BRAF Inhibition: Bridge or boost to T-cell therapy. Clin. Cancer Res. 25:2682-2684, 2019.
1191. Cafri, G., Yossef, R., Pasetto, A., Deniger, D.C., Lu, YC., Parkhurst, M., Gartner, J.J., Jia, L., Ray, S., Ngo, L.T., Jafferfi, M., Sachs, A., Prickett, T., Robbins, P.F. and Rosenberg, S.A.: Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat. Commun. 10:449, 2019.
1192. Goff, S.L., Morgan, R.A., Yang, J.C., Sherry, R.M., Robbins, P.F., Restifo, N.P., Feldman, S.A., Lu, YC., Lu, L., Zheng, Z., Xi, L., Epstein, M., McIntyre, L.S., Malekzadeh, P., Raffeld, M., Fine, H.A., and Rosenberg S.A.: Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42:126-135, 2019.
1193. Leko, V., McDuffie, L.A., Zheng, Z., Gartner, J.J., Prickett, T.D., Apolo, A.B., Agarwal, P.K., Rosenberg, S.A., Lu, Y.C.: Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer. J. Immunol. 202:3458-3467, 2019.
1194. Sana, G., Madigan, J.P., Gartner, J.J., Fourrez, M., Lin, J., Qutob, N., Jitendra, N., Sunneet, S., Ambudkar, S.V., Xia, D., Rosenberg, S.A., Gottesman, M.M., Samuels, Y., Gilet, J.P.: Exome sequencing of ABCB5 identifies recurrent melanoma mutations that result in increased proliferative and invasive capacities. J. Invest. Dermatol. 139:1985-1992, 2019.

1195. Ahmadzadeh, M., Pasetto, A., Jia, L., Deniger, D.D., Stevamoc, S., Robbins, P.F., Rosenberg, S.A.: Tumor-infiltrating human CD4⁺ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci Immunol. 4:4310, 2019.
1196. Parkhurst, M.R., Robbins, P.F., Tran, E., Prickett, T.D., Gartner, J.J., Jia, L., Ivey, G., Li, Y.F., El-Gamil, M., Lalani, A., Crystal, J.S., Sach, A. Groh, E.M., Ray, S., Ngo, L.T., Kivitz, S., Pasetto, A., Yossef, R., Lowery, F.J., Goff, S.L, Lo, W., Cafri, G., Deniger, D.C., Malekzadeh, P., Ahmadzadeh, M., Wunderlich, J.R., Somerville, R.P.T, Rosenberg, S.A.: Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9:1022-1035, 2019.
1197. Doran, S.L., Stevanovic, S., Adhikary, S., Gartner, J.J., Jia, L., Kwong, M.L.M., Faquin, W.C., Faquin, W.C., Hewitt, S.M. Sherry, R.M., Yang, J.C., Rosenberg, S.A., Hinrichs, C.S.: T-cell receptor gene therapy for human papillomavirus-associated epithelial cancer: A First-in-Human, Phase I/II study. J Clin Oncol. 37:2759-2768, 2019.
1198. Lu, Y.C., Jia, L., Zheng, Z., Tran, E., Robbins, P.F., Rosenberg, S.A.: Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. Cancer Immunol Res. 7:1824-1836, 2019.
1199. Gros, A., Tran, E., Parkhurst, M.R., Ilyas, S., Pasetto, A., Groh, E.M., Robbins, P.F., Yossef, R., Garcia-Garajo, A., Fajardo, C.A., Prickett, T.D., Jia, L., Gartner, J.J., Ray, S., Ngo, L., Wunderlich, J.R., Yang, J.C., Rosenberg, S.A.: Recognition of human gastrointestinal cancer neoantigens by circulating PD-1⁺ lymphocytes. J Clin Invest. 129:4922-5004, 2019.
1200. Zhang, L., Davies, J.S., Serna, C., Yu, Z., Restifo, N.P., Rosenberg, S.A., Morgan, R.A., Hinrichs, C.S.: Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. J Immunother Cancer. 8:210, 2020.
1201. Brudno, J.N., Lam, N., Vanasse, D., Yuey-Wei, S., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., Roschewski, M., Dean, R., Cachau, R., Youkharibache, P., Patel, R., Hansen, B., Stroncek, D.F., Rosenberg, S.A., Gress, R.E., Kochenderfer, J.N.: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 26:270-280, 2020.
1202. Malekzadeh, P., Yossef, R., Cafri, G., Paria, B.C., Lowery, F., Jafferji, M., Good, L., Sachs, A., Copeland, A.R., Kim, S.P., Kivitz, S., Parkhurst, M.R., Robbins, P.F., Ray, S., Xi, L., Raffeld, M., Yu, Z., Restifo, N. P., Somerville, R.P.T., Rosenberg, S.A., Deniger, D.C.: Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clin Cancer Res. 26:1267-1276, 2020.

1203. Kalaora, S., Sang Lee, J., Barnea, E., Levy, R., Greenberg, P., Alon, M., Yagel, G., Bar Eli, G., Oren, R., Peri, A., Patkar, S., Bitton, L., Rosenberg, S.A., Lotem, M., Levin, Y., Admon, A., Ruppin, E., Samuels, Y.: Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat Comm. 11: 896, 2020.
1204. Sim, M.J.W., Lu, J., Spencer, M., Hopkins, F., Tran, E., Rosenberg, S.A., Long E.O., Sun, P.D.: High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proc Natl Acad Sci. 117: 12826-12835, 2020.
1205. Sachs, A., Moore., Kosaloglu-Yalcin, Z., Peters, B., Sidney, J., Rosener, S.A., Robbins, P.F., Sette, A.: Impact of cysteine residues on MHC binding predictions and recognition by tumor-reactive T Cells. J Immunol. 205: 539-549, 2020.
1206. Leko, V., Rosenberg, S.A.: Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell. 38: 454-472, 2020.
1207. Cafri, G., Gartner, J.J., Zaks, T., Hopson, K., Levin, N., Paria, B.C., Parkhurst, M.R., Yossef, R., Lowery, F.J., Jafferji, M.S., Prickett, T.D., Goff, S.L., McGowan, C.T., Seitter, S., Shindorf, M.L., Parikh, A., Chatani, P.D., Robbins, P.F., Rosenberg, S.A.: mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 130: 5976-5988, 2020.
1208. Cappell, K.M., Sherry, R.M., Yang, J.C., Goff, S.L., Vanasse, D.A., McIntyre, L., Rosenberg, S.A., Kochenderfer, J.N. Long-term follow-up of anti-CD19 chimeric antigen receptor t-cell therapy. J. Clin. Oncol. 38: 3805-3815, 2020.
1209. Paria, B.C., Levin, N., Lowery, F.J., Pasetto, A., Deniger, D.C., Parkhurst, M.R., Yossef, R., Kim, S.P., Florentin, M., Ngo, L.T., Ray, S., Srishna, S., Robbins, P.F., Rosenberg, S.A. Rapid identification and evaluation of neoantigen-reactive T-cell receptors from single cells. J. Immunother. 44: 1-8, 2021.
1210. Gastman, B., Agarwal, P.K., Berger, A., Boland, G., Broderick, S., Butterfield, L.H., Byrd, D., Fecci, P.E., Ferris, R.L., Fong, Y, Goff, S.L., Grabowski, M.M., Ito, F., Lim N., Lotze, M.T., Mahdi, H., Malafa, M., Morris, C.D., Murthy, P., Neves, R.I., Odunsi, A., Pai, S.I., Prabhakaran, S., Rosenberg, S.A., Saoud R., Sethuraman, J., Skitzki, J., Slingluff, C.I., Sondak, V.K., Sunwoo, J.B., Turcotte, S., Yeung, C.C., Kaufman, H.L. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 8: 1583, 2020.

1211. Krishna, S., Lowery, F.J., Copeland, A.R., Bahadiroglu, E., Mukherjee, R., Jia, L. Anibal, J.T., Sachs, A., Adebola, S.O., Gurusamy, D., Yu, Z., Hill, V., Gartner, J.J., Li, Y.F., Parkhurst, M., Paria, B., Kvistborg, P., Kelly, M.C., Goff, S.L., Altan-Bonnet G., Robbins, P.F., Rosenberg, S.A. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 370: 1328-1334, 2020.
1212. Gartner, J.J., Parkhurst, M.R., Gros, A., Tran, E., Jafferji, M.A., Copeland, A., Hanada, K., Zacharakis, N., Lalani, A., Krishna, S., Sachs, A., Prickett, T.D., Li, Y.F., Florentin, M., Kivitz, S., Chatmon, S.C., Rosenberg, S.A., Robbins, P.F. A machine learning model for making candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. Nature Cancer. 2: 563-574, 2021.
1213. Rosenberg, S.A. Immersion in the search for effective cancer immunotherapies. Molecular Medicine. 27: 63, 2021.
1214. Levin, N., Paria, B.C., Vale, N.R., Yoseph, R., Lowry, F.J., Parkhurst, M.R., Yu, Z., Florentin, M., Cafri, G., Gartner, J.J., Shindorf, M.L., Ngo, L.T., Ray, S., Kim, S.P., Copeland, A.R., Robbins, P.F., Rosenberg, S.A. Identification and validation of T-cell receptors targeting RAS hot-spot mutations in human cancers for use in cell-based immunotherapy. Clin Cancer Res. 27: 5084-5095, 2021
1215. Leko, V., Cafri, G., Yossef, R., Paria, B., Hill, V., Gurusamy, D., Zheng, Z., Gartner, J.J., Prickett, T.D., Goff, S.L., Robbins, P., Lu, Y.C., Rosenberg, S.A. Identification of neo-antigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. J. Immunother Cancer. 9: 2595, 2021.
1216. Lu, Y.C., Zheng, Z., Lowery, F.J., Gartner, J.J., Prickett, T.D., Robbins, P.F., Rosenberg, S.A. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. J. Immunother Cancer. 9: 2595, 2021.
1217. Seitter, S.J., Sherry, R.M., Yang, J.C., Robbins, P.R., Shindorf, M.L., Copeland, A.R., McGowan, C.T., Epstein, M., Shelton, T.E., Langham, M.M., Franco, Z., Danforth, D.N., White, D.E., Rosenberg, S.A., Goff, S.L. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res. 10: 5289-5298, 2021.
1218. Zacharakis, N., Huq, L.M., Seitter, S.J., Kim, S.P., Gartner, J.J., Sindiri, S., Hill V.K., Li, Y.F., Paria, B.C., Ray, S., Gasmi, B., Lee, C.C., Prickett, T.D., Parkhurst, M.R., Robbins, P.F., Langan, M.M., Shelton, T.E., Parkih, A.Y., Levi, S.T., Hernandez, J.M., Hoang, C.D., Sherry, R.M., Yang, J.C., Feldman, S.A., Goff, S.L., Rosenberg, S.A. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol. 40: 1741-1754, 2022.

1219. Lowery, F.J., Krishna, S., Yossef, R., Parikh, N.B., Chatani, P.D., Zacharakis, N., Parkhurst, M.R., Levin, N., Sindiri, S., Sachs, A., Hitscherich, K.J. Yu, Z., Vale, N.R., Lu, Y-C., Zheng, Z., Jia, L., Gartner, J.J., Hill, V.K., Copeland, A.R., Nah, S.K., Masi, R.V., Gasmi, B., Kivitz, S., Paria, B.C, Florentin, M. Kim., S.P., Hanada, K., Li, Y.F., Ngo, L.T., Ray, S. Shindorf, M.L., Levi, S.T., Shepherd, R., Toy, C., Parikh, A.Y., Prickett, T.D., Kelly, M.C., Beyer, R., Goff, S.L., Yang, J.C., Robbins, P.F., Rosenberg, S.A. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 375: 877-884, 2022.
1220. Levi, S.T., Copeland, A.R., Nah, S., Crystal, J.S., Ivey, G.D., Lalani, A., Jafferji, M., White, B.S., Parikh, N.B., Leko, V., Krishna, S., Lowery, F., Prickett, T.D., Gartner., J.J., Jia, L., Li, Y.F., Sachs, A., Sindiri, S., Robinson, W., Gasmi, B, Yang, J.C., Goff, S., Rosenberg, S.A., Robbins, P.F. Neoantigen identification and response to adoptive cell transfer in anti PD-1 naive and experienced patients with metastatic melanoma. Clin Cancer Res. 28: 3042-3052, 2022.
1221. Hanada, K.I., Zhao, C., Gil-Hoyos, R., Gartner, J.J., Chow-Parmer, C., Lowery, F.J., Krishna, S., Prickett, T.D., Kivits, S., Parkhurst, M.R., Wong, N., Rae, Z., Kelly M.C., Goff, S.L., Robbins, P.F., Rosenberg, S.A., Yang, J.C. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell. 40: 479-493, 2022.
1222. Leidner, R., Silva, N.S., Huang, H., Sprott, D., Zheng, C., Shih, Y.P., Leung, A., Payne, R., Sutcliffe, K., Cramer, J., Rosenberg, S.A., Fox, B.A., Urba., W.J., Tran, E. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 386: 2112-2119, 2022.
1223. Seitter, S.J., McClelland, P.H., Ahlman, M.A., Goff, S.L., Yang, J.C., McIntyre L., Rosenberg, S.A., Kochenderfer, J.N., Brudno, J.N. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. Leuk Lymphoma. 10: 2469-2473, 2022.
1224. Kim, S.P., Vale, N.R., Zacharakis, N., Krishna, S., Yu, Z., Gasmi, B., Gartner, J.J., Sindiri, S., Malekzadeh, P., Deniger, D.C., Lowery, F.J., Parkhurst, M.R., Ngo, L.T., Ray, S., Li, Y.F., Hill, V., Florentin, M., Masi, R.V., Paria, B.C., Levin, N., Bera, A., Hedges, E.A., Choi, A., Chatani, P.D., Parikh, A.Y., Levi, S., Seitter, S., Lu, Y.C., Zheng, Z., Prickett, T.D., Jia, L., Hernandez, J.M., Hoang, C.D., Robbin, P.F., Goff, S.L., Sherry, R.M., Yang, J.C., Rosenberg, S.A. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 10: 932-946, 2022.
1225. Cornetta, K., Yao, J., House, K., Duffy, L., Adusumilli, P.S., Beyer, R., Booth, C., Brenner, M., Curran, K., Grilley, B., Heslop, H., Hinrichs, C.S., Kaplan, R.N., Kiem, H.P., Kochenderfer, J., Kohn, D.B., Mailankody, S., Norberg, S.M., O’Cearbhaill, R.E., Pappas, J., Park, J., Ramos, C., Ribas, A., Riviera, I., Rosenberg, S.A., Sauter, C., Shah,

- N., Slovin, S.F., Thrasher, A., Williams, D.A., Lin, T.Y. Replication competent retrovirus testing (RCR) in the national gene vector biorepository: No evidence of RCR in 1595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 31: 801-809, 2022.
1226. Palmer, D.C., Webber, B.R., Patel, Y., Johnson, M.J., Kariya, C.M., Lahr, W.S., Parkhurst, M.R., Gartner, J.J., Prickett, T.D., Lowery, F.J., Kishton, R.J., Gurusamy, D., Franco, Z., Vodnala, S.K., Diers, M.D., Wolf, N.K., Slipek, N.J., McKenna, D.H., Sumstad, D., Viney, L., Henley, T., Burckstummer, T., Baker, O., Hu, Y., Yan, C., Meerzaman, D., Padhan, K., Lo, W., Malekzadeh, P., Jia, L., Deniger, D.C., Patel, S.J., Robbins, P.F., McIvor, R.S., Choudhry, M., Rosenberg, S.A., Moriarity, B.S., Restifo, N.P. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med. 3: 682-704, 2022.
1227. White, B.S., Sindiri, S., Hill, V., Gasmi, B., Nah, S., Gartner, J.J., Prickett, T.D., Li, Y., Gurusamy, D., Robbins, P., Rosenberg, S.A., Leko, V. Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma. J Immunother Cancer. 11: 6303, 2023.
1228. Rosenberg, S.A., Parkhurst, M.R., Robbins, P.F. Adoptive cell transfer immunotherapy for patients with solid epithelial cancers. Cancer Cell. 41: 646-648, 2023.
1229. Chatani, P.D., Lowery, F.J., Parikh, N.B., Hitscherich, K.J., Yossef, R., Hill, V., Gartner, J.J., Paria, B., Florentin, M., Ray, S., Bera, A., Parkhurst, M., Robbins, P., Krishna, S., Rosenberg, S.A. Cell surface marker-based capture of neoantigen-reactive CD8⁺ T-cell receptors from metastatic tumor digests. J Immunother Cancer. 11: 6264, 2023.
1230. Yossef, R., Krishna, S., Sindiri, S., Lowery, F.J., Copeland, A.R., Gartner, J.J., Parkhurst, M.R., Parikh, N.B., Hitscherich, K.J., Levi, S.T., Chatani, P.D., Zacharakis, N., Levin, N., Vale, N.R., Nah, S.K., Dinerman, A., Hill, V.K., Ray, S., Bera, A., Levy, L., Jia, L., Kelly, M.C., Goff, S.L., Robbins, P.F., Rosenberg, S.A. Phenotypic signatures of circulating neoantigen-reactive CD8⁺ T cells in patients with metastatic cancers. Cancer Cell. 41: 2154-2165, 2023.
1231. Parikh, A.Y., Masi, R., Gasmi, B., Hanada, K., Parkhurst, M., Gartner, J., Sindiri, S., Prickett, T., Robbins, P., Zacharakis, N., Beshiri, M., Kelly, K., Rosenberg, S.A., Yang, J.C. Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens. Cancer Immunol Immunother. 72: 3149-3162, 2023.
1232. Levin, N., Kim, S.P., Marquardt, C.A., Vale, N.R., Yu, Z., Sindiri, S., Gartner, J.J., Parkhurst, M., Krishna, S., Lowery, F.J., Zacharakis, N., Levy, L., Prickett, T.D., Benzine, T., Ray, S., Masi, R.V., Gasmi, B., Li, Y., Islam, R., Bera, A., Goff, S.L., Robbins, P.F., Rosenberg, S.A. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like

- memory phenotypes. J Immunother Cancer. 12, 2024.
1233. Mikkilineni, L., Natrakul, D.A., Lam, N., Manasanch, E.E., Mann, J., Weissler, K.A., Wong, N., Brudno, J.N., Goff, S.L., Yang, J.C., Ganaden, M., Patel, R., Zheng, Z., Gartner, J.J., Martin, K.R., Wang, H.W., Yuan, C.M., Lowe, T., Maric, I., Shao, L., Jin, P., Stroncek, D.F., Highfill, S.L., Rosenberg, S.A., Kochenderfer, J.N. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only-antigen-binding domain. Mol Ther. 32: 503-526, 2024.
 1234. Rosenberg, S.A. Lymphocytes as a living drug for cancer. Science. 385: 25-26, 2024.
 1235. Parkhurst, M., Goff, S.L., Lowery, F.J., Beyer, R.K., Halas, H., Robbins, P.F., Prickett, T.D., Gartner, J.J., Sindiri, S., Krishna, S., Zacharakis, N., Ngo, L., Ray, S., Bera, A., Shepherd, R., Levin, N., Kim, S.P., Copeland, A., Nah, S., Levi, S., Parikh, N., Kwong, M.L.M., Klemen, N.D., Yang, J.C., Rosenberg, S.A. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat Med. 30: 2586-2595, 2024.
 1236. Leko, V., Groh, E., Levi, S.T., Copeland, A.R., White, B.S., Gasmi, B., Li, Y., Hill, V., Gurusamy, D., Levin, N., Kim, S.P., Sindiri, S., Gartner, J.J., Prickett, T.D., Parkhurst, M., Lowery, F.J., Goff, S.L., Rosenberg, S.A., Robbins, P. Utilization of primary tumor samples for cancer neoantigen discovery. J Immunother Cancer. 13: 1-14, 2025.
 1237. Lowery, F.J., Goff, S.L., Gasmi, B., Parkhurst, M.R., Ratnam, N.M., Halas, H.K., Shelton, T.E., Langan, M.M., Bhasin, A., Dinerman, A.J., Dulemba, V., Goldlust, I.S., Gustafson, A.M., Hakim, A., Hitscherich, K.J., Kenney, L.M., Levy, L., Rault-Wang, J.G., Bera, A., Ray, S., Seavey, C.D., Hoang, C.D., Hernandez, J.M., Gartner, J.J., Sindiri, S., Prickett, T.D., McIntyre, L.S., Krishna, S., Robbins, P.F., Klemen, N.D., Kwong, M.L.M., Yang, J.C., Rosenberg, S.A. Neoantigen-specific tumor infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat Med. 31: 1994-2003, 2025.
 1238. Goff, S.L., Rosenberg, S.A. Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCI. J Immunother Cancer. 13: 1-4, 2025.
 1239. McClelland, P.H., Nah, S.K., Gustafson, A.M., Dinerman, A.J., White, B.S., Gasmi, B., White, D.E., Sindiri, S., Gartner, J.J., Prickett, T.D., Robbins, P.F., Parkhurst, M.R., Halas, H., Kwong, M.L.M., Goff, S.L., Yang, J.C., Rosenberg, S.A., Klemen, N.D. Adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic acral lentiginous melanoma. J Clin Oncol. 43: 2479-2489, 2025.
 1240. Gustafson, A.M., Dinerman, A.J., Hitscherich, K.J., Parkhurst, M.R., Halas, H., White, D.E., Hoang, C.D., Hernandez, J.M., Kwong, M.L.M., Klemen, N.D., Rosenberg, S.A., Goff, S.L., Yang, J.C. Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers. Cancer Immunol

Immunother. 74: 244, 2025.

1241. Gavrilova, T., McIntyre, L., Goff, S.L., Yang, J.C., Natrakul, D.A., Rosenberg, S.A., Kochenderfer, J.N., Brudno, J.N. Survival after anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma and CLL with 10 years of follow-up. Blood Adv. 9: 5362-5366, 2025.
1242. Kim, S.P., Levin, N., Jo, Y., Marquardt, C., Yu, Z., Levy, L., Vale, N.R., Parkhurst, M., Ray, S., Magna, M., Farid, S., Khateb, M., Halas, H., Goff, S.L., Klemen, N.D., Rosenberg, S.A. Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation. J Immunother Cancer. 13: 1-15, 2025.
1243. Islam, R.S.M., Seitter, S., Parkhurst, M., Lowery, F.J., Fukuhara, M., Kim, S.P., Levin, N., Gartner, J.J., Ray, S., Prickett, T., Hill, V., Robbins, P.F., Goff, S.L., Rosenberg, S.A., Zacharakis, N. Identification of HLA class II-restricted T cell receptors against shared PIK3CA mutations in patients with epithelial cancers. Cancer Immunol Immunother. 18: 1-14, 2025.
1244. Kenney, L.M., Dinerman, A.J., Gustafson, A.M., Hakim, A.A., Goff, S.L., Kwong, M.L.M., Kammula, U.S., Hernandez, J.M., Yang, J.C., Rosenberg, S.A., Klemen, N.D. Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience. Ann Surg Oncol. 2026.
1245. Dinerman, A.J., Gustafson, A.M., Hitscherich, K.J., White, D.E., Krishna, S., Schrupp, D.S., Hoang, C.D., Hernandez, J.M., Gartner, J.J., Robbins, P.F., Kwong, M.L.M., Goff, S.L., Yang, J.C., Rosenberg, S.A., Klemen, N.D. Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates. Ann Surg Oncol. 2026.
1246. Krishna, S., Yu, Z., Chakravarti, M., Dulemba, V., Dinerman, A.J., Levy, L., Hitscherich, K.J., Gartner, J.J., Sindiri, S., Skonieczny, K., Prickett, T.D., Robbins, P.F., Goff, S.L., Lowery, F.J., Yang, J.C., Rosenberg, S.A. Vaccination rescues dysfunctional T cell therapy by amplifying rare stem-like antitumor CD8⁺ T cells. Res Sq. [Preprint]. 2026.
1247. Gattinoni, L., Inchingolo, G., Harrer, D.C., Susana, A., Puccio, S., Slavkovic-Lukic, D., Natrakul, D.A., Strieder, N., Heuser-Loy, C., Baldwin, J.G., Fioravanti, J., Ji, Y., Gautam, S., Suriano, C., Martin-Santos, A., Schelker, R.C., Patel, N., Mann, J., Goff, S.L., Mikkilineni, L., Kochenderfer, J.N. Distinct *in vivo* dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse. Cell. 189: 1-15, 2026.
1248. Gustafson, A.M., Bhasin, A., Gasmi, B., Bui, B.D., Ade, C.M., Hanada, K., Halas, H.K., Gartner, J.J., Prickett, T.D., Salazar, J., Parkhurst, M.R., Robbins, P., Klemen, N.D., Kwong, M.L., Goff, S.L., Rosenberg, S.A., Yang, J.C. Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response. J Immunother Cancer. 2026.